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Abstract 
 
Cavitation is a key facilitator in transmission of Mycobacterium tuberculosis (M. tb). 
Upregulation of matrix metalloproteases (MMPs) has been documented in patients with 
tuberculosis (TB), while their tissue inhibitor (TIMPs) levels remained the same. Animals 
which can develop cavities have well-conserved MMP-1 orthologs suggesting a pivotal role 
of MMP-1 in cavitation. The migration of immune cells to the site of infection and 
maturation of the granuloma is associated with MMP-9 expression. Our understanding of 
the phenotypic changes induced by Mycobacterium smegmatis (M. smeg) in THP-1 
macrophages is central to understanding its avirulent nature especially its effects on MMPs. 
The aim of this study was to evaluate the role of MMP-1 and MMP-9, and their effectors in 
macrophages infected with M. smeg. Differentiated THP-1 monocytes were incubated in 
serum-free media with or without bacilli. Thereafter, the secretome and lysate were 
harvested at different time points. The activity of MMPs was analysed by zymography. The 
activity of MMP-1 and MMP-9 were specifically determined using an MMP-1 fluorogenic 
assay and a non-fluorogenic MMP-9 substrate monitored using the HPLC. Discovery 
proteomics was performed for the 18-hour time point with the use of mass spectrometry. 
The generated data was used to evaluate dysregulated proteins and those that act as 
upstream and downstream effectors of MMPs. The phenotypic changes induced by M. smeg 
were also analysed. In addition to that, the hosts’ response to lipoarabinomannan H37Rv 
(LAM) treatment was assessed by discovery proteomics and zymography. There was an 
increase in gelatinase activity of secreted MMP-9 which was maintained between the 1 and 
18-hour time points. The fold difference in activity between uninfected and infected 
declined at 24 hours, and at the 72-hour time point the uninfected was slightly higher versus 
the infected. The data also suggests a switch in the proteolytic repertoire of the 
macrophages between the 6- and 18-hour time points to one that potentially generates the 
same degradation products as the uninfected macrophages. The intracellular gelatinase 
activity of MMP-9 (82 kDa) was not significantly altered by the M. smeg infection, in fact the 
activity was slightly higher in the uninfected in the 18 and 24-hour time points. 
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In contrast to MMP-9, MMP-1 was secreted in the later time points and was significantly 
decreased by the infection. This supports the postulation that upregulation of MMP-1 is 
specific for M. tb infection. The proteomics data depict significant upregulation of MMP-9 in 
the lysate and secretome, while TIMP-1 was exclusively expressed and secreted by infected 
macrophages, validating the non-destructive ECM phenotype induced by M. smeg. The 
dysregulation of IL-1β and COX pathways were implicated in the overexpression of MMP-9, 
as well as tRNA aminoacylation in alternative splicing of MMPs. The GO enrichment of 
exosomes is postulated to play a role in the recycling of MMP-9. Intercellular 
communication is hypothesised to be delivered to neighbouring cells through exosomes 
carrying DNA, RNA, proteins and DNA/RNA binding proteins, and via signalling scaffolds 
formed by the 14-3-3 proteins amongst others. LAM treatment did not induce dysregulation 
in the activity of expressed and secreted MMP-9, however, TIMP-1 was upregulated 
explaining the lack of differential gelatinase activity between treated and non-treated 
macrophages. The C-type mannose receptor 2 (MRC2) and C-type lectin domain family 11 
(CLEC11A) were only expressed by the LAM-treated macrophages and may partake in the 
recognition and uptake of M. tb. Interestingly, the data indicates the presence of chromatin 
in the secretome which may be responsible for the formation of extracellular traps (NETs) 
and facilitating the transport of LAM across the glomerular basal membrane (GBM) through 
exosomes. Inhibition of MMP activity by TIMPs could result in decreased aggregation of 
NETS (aggNETS) that trap the LAM from being transported by binding to the chromatin. This 
decreases the concentration of LAM in urine and means MMP inhibitors that chelate the 
active-site zinc could decrease the sensitivity of urine-LAM detection kits.  
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Chapter 1 
Introduction and literature review 
 
1.1 Tuberculosis: Burden of disease and efficiency of transmission  
Tuberculosis is one of the oldest diseases known to mankind dating as far back as the 
earliest migration and civilization of humans. Initially thought to be a hereditary disease, it 
was only in 1882 that Robert Koch demonstrated that in fact TB was caused by 
Mycobacterium tuberculosis (M. tb) (Ahidjo et al. 2016). TB is a highly infectious disease that 
propagates in humans through aerosol transmission. Only 10% of the infected individuals 
develop active TB and the remaining can contain or clear the infection (Kaplan et al. 
2003;van Crevel et al. 2002). The burden of this disease has since risen due to co-infection 
with the immuno-compromising HIV/AIDS. The world health organisation predicts that there 
will be 1 billion new M. tb infections, 150 million new active TB cases and 37 million TB-
related deaths by year 2020. Africa bares the most burden with South Africa recording an 
alarming 155 743 TB cases in 2014 (WHO, 2014).  
 
Cavitation has been recognised as one of the key factors in transmission of TB. A single 
cavity is known to harbour 107 to 109 active bacilli and presents an ideal environment for 
rapid bacterial growth since they are isolated from the immune system (Nedeltchev et al. 
2009). In turn, bacteria capitalise by mutating, forming strains that are immune and therapy 
resistant. This undermines the success of existing therapeutic drugs such as isoniazid and 
rifampicin influencing the emergence of drug resistant strains. Another factor posing a 
challenge is the rate of relapse, with cavitary lung disease being one of the key causes. The 
estimated relapse rate in patients with cavitary disease is between 21 to 25% and in some 
cases, this was observed after only 2 months of therapy (Nedeltchev et al. 2009). The 
mechanisms and mediators of cavity formation are yet to be fully described given the 
inherent complexity of the host and bacterial interactions. Studies toward understanding 
the host’s response is novel and discovery of possible host targets is a critical area of 
research hence the interest of the current study.  
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Figure 1-1: World map representing the rate of fatalities due to tuberculosis. Africa is 
mostly affected as indicated by darker areas. [Picture was adapted from WHO website, 
2014]. 
 
 
1.2 Postulated mechanism (s) of cavity formation in TB 
Although granuloma formation may be common in some diseases it is one of the 
pathological hallmarks that is best described in M. tb infection. Its function is to contain the 
infectious bacilli from spreading, however, the outcome of its formation is complex since it 
is also believed to be ‘hi-jacked’ by bacteria for replication and survival (Salgame 2011). The 
granuloma is well-structured (Figure 1-2) and is composed of monocytes, macrophages, 
dendritic cells (DC), T- and B- cells (small lymphocytes) and natural killer cells (large 
lymphocytes). Surrounding it, is a layer of fibroblasts that separate it from the lung tissue 
(Dartois 2014). The fibrotic layer surrounding the granuloma is meant to benefit the host by 
preventing active disease and dissemination of the bacteria but also inhibits vascularisation 
making the delivery of drugs to the bacteria which can still replicate under anaerobic 
conditions difficult. 
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Figure 1-2: Schematic representation of different stages of the granuloma. Cells making up 
the granuloma are indicated along with their arrangement. [Adapted from (Dartois 2014)].  
 
When a droplet of M. tb-containing nuclei is inhaled, a series of events are triggered upon 
reaching the lung. The initial encounter of the bacilli is with the residential alveolar 
macrophages where it is recognised by several receptor types. These include Toll-like 
receptors, Fc receptors, mannose receptors, scavenger receptors and complement 
receptors (Flannagan et al. 2009;Korb et al. 2016). Intriguingly, these receptors seem to 
confer different responses to macrophages stimulated with M. tb. For example in vitro 
studies investigating the ligation of Fc receptors to macrophages showed production of 
reactive oxygen intermediates and promotion of phagosome-lysosomal fusion, while 
complement receptor 3 prevented maturation of the phagosome (Sakamoto 2012). 
Recognition of the bacilli leads to phagocytosis by the macrophages which in turn causes the 
release of cytokines and chemokines. Cells of the immune system such as monocytes, 
macrophages, dendritic cells and neutrophils are then recruited to the site of infection 
where monocytes are differentiated to macrophages. Neutrophils and dendritic cells can 
engulf bacteria not phagocytosed by the alveolar macrophages. The adaptive immune 
system will be stimulated by the migration of activated alveolar macrophages and dendritic 
cells from the site of infection to the lung lymph nodes where they prime T-cells and recruit 
lymphocytes as components of the granuloma (Dheda et al. 2010). For these events to 
occur, namely the migration of cells, the basal membrane has to be broken down. As bacilli 
continue to replicate and grow within the granuloma, cells may undergo necrosis and in 
time form what is referred to as a ‘caseous’ necrosis centre owing to its cheese-like 
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appearance. If the caseous centre liquefies, it can spill into the airways leaving a cavity in 
the lungs. Aerosol transmission will occur once the infected individual coughs out the bacilli 
which will ultimately be inhaled by a susceptible individual. Another proposed mechanism 
of cavity formation is through sites of lipoid pneumonia, also requiring tissue remodelling 
(Elkington et al. 2011b;Korb et al. 2016). It is suggested that bacterial infection induces an 
imbalance in the efflux and influx of the hosts lipids culminating in the accumulation of lipids 
thereby transforming macrophages to foamy macrophages. These foamy macrophages, 
which can also form by engulfment of phagocytic cells, are a source of bacterial persistence 
that causes progression of disease to cavity formation. The architecture of the granuloma 
seems to aim for a balance of pro- and anti-inflammatory immune responses, where the 
caseous necrotic centre and cells that surround it express effectors that support the earlier 
and the latter, respectively (Marakalala et al. 2016). Interestingly in the same study the 
lipid-based inflammatory factor, LTA4H was expressed more abundantly in the necrotic 
caseum when compared to solid granulomas, where the necrotic centre was mostly 
composed of macrophages. What was also important to note was that the outermost cells 
of the granuloma in addition to increased expression of protein synthesis machinery 
(ribosomal and ER proteins) elicited a more reducing environment contrasting its necrotic 
centre. It is apparent that the mechanism of M. tb transmission is highly complex and 
efficient. This highlights the importance of attenuation of transmission in combating TB. 
What is also evident is that remodelling of the extracellular matrix is an integral component 
of cavity formation and dissemination from the lung interstitium into the airways for 
transmission. Studying host proteases such as MMP-1 that are involved and factors 
downstream and upstream of them is therefore essential (Elkington et al. 2011a).  
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1.2.1 Phagocytosis of bacilli and lysosomal fusion 
The persistence of Mycobacteria owes to a large part its complex ability to inhabit the host 
environment by escaping killing and exploiting it for its survival (Case and Samuel 
2016;Pieters and Gatfield 2002). It does this by a series of steps that uses the hosts proteins 
and lipids (including glycolipids) essential for phago-lysosomal fusion and/or using its own 
proteome to mimic that of the host for its survival. Phagocytosis is a process that cells, 
including the professional phagocytes such as macrophages, neutrophils and dendritic cells, 
employ to engulf extracellular material such as nutrients, bacteria, antigens and apoptotic 
cells which in this case is referred to as efferocytosis. It involves a series of steps such as, 
binding of the particle to a receptor, receptor clustering, cytoskeletal re-organisation which 
causes the extension of pseudopodia and membrane re-organisation, and finally entry of 
the ingested particle enclosed by the membrane leading to formation of the phagosome. 
This is followed by phagosomal maturation (Figure 1-3) entailing sequential interaction and 
fusion with endosomal compartments and cellular organelles causing the exchange of 
bactericidal and antigen processing molecules (Flannagan et al. 2009). The final and critical 
step is the fusion of the phagosome with the late endosomal/lysosomal compartments 
where majority of the bacterial killing occurs by hydrolases and bactericidal molecules. At 
this stage the phagosome has undergone intense acidification steps becoming more acidic 
with fusion to the lysosome. The pH has been documented to drop from 7.4 to 4.5 
(Flannagan et al. 2009). This highlights the importance of pH in the spatial and temporal 
recruitment of different proteases such as matrix metalloproteases and cathepsins, which in 
general degrade the ECM optimally around pH 7 and 4.5, respectively. The drop in pH is 
largely influenced by recruitment of the proton pumping V-ATPases.   
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Figure 1-3: The maturation process of the phagosome. The series of steps leading to 
phagosome-lysosomal fusion and some of the essential markers acquired during this 
process have been indicated [Adapted from (Flannagan et al. 2009)]. 
 
Binding of bacilli is facilitated by recognition through pattern recognition receptors and by 
host factors such as opsonins (IgG and complement molecules) which bind to the Fcγ and 
complement receptor 3 (Flannagan et al. 2009;Sano et al. 2003).  Galectin-3 (Gal-3) is a 
member of the lectin family of proteins that binds to β-galactoside. It functions both 
extracellularly in cell-cell adhesion, cell-ECM adhesion, cell activation and induction of cell 
migration such as neutrophils, monocytes and macrophages (Sano et al. 2003). 
Intracellularly it has been documented to be involved in inflammation, pre-mRNA splicing, 
cell cycle regulation and apoptosis. Gal-3 is also implicated in the opsonisation of apoptotic 
macrophages and their clearance. Accumulation of Gal-3 on the surfaces of phagosomal 
membranes that were generated from Mycobacterium bovis (BCG) infected macrophages 
(murine bone marrow-derived) was observed in macrophages that contained live rather 
than dead bacilli (Beatty et al. 2002). Some of the important proteins that are involved in 
the phagosomal maturation are summarised in Figure 1-3. The direct and specific 
participation of MMPs in these series of steps has not been exhaustively researched and 
documented, however MMPs can form direct/indirect interactions with some of the 
proteins involved such as v-ATPase, cathepsins, Gal-3 and the actin/microtubule family of 
proteins which are employed for cytoskeletal remodelling during phagocytosis (Bildyug 
2016;Chen et al. 2014;Christensen and Shastri 2015;Feeley et al. 2017;Ochieng et al. 1994). 
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1.3 Components of the lung extracellular matrix 
The lung is largely comprised of connective tissue which is intricately maintained by a 
balance between its components and proteases responsible for their turnover. The alveoli 
are mainly supported by fibrillar collagens and elastin providing the elastic and tensile 
strength to the lung with collagen I and III being the dominant components (Davidson 
1990;Elkington et al. 2011a;Toshima et al. 2004). Additionally, the interaction of the 
extracellular matrix with cells is facilitated by adhesive molecules such as integrins, 
cadherins, fibronectin, laminin, thrombospondin, vitronectin and entactin. Under neutral pH 
physiological conditions, matrix metalloproteases are mainly responsible for the 
degradation of the ECM and its remodelling, hence their implicated role in disease 
pathologies when dysregulated.  
 
1.3.1 Matrix metalloproteinases (MMPs): Structure and function 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases belonging to the 
metzincin superfamily, which also includes the ADAMs (a disintegrin and 
metalloproteinases) (Jackson et al., 2006). The first MMP was discovered in 
metamorphosing tadpoles in 1962 (Gross and Lapiere 1962)  by the ability of the respective 
tissue extracts to degrade fibrillar collagen at neutral pH (Gross and Lapiere 1962, this was 
then appropriately named MMP-1 or interstitial collagenase (Pardo and Selman 2005). To 
date, there are 28 membrane-bound and secreted vertebrate MMPs, 24 have been 
discovered in humans. Their substrate specificity (Figure 1-4), protein structure and 
localisation in the cell determines their classification (Klein and Bischoff 2011;Tokito and 
Jougasaki 2016) . Amongst the membrane-type MMPs, MMP-14 has collagenolytic activity 
and can degrade collagen I, II and III (Klein and Bischoff 2011). These membrane-type MMPs 
are anchored to the cell surface membrane through a transmembrane domain (type I) or a 
glycosyl-phosphatidylinosotol (GPI) anchor (Elkington et al. 2005b). In comparison, the 
Drosophila melanogaster expresses only two MMPs, DmMMP-1 and DmMMP-2 (LaFever et 
al. 2017) which were initially thought to be soluble and GPI-anchored, respectively, 
however, both possess a GPI-anchoring domain. Interestingly, the mammalian antibodies 
cannot detect the DmMMP-1 and DmMMP-2 confirming that they are not orthologous. The 
full length recombinant proteins DmMMP-1 and DmMMP-2 specifically cleaved casein and 
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gelatin, respectively (LaFever et al. 2017). Despite their substrate specific classification there 
is overlapping ability to degrade certain substrates, for instance the gelatinases can degrade 
different types of collagens. MMP-1 can hydrolyse collagen I, II and III, but more 
preferentially collagen I and III (Davidson 1990;O'Connor and FitzGerald 1994). In vitro, the 
levels of collagen I and III had the most effect on the expression of MMP-1 compared to 
collagen IV (Kerkvliet et al. 2003). This was attributed to the spatial arrangement of 
fibroblasts with respect to the type of collagen. It was suggested that under normal 
conditions type IV collagen makes contact with fibroblasts whereas contact with type I or 
type III collagen is initiated during wound healing when increased cell proliferation is 
required (Kerkvliet et al. 2003). Thus, the spatiotemporal arrangement of the ECM and its 
molecules is essential in the progression of disease. 
Fundamentally all MMPs contain a signal peptide, prodomain, catalytic domain and a 
hemopexin domain (except for MMP-7, MMP-23 and MMP-26) at the C-terminal region 
which partakes in catalysis either in substrate binding and/or recognition. The gelatinases, 
MMP-2 and MMP-9 contain fibronectin type II motifs while the MT-MMPs contain a 
transmembrane and cytoplasmic domain (Klein and Bischoff 2011). The zinc binding motif of 
the catalytic domain comprises three histidine residues (Figure 1-5), HEXXHXXGXXH, which 
coordinate the Zn in the active and inactive form. The role of the prodomain is to prevent 
accessibility of the zinc to a water molecule which is essential for catalysis. This is achieved 
through interaction of the zinc ion with the cysteine residue embedded in the prodomain’s 
so called ‘cysteine switch’ motif, PRCGXPD (Klein and Bischoff 2011;Nagase et al. 2006;Ra 
and Parks 2007). This is represented by the ribbon structure in Figure 1-5. Additionally, 
there are 18 more cysteine residues within the structure including the two located in the 
signal peptide, seven pairs forming disulphide bonds, six located in the fibronectin repeats 
and two in the hemopexin domain, the other two are in hemopexin and in the loop region 
connecting the hemopexin and fibronectin repeat (Khan et al. 2012). During catalysis the 
glutamate residue in the catalytic domain and the Zn polarises the water molecule bound at 
the active site. The water acts as a nucleophile which in turn attacks the Scissile bond 
forming the Michaelis complex with the substrate (Ra and Parks 2007). There has been 
evidence that binding to gelatin or collagen IV induces activity of proMMP-9 via 
perturbation of its prodomain (Bannikov et al. 2002). In the same study the authors 
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highlight the lack of detection of active MMP-9 in vivo in both pathological and normal 
states, also the lack of proMMP-9 detection in tissues which had active MMP-9. In contrast 
to that, cancer cell lines express active forms of MMP-9 (Schröpfer et al. 2010). Others have 
suggested that in cancer cells, active MMP-9 is only present due to the presence of MMP-3 
which activates it (Ramos-DeSimone et al. 1999). Thus, it is crucial to differentiate between 
active and non-active state of MMPs in different types of cells including the comparison 
between control and treated cells. This has implications on the phenotype of the MMP 
degradome. Targeting the proform of MMPs is one of the novel strategies that has been 
developed against proMMP-9 by Scannevin and colleagues (Scannevin et al. 2017).  
MMPs are mainly recognised, as their name implies, for their ability to turn over and 
degrade the extracellular matrix. Also, of equal importance is their ability to process, 
amongst other substrates, the chemokines, cytokines, receptors and antimicrobial peptides 
(Ra and Parks 2007). Therefore, other vital processes they participate in, are immunity, 
apoptosis, cell migration, angiogenesis and wound healing (Zucchi et al. 2013). Their ability 
to localize to the cell surface is highly important with potential roles such as cell adherence 
and migration, invadopodia formation (Garamszegi et al. 2012;Van Doren et al. 
2017;Watanabe et al. 2013) and cell-to-cell signal transduction which may be important in 
progression of diseases (Elkington et al. 2011b). It is hence not surprising that their 
expression and activity are tightly regulated under normal physiological conditions.  
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Figure 1-4 Basic structure and classification of MMPs. Structural components making up 
the different MMPs as per category (left-hand side) are depicted on the right-hand side [The 
picture was taken from (Tokito and Jougasaki 2016)]. 
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Figure 1-5 Cartoon representation of the structure of proMMP-9. The cysteine residue 
from the prodomain (red) is shown to interact with the N-domain’s (blue) catalytic Zinc 
(black sphere). Fibronectin repeats (green) and the 12 cysteines forming disulphide bonds 
are indicated. The HEXXHXXGXXH motif that co-ordinates the Zinc is indicated on the right-
hand side. Also included is the non-catalytic Zinc (orange sphere) and the calcium ions 
(purple spheres) [Generated using PyMOL v0.99 (DelaNo Scientific, 2006); PDB: 1L6J (Elkins 
et al. 2002)]. 
 
 
1.3.2 The expression, secretion and activation of matrix metalloproteases 
Under homeostatic conditions, most of the MMPs are almost undetectable in tissues but are 
inducible in macrophages, fibroblasts, epithelial and endothelial cells (Pardo and Selman, 
2005). They are differentially expressed during tissue remodelling and repair and also 
dysregulated in various diseased states including cancer, immune system disorders, diseases 
of the central nervous system (Fingleton 2008) and of course tuberculosis (Elkington et al., 
2005). Their mode of action in these diseases is mostly through proteolysis of ECM 
components. Once MMPs are secreted, which is in their zymogenic form they are ultimately 
activated in the ECM where they also regulate cell-cell and cell-matrix signalling.  
32 
 
Their catalytic activity is regulated by control of gene expression, compartmentalisation, 
inhibition and by availability of substrate and affinity for the substrate (Ra and Parks 2007). 
MMPs are majorly and specifically inhibited through binding of endogenous tissue inhibitors 
of matrix metalloproteases (TIMPs). Other proteases able to inhibit their activity amongst 
others are α-macroglobulin, a general protease inhibitor and plasmin. As mentioned 
previously, breaking the Zn-cysteine interaction renders the MMP active by either allowing 
direct cleavage of the prodomain by other proteinases or autocatalysis, or reduction of the 
thiol group by oxidants. The prodomain of some MMPs, including MMP-11, MMP-28 and 
most of the membrane-anchored MMPs, MMP-14, MMP-15, MMP-16, MMP-17, MMP-23, 
MMP-24 and MMP-25 contain a furin-like proprotein convertase recognition site which 
allows proteolytic cleavage by furin or other proprotein convertases. This processing, which 
occurs intracellularly prior to secretion is relevant in about one third of MMPs containing 
the furin like protein sequence (Ra and Parks 2007). The furin itself is localised in the trans-
Golgi network and has a secreted form referred to as shed furin (Cao et al. 2005). The rest of 
the MMPs, like MMP-1 and MMP-9, lack this recognition site suggesting they are secreted in 
their zymogenic form (Cao et al. 2005;Watanabe et al. 2001). Proteolytic cleavage of the 
prodomain can also be carried out by other proteins such as plasmin, kallikrein, other serine 
proteases such as trypsin and serine elastase, cathepsins or by other MMPs (MMP-2, MMP-
3 and MMP-13) (Bouchet and Bauvois 2014;Christensen and Shastri 2015;Klein and Bischoff 
2011;Saunders et al. 2005;Shamamian et al. 2001). The non-proteolytic activation of 
proMMPs can be artificially initiated by denaturants such as SDS during zymography or 
organomercuric compounds such as the widely used 4-aminophenylmercuric acetate 
(APMA). These cause allosteric perturbation of the Zn-cysteine interaction that primes 
autolytic and/or proteolytic cleavage of the MMP prodomain (Ra and Parks 2007). 
Activation of proMMPs with mercurial compounds such as APMA are only able to perturb 
the cysteine switch motif by direct interaction with the prodomain’s cysteine residue but 
the MMP and TIMP complex is not perturbed. In addition to reacting to the prodomain’s 
C75 residue, there is evidence of APMA interacting directly with the salt bridge forming 
residues R74 and D29 (Galazka et al. 1996). This was investigated using MMP-3. Production 
of reactive oxygen species can break the Zn-cysteine bond by reducing the thiol group of the 
cysteine residue. 
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Monocytes/macrophages secrete a 92 kDa proform of MMP-9 referred to as proMMP-9. 
The binding of TIMPs to MMPs is crucial and it can either be inhibitory or non-inhibitory. 
This is through direct binding of the TIMPs N-terminal domain to the active site and the 
latter by interaction of the C-terminal hemopexin domain and the TIMP C-terminal domain 
(Hamze et al. 2007;Roderfeld et al. 2007). The secretion and activity of MMP-9 in the 
extracellular matrix is controlled by TIMP-1. This was corroborated in vitro where MMP-9 
was reported to co-localize with TIMP-1 in the Golgi apparatus and not the endoplasmic 
reticulum (Roderfeld et al. 2007) implying that the proMMP-9.TIMP-1 complex forms 
intracellularly prior to secretion. This is true for most cell types, with the exception of 
neutrophils which store and secrete MMP-9 from secondary granules not associated with 
TIMP-1. (Ogata et al. 1995;Roderfeld et al. 2007;Shapiro et al. 1995). Once in the ECM the 
proMMP-9.TIMP-1 can either be processed to yield the active form of MMP-9 or can remain 
in this form which may function to inhibit other MMPs by forming complexes with them 
(Figure 1-6). For example, the ternary complex that forms with MMP-3 abrogates the 
activity of MMP-3 (Figure 1-6), the same inhibitory mechanism occurs with MMP-1 (Ogata et 
al. 1995). Since MMP-3 can activate proMMP-9 in a stepwise manner (Ogata et al. 1992), 
the ternary complex formation may in turn act negatively in regulating the activation of 
proMMP-9.  
The mechanism of activation also defines the subsequent forms of MMP-9 (Roderfeld et al. 
2007). Cleavage of the propeptide accompanying APMA activation has been observed by 
circular dichroism to cause a decrease in the β-sheet content of MMP-2 (Crabbe et al. 1996) 
implying activation causes conformational perturbation. Activating the MMP-9.TIMP-1 
complex with APMA yields the ‘classic’ active 82 kDa form while activation with MMP-3 
yields the 82 kDa form which is further processed to the 50 kDa inactive form. Interestingly, 
incubating MMP-9 that is not in complex with TIMP-1 using APMA causes the conversion of 
the 92 kDa form to the 82 kDa followed by the 74 kDa intermediate within an hour of 
incubation. After four hours of incubation with APMA the 74 kDa intermediate is further 
converted to the 67 kDa active form lacking the C-terminal hemopexin domain. This 
suggests that the lack of further processing of MMP-9.TIMP-1 to the 67 kDa species is due to 
stabilisation of the C-terminal hemopexin by the TIMP-1. This 67 kDa form cannot be 
inhibited by TIMP-1 (Rossano et al. 2014). The C-terminal hemopexin domain does not show 
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any activity in zymography but its binding affinity to gelatin has been reported to be 
comparable to that of TIMP-1. Interestingly this domain has been reported to reduce the 
activity of MMP-9 (Roeb et al. 2002) This was demonstrated by use of gelatin zymography 
the activity of MMP-9 (1 ng and 0.2 ng) was inhibited by 61 and 71%, respectively. The 
inhibition was via its high affinity for gelatin rather than an antagonistic effect to MMP-9 
(Ugarte-Berzal et al. 2016) since other substrates could be hydrolysed with the same 
efficiency despite the presence of the hemopexin domain. 
 
Figure 1-6 Activation of proMMP-9.TIMP-1 complex. Activation of the proMMP-1.TIMP-1 
complex by MMP-3 (or other MMPs) and APMA/Trypsin.  The proMMP-9.TIMP-1 complex 
inhibits MMP-3 (in other case MMP-1) with the MMP-9 catalytic site unbound [Picture is 
adapted from (Ogata et al. 1995)].  
Under physiological conditions the C-terminal hemopexin domain of MMP-9 has been 
observed to inhibit not only angiogenesis an important factor that influences cavitation but 
also the migration of neutrophils and of colorectal cancer cells (Burg-Roderfeld et al. 
2007;Spiller et al. 2011). MMPs form part of the major subgroup of the hemopexin 
superfamily. The hemopexin domain is associated with substrate recognition and binding, 
and has been reported to be responsible for the initial and local unwinding of the triple-
helical collagen (Chung et al. 2004) which is followed by cleavage of the peptide bond at the 
unwound site.  
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Apparently, collagen binds at a pocket between the N- and C-domain and not directly to the 
hemopexins four-bladed propeller (Chen et al. 2011) which is affiliated with substrate 
recognition and binding.  
Activation of proMMP-9 by trypsin cleavage of the propeptide has also been shown to be a 
stepwise process (Duncan et al. 1998), where complete cleavage to the 67 kDa form is 
observed after a 3-hour incubation with trypsin.   
MMP-14 also referred to as membrane-type 1 matrix metalloprotease (MT-MMP-1) is a 
membrane bound collagenase that is also regulated by autolytic degradation, shedding, 
oligomerization and membrane trafficking (Wu et al. 2004). It is expressed as a 68 kDa 
zymogen containing a furin cleavage site which allows processing to the active 55 kDa form. 
Further cleavage at the linker region yields an inactive 34 kDa form (Wu et al. 2004). Only 
TIMP-2 and not TIMP-1 can inhibit MMP-14, and of importance is that the complex 
formation between TIMP-2 and MMP-14 catalyses the activation of proMMP-2. This ternary 
complex occurs via interaction of the TIMP-2 catalytic domain of MMP-14 and C-terminal 
hemopexin domain of proMMP-2.  
 
 
1.3.3 Glycosylation of MMPs and effect in protein-protein interactions  
Post-translational modification is a process that is exploited by cells for the modulation of 
proteins by specifically attaching chemical moieties to amino acids.  This adds another layer 
of complexity and diversity to the functionality of proteins with respect to signal 
transduction, substrate (inhibitor) recognition/binding, metabolism, protein stability, folding 
and secretion. To date there are 200 types of PTMs that have been identified, these include 
glycosylation, phosphorylation, acetylation, ubiquitination, sumoylation, methylation and 
other forms (Kotra et al. 2002;Prabakaran et al. 2012). 
Glycosylation involves the addition of oligosaccharides via N-glycosidic and O-glycosidic 
bonds. These modifications occur during translation and after folding in the Golgi and trans-
Golgi, respectively (Boon et al. 2016). Glycans are important for the correct folding of 
proteins, protein-protein interactions and interaction of proteins with cell surface 
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molecules. Of all the MMPs, MMP-9 possesses the most glycosylation sites (Boon et al. 
2016) with proMMP-9 having three N- and several O-glycosylation potential sites.  
The O-glycosylation sites are mainly at the hinge region (Kotra et al. 2002) which comprises 
a proline rich stretch like α2(V) chain of collagen V. 14 potential sites are clustered in 50 
amino acid region, thus MMP-9 is referred to being mucin-like in structure (Boon et al. 
2016).  
O-glycosylation has also been reported to influence the binding of its inhibitors including 
TIMP-1, LRP-2 (lipoprotein receptor-related protein-2) and LRP-1 (Duellman et al. 2015), the 
latter being essential for the re-internalisation of MMP-9. Also, this O-glycosylation site 
increases affinity for Gal-3 (Fry et al. 2006;Tandon and Sinha 2011). The N-glycosylation sites 
are at positions N38, N120 and N127 of the prodomain and the latter two at the catalytic 
domain, though the N127 site which is close to the gelatin binding domain is inaccessible to 
modification because of it being shielded from the solvent. (Kotra et al. 2002). However, the 
authors report that the N120 residue although being shown to be glycosylated does not 
partake in catalysis and substrate recognition suggesting another potential function for it. 
Interestingly desialyation has been reported to increase the activity of MMP-9 by perturbing 
its interaction with TIMP-1 (Boon et al. 2016;Wu et al. 2004).   
Unlike MMP-9, MMP-14 (MT1MMP) contains only O-glycosylated sites, four in total, located 
in the linker region which is predicted to be important for catalysis. However, glycosylation 
is not important for collagenolysis but was found to be crucial for activation of proMMP-2. 
The authors suggest that a defect in MMP-14 glycosylation MMP-14 impairs the ability of 
TIMP-2 to facilitate its endocytosis hence affecting the activation of proMMP-2 (Wu et al. 
2004). Differential glycoforms of MMP-14 were found in different cancer cell lines which 
suggests a role in pathology. Therefore, glycosylation may act as a regulatory mechanism 
that leads to differential MMP phenotypes repurposing their physiological functioning.  
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1.4 The role of matrix metalloproteinases (MMPs) in TB cavitation 
The role of MMPs in M. tb granuloma and cavity formation has been emphasized (Elkington 
et al. 2011a;Elkington et al. 2007;Elkington et al. 2005a;Reece and Kaufmann 2012;Salgame 
2011). Their role in TB cavitary pathogenesis is evolving, with particular interest in MMP-1 
and MMP-9. Increased levels of MMPs, specifically MMP-9, were first identified in the 
bronchoalveolar fluid (BALF) of a TB patient (Chang et al. 1996). Severity of the disease as 
per extent of pulmonary lesion was later correlated with an increase in the levels of MMP-9 
from the sera of TB patients (Elkington et al. 2007;Elkington et al. 2005a;Hrabec et al. 2002). 
Its function in granuloma cell recruitment and maturation, first reported in the zebra fish 
model is a well-documented phenomenon (Davis and Ramakrishnan 2009;Reece and 
Kaufmann 2012). This was also validated by use of MMP-9 knock-out mice which were 
shown to develop smaller granulomas with lesser macrophages recruited to the site of 
infection (Elkington et al. 2011a). Similarly, elevated levels of MMP-1, -2, -8 and -9 were 
detected in the pleural fluid of TB patients compared to those with heart failure (Elkington 
et al. 2011b) suggesting that M. tb is deliberately driving the upregulation MMPs.  
Distribution of overexpressed MMPs varies within the cell types making up the granuloma. 
MMP-1 and MMP-7 were expressed in epithelioid and Langerhans cells, MMP-1 and MMP-9 
in pulmonary epithelial cells and MMP-9 in epithelioid and multinucleated giant cells in 
tuberculosis of the lymph node (ref). Also, of note is that granulomas in an infected 
individual tend to vary in terms of their protein expression profile having an influence in the 
inflammation/immune response and ability to contain bacterial growth (Via et al. 2015). In 
granulomas of patients with tuberculosis of the central nervous system MMP-1, MMP-3 and 
MMP-9 were elevated (Elkington et al. 2011b). However, the levels of TIMPs in the above-
mentioned studies were not elevated, again suggesting that M. tb infection induces this 
imbalance either as a host protective mechanism or for bacilli propagation. Mycobacterial 
factors that induce MMPs have not been investigated exhaustively. But, the Mycobacterium 
factor ESAT6 (early secretory antigenic target-6), is reported to stimulate MMP-9 expression 
in epithelial cells which in turn recruited new monocytes and macrophages to maintain 
granuloma formation and maturation (Davis and Ramakrishnan 2009;Volkman et al. 2010).  
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Animals have been used as models for TB studies, although they do not represent the 
complete repertoire of TB in humans (Converse et al. 1996;Elkington et al. 
2011a;Nedeltchev et al. 2009). For instance, infected mice form cellular-like granulomas, 
but caseation and cavitation do not occur, similarly, guinea pigs form caseous necrosis 
without progression to cavitation. In rabbits though, necrotic granulomas do form with 
caseation, but only under certain conditions does liquefaction occur accompanied by 
cavitation (Nedeltchev et al. 2009). Of importance is that animals which do develop 
pulmonary cavities including humans, primates and rabbits have a conserved ortholog of 
MMP-1 (Elkington et al. 2011a). Also, mice do not express MMP-1 but its closest human 
ortholog McolA, is distantly related to it and shares only 58% amino acid identity (Pardo and 
Selman 2005). This strongly suggests that the lack of MMP-1 in mice is responsible for the 
lack in progression of disease to cavitation upon infection with M. tb. Even so, the mouse 
model has yielded key input in the probable role of MMP-1 in TB cavitation.  
In wildtype mice infected with M. tb, McolA, MMP-8 and MMP-13 were not upregulated in 
the lungs, however McolA was expressed in the testis. M. tb infected MMP-1 transgenic 
mice depicted extensive damage of the lung tissue, but the architecture of the granuloma 
was unaffected, and the bacterial load was not increased. This led to the critical conclusion 
that ECM destruction and granuloma necrosis occur as separate events (Elkington et al. 
2011a;Elkington et al. 2005a).  
Granted that the mouse model has greatly facilitated the accumulated understanding of TB 
pathogenesis, it is even more crucial to note the importance of using the correct model 
since differences that maybe thought to be insignificant can in fact be fundamental in the 
pathophysiology of disease. The findings also give a strong indication that M. tb deliberately 
induces upregulation of MMP-1 and downregulation of TIMPs to yield an ECM degrading 
phenotype followed by cavity formation to promote dissemination. Children rarely form 
cavities upon M. tb infection. Interestingly, like adults, the MMPs are also upregulated, 
including MMP-1, MMP-7 and MMP-8 but in contrast the TIMPs (TIMP-1 and TIMP-3) are 
also elevated (Pavan Kumar et al. 2013).      
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Mycobacterial factors which drive these MMP upregulation have not been fully elucidated, 
however, M. tb strains which lack the region of difference 1 (RD1) gene, failed to cause 
MMP-1 upregulation, ECM damage and immunopathology (Elkington et al. 2011a;Elkington 
et al. 2011b). This RD1 gene which expresses the ESAT-6 and CFP-10 proteins, which are 
potent T-cell activators is absent in BCG, a strain which cannot cause cavities in humans 
(Dheda et al. 2010;Elkington et al. 2007). This suggests that the RD1 is a vital component in 
the pathogenesis of cavitation in humans.  
In addition, M. tb-infected macrophages secrete detectable levels of MMP-1 compared to 
lipopolysaccharide (LPS) stimulated macrophages, whereas both LPS and M. tb increased 
MMP-7 secretion (Elkington et al. 2005a). Chang and colleagues have also indicated an 
upregulation of MMP-1 and MMP-9 mRNA when differentiated THP-1 macrophages were 
treated with lipoarabinomannan (LAM), one of the key components of the M. tb cell 
conferring virulence to the bacilli. An increase in MMP-9 activity correlated with increase in 
concentration of LAM treatment was also indicated by gelatin zymography (Chang et al. 
1996).  Since LAM is one of the breakdown products from the cell wall of M. tb it has been 
researched as a biomarker for TB (lung TB and TB pericarditis) diagnosis, however the 
mechanism by which it is processed and excreted in the kidney remains to be elucidated. 
Interestingly co-infection with HIV (with CD4 less than 100 cells/mm3) enhanced the 
sensitivity of the urinary LAM diagnostic performance (Pandie et al. 2016).  
It is also interesting to note that patients co-infected with HIV rarely present with cavitary 
TB (Munthali et al. 2014). In these patients and HIV negative controls MMP-1 was 
upregulated, however, the concentration of TMP-1 was lower in the latter (Elkington et al. 
2011a). The ECM degrading phenotype characterised by elevation of MMPs is also depicted 
in sarcoidosis, a granulomatous pulmonary disease of unknown etiology. Like TB, 
bronchoalveolar fluid from sarcoidosis patients contained elevated levels of MMP-1, MMP-
8, MMP-9 and MMP-13 with high collagenase activity. But cavitation is rarely reported in 
sarcoidoisis, which means additional/differential factors and pathways are required in TB 
cavitation that have not been fully understood. 
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1.5 Interaction of MMPs with other proteins 
Protein-protein interactions are essential in regulating the function of proteins either as 
inhibitory or activating. Also, matrix metalloproteases have a broad spectrum of substrates 
aside from components of the ECM (Morrison et al. 2009) including CTGF, IL-8, APOE, 
Galectins, S100A8, S100A9, TNFα-pro and many others. They can also form complexes with 
other proteins, for example MMP-9 has been shown to form complexes via its C-terminal 
hemopexin domain suggesting a regulatory role with the respective proteins. These proteins 
include TIMPs, other MMPs, α2-macroglobulin, kallikrein, neutrophil gelatinase-associated 
lipocalin amongst others (Vemula et al. 2016). Neutrophil gelatinase-associated lipocalin 
and α2-macroglobulin have been shown to form disulphide bonds with the hemopexin 
domain. Since Mycobacteria is well-known for its ability to surpass the hosts immune and 
inflammatory system through the manipulation of its signalling pathways, better 
understanding of these pathways is thus important. 
 
 
1.5.1 Pathways and intercellular networks involved in the regulation of 
MMPs  
Two major pathways, p38 and extracellular signal-related pathway/mitogen activated 
protein kinase (ERK/MAPK) function in most cell types and they respond to direct M. tb 
infection and through cell-to-cell interactions. In macrophages, cyclooxygenase-II (COX II) 
and prostaglandin (PGE2), which are downstream p38 have a predominant function. 
Treatment of TB by the COX targeting drug p-amino salicylic acid (PAS) has proven 
efficacious when administered with other TB drugs and it has been suggested to attenuate 
tissue distraction by inhibiting MMP-1 expression. At the transcriptional level, M. tb-induced 
MMPs are regulated by NFκB, activator protein-1 (AP-1) and signal transducer and activator 
of transcription 3 (STAT-3) signalling pathways.  
The imbalance in the MMPs/TIMPs ratio in cavitary TB has been associated with the lack of 
promoter binding region of TIMP-1 (Elkington et al. 2011b) although other studies have 
discovered the presence of NFκB regulatory site about - 2.7 kb upstream of the TIMP-1 
transcription site (Wilczynska et al. 2006). In addition to that, NFκB interacts with ESAT-6, 
this interaction might be essential in regulating the transcription of MMPs. Therefore, 
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different pathways may be switched on/off at different stages of infection to skew the ratio 
toward an increase in MMPs. Once these pathways are thoroughly understood then 
potential drug targets can be identified. These targets may have greater therapeutic 
potential over MMPs, which have diverse function in tissue homeostasis.  
In TB pathology, intercellular networks are also integral in driving MMP expression. It has 
been shown that MMP-9 is upregulated by monocyte-monocyte networks; MMP-1 and 
MMP-9 are upregulated by monocyte-epithelial cell networks; and MMP-1 and MMP-3 are 
upregulated by monocyte-fibroblast networks whereby the latter is also able to activate 
MMP-1 (Elkington et al. 2005a;O'Kane et al. 2008). Through intercellular networks the 
upregulation of MMP-1 is not induced by a single cytokine but by a combination of two or 
more of the Th1 cytokines (Zhou et al. 2003). These cytokines include TNF-α, IL-1β, IFN-γ 
and GM-SCF. IFN-γ and GM-CSF stimulate the production of TNF-α resulting in the 
production of MMP-1 in macrophages (Zhou et al. 2003). Cytokine stimulation of MMP-1 is 
PGE2-dependent, like LT4AH it is lipid-based inflammatory molecule. In contrast MMP-9 and 
TIMP-1 stimulation is PGE2-independent in macrophages (Zhang et al. 1998b). Stimulation of 
MMP-9 by cytokines is higher compared to LPS which is PGE2-dependent. In contrast 
macrophages stimulated with LPS released higher amounts of MMP-1 compared to 
cytokines. Also, MMP-9 and TIMP-1 could be induced by presence of the Th1 cytokines TNF-
α, IL-1β or GM-CSF. MMP-1 was only detectable in the presence of GM-CSF with TNF-α or 
IL-1β or all three cytokines (Zhang et al. 1998b). This difference in the induction of MMP-1 
and MMP-9 implies that they may be required at different stages of M. tb infection. The Th2 
cytokines, IL-4 and IL-10 inhibited MMP and TIMP-1 expression via PGE2.  
Since cytokines are reported not to be upregulated in patients with TB, it means stimulation 
of MMP-1 in vivo, requires additional factors including Mycobacterial factors. A significant 
upregulation of MMP-1 and MMP-3 was observed when human fibroblasts were stimulated 
with a combination of cytokines, including TNF-α and oncostatin M (O'Kane et al. 2008;Wolf 
et al. 2011). Oncostatin M is a member of the IL-6 family and is said to be pro-angiogenic. It 
is expressed in monocytes and T-lymphocytes upon stimulation with LPS. MMP upregulation 
by OSM is PGE2-dependent. In contrast, TIMP-1 and TIMP-2 were significantly 
downregulated.  
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1.5.2 Effects of MMPs on angiogenesis: Dissociation of the CTGF.VEGF165 
complex 
Angiogenesis does not only play a major role in the pathology of TB and its progression but 
also in drug therapy. The early stages of granuloma formation are characterised by 
neovascularisation of the tubercle which has been attributed to a response in the VEGF 
signal (Korb et al. 2016). The increased blood vessels indicate that there is migration of 
dendritic cells, macrophages and lymphocytes to the infected area. When the serum levels 
of VEGF from patients with active and inactive pulmonary TB, and healthy controls were 
compared, levels were higher for active TB followed by inactive TB and healthy controls, 
respectively (Alatas et al. 2004). 
Besides its collagenase activity MMP-1 has diverse functions in apoptosis, immunology and 
angiogenesis. In addition to collagen, MMP-1 can degrade other substrates including the 
connective tissue growth factor (CTGF), which is a downstream mediator of TGF-β. CTGF, 
also known as CCN2 belongs to the CCN family of extracellular matrix-associated heparin-
binding proteins. Its functions include angiogenesis, ECM production, integrin expression 
and wound healing. Also, notably, it promotes granulation tissue formation (Hashimoto et 
al. 2002;Inoki et al. 2002). CTGF can complex with and inactivate the angiogenic factor 
VEGF165. VEGF-A occurs in various isoforms that originate from alternative splicing of the 
same gene. The isoforms include VEGF121, VEGF145, VEGF189, VEGF206 and VEGF165. VEGF165 
and VEGF121, they are reported to have the greatest influence on angiogenesis and may 
account for about 98% of the expressed VEGF-A (Ozaki et al. 2002).  
The most abundant isoform in the lungs is VEGF165 (Marwick et al. 2006). VEGF121, VEGF165, 
and VEGF189 are expressed in most tissue types, including human chondrocytes that form 
normal cartilage and to a larger extent in cartilage of osteoarthritis and rheumatoid arthritis. 
These tissues are known to be resistant to angiogenesis and the inhibition of VEGF by CTGF 
has been implicated in this phenomenon through the formation of the CTGF.VEGF165 
complex (Inoki et al. 2002). This complex has been localised to the extracellular matrix and 
CTGF has been said to anchor VEGF165 to the extracellular matrix (Burgess et al. 2006).  
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Since both CTGF and VEGF are susceptible to degradation by proteolytic enzymes it would 
seem that the complex is a regulatory mechanism which can be disrupted by proteolysis 
(Hashimoto et al. 2002). MMP-1, MMP-2, MMP-3, MMP-13 and MMP-14 are able to 
degrade CTGF and not VEGF165 which itself is degradable by plasmin, chymotrypsin and 
elastase. MMP-9 slowly degrades CTGF, while MMP-3 and MMP-13 degrade CTGF more 
efficiently than other MMPs including MMP-1. In the same study, it was found that the 
MMP cleavage sites are identical when incubation was with CTGF alone and with CTGF in 
complex with VEGF165 given that the degradation fragments were identical. Some of these 
degradation fragments were detected in breast carcinoma (Hashimoto et al. 2002). Once 
VEGF165 is released from the complex it is reactivated to induce angiogenesis. Therefore, it is 
important to investigate the influence of M. tb infection on the regulation of CTGF, VEGF165 
and CTGF.VEGF165 complex formation in correlation to proteolysis by MMP-1 compared to 
MMP-9. This may give an indication of the possible roles of these MMPs in tissue 
remodelling at different time points of M. tb infection.  
  
 
1.5.2.1 The role of angiogenesis in the pathology of tuberculosis 
Extracellular membrane degradation can cause the release of the ECM/basement 
membrane-sequestered angiogenic factors such as VEGF, TGF-β and bFGF (Benjamin and 
Khalil 2012). Angiogenic factors can induce the expression of MMPs, and in turn the MMPs 
can increase their bioavailability. This induction of MMPs has been demonstrated in 
endothelial and stromal cells. The positive feedback loop may be another possible 
explanation for the upregulated MMP-1 and -9 in cavitary TB. Upregulation of VEGF has 
been reported in sarcoidosis and active pulmonary TB (Zucchi et al. 2013). Abe and 
colleagues investigated the relationship of VEGF with cavity formation in active pulmonary 
TB (Abe et al. 2001). Their study compared the serum levels of VEGF and cytokines (TNF-α 
and IL-8) between patients with cavities and those without cavities. VEGF was higher in the 
non-cavity group and the cytokine levels were not significantly different between the two 
groups. They concluded that overexpression of VEGF causes increased generation of blood 
vessels and oxygen supply, which hinders the formation of cavities in TB (Abe et al. 2001). 
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In another study which highlighted the role of angiogenesis in TB, Zielonka and colleagues 
examined the number of microvessels formed in mice post injection with lymphocytes or 
mononuclear cells (MNC) pre-treated with sera from TB patients or healthy donors (Zielonka 
et al. 2011). There was a significant decrease in the number of microvessels when mice 
were treated with lymphocytes pre-treated with TB sera compared to the MNC treated with 
same sera. In contrast, lymphocytes treated with sera from healthy donors caused a 
significant increase in number of microvessels compared to injection with MNC treated with 
same sera (Zielonka et al. 2011). The authors then concluded that M. tb infected monocytes 
develop a matrix-degrading phenotype which initiates angiogenesis. The anti-angiogenic 
role of CTGF has not been investigated in the pathogenesis of TB cavitation but it may be 
acquired for resistance to VEGF-induced angiogenesis leading to cavitation. In systemic 
sclerosis (SSc) fibroblasts, CTGF silencing with specific siRNA caused increase in MMP-1 and 
decreased TIMP-1 and collagen type I after stimulation with TGF-β (Ishibuchi et al. 2010). In 
contrast, the fibroblasts of normal subjects showed decreased collagen type Ι after 
stimulation with TGF-β and no increase in MMP-1. Therefore, there may be some overlap in 
the pathways that regulate the expression of MMP-1 and CTFGs 
Both CTGF and VEGF have been implicated in the pathophysiology of cancer, including 
MMPs which have influence on tumour metastasis and invasion. In non-small cell lung 
cancer (NSCLC), administration of Bevacizumab, a monoclonal antibody targeting VEGF-A, 
although beneficial caused cavitation in the pulmonary lesions (Nishino et al. 2012). 
Cavitation occurred in 14% of patients treated with Bevacizumab and in another study 
where VEGF inhibitor was used, 24% of those patients developed cavities (Nishino et al. 
2012). Some of these patients also showed interstitial abnormalities. Its thus not surprising 
that recent evidence suggests that Mycobacteria exploits angiogenesis for its own growth 
and dissemination (Oehlers et al. 2015;Polena et al. 2016). Therefore, it is critical to 
investigate the role of angiogenic factors in TB cavitation.  
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1.6 Infection of THP-1 macrophages with Mycobacterium smegmatis as an in 
situ model 
The illustration of what manifests in situ during disease states by using systems in vitro 
poses various limitations one being choosing models that would closely resemble the 
system being studied. Phenotypic differences in macrophages are associated with their 
origin (e. g cell line, primary, human, mouse) accounting for the differences in their 
properties and interaction with Mycobacteria hence having the possibility of eliciting 
responses that differ slightly or majorly to the state in situ. Ultimately, downstream 
conclusions should be taken with careful consideration. Although the use of monocyte-
derived macrophages (MDM) over cell line macrophages would be ideal for mimicking 
alveolar macrophages, there are advantages to using cell line macrophages further 
elaborated below. The THP-1 cell line was first established in the 1980s by Tsuchiya and 
colleagues (Tsuchiya et al. 1980), and it was derived from a male patient with acute 
monocytic leukaemia. They are morphologically alike primary monocytic cells. Post-
differentiation with phorbol-12-myristate-13-acetate (PMA) these cells acquire the 
repertoire of monocyte-derived macrophages including a flat spindle-shaped like 
morphology that is adherent to the culture plate, with a low rate of proliferation and a 
higher rate of phagocytosis than do monocytic cells.  
In addition to that, the THP-1 macrophages overexpress markers such as CD11b, acquire 
free ribosomes in abundance, and have well-developed Golgi apparatuses and rough 
endoplasmic reticula (Qin 2012). This makes them ideal and still relevant to date in 
mimicking in vivo conditions since they resemble primary and monocyte-derived 
macrophages. There are advantages to using these cells over monocyte-derived 
macrophages including longer periods of survival (in both liquid nitrogen storage and in 
culture), no donor variability and purification steps making them good for experimental 
reproducibility. Other studies have demonstrated successfully the exploitation of THP-1 
macrophages as models of alveolar macrophages e.g. in M. tb-induced apoptosis (Riendeau 
and Kornfeld 2003), several studies have used the THP-1 macrophages as host response 
models mimicking Mycobacterium infections as it occurs in vivo (Kaewseekhao et al. 
2015;Stokes and Doxsee 1999;Theus et al. 2004;Wong et al. 2018). Direct comparison 
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between differentiated THP-1 macrophages and monocyte-derived macrophages indicated 
that the percentage of macrophages that interacted with M. tb did not differ between the 
two, however the percentage of MDM’s with bound zymosan were higher when compared 
to the THP-1 macrophages (Stokes and Doxsee 1999). The authors implied this being 
attributed to low expression levels of glucan and mannan receptors by the latter. Killing of 
the intracellular bacteria by isoniazid was similarly efficient between the cell types. 
Therefore, the similarity or contrasts of the elicited response depends on what is being 
investigated.  
Mycobacterium smegmatis (M. smeg) which acquired its name in 1885 after isolation from 
human smegma (Reyrat and Kahn 2001) has been widely used as a model for the virulent M. 
tuberculosis because of its fast-growing, less laboriously intensity and ease of genetic 
manipulation nature. It has contributed immensely in understanding the pathogenesis of 
tuberculosis and drug development albeit its inability to disseminate in humans. Thus far, it 
has been established/estimated that its genome is approximately twice as large as that of 
M. tb and about 69.8% of 4034 of proteins encoded in M. tb (H37Ra) have orthologues in 
M. smeg (Altaf et al. 2010). In the same study, it was found that 48 to 58% of a library of 
inhibitors that were active against M. tb were effective in deterring the growth of M. smeg. 
Even so the discovery of the clinically used therapeutic drug diarylquinolines was discovered 
by using M. smeg. The dormancy of M. tb has been successfully modelled using M. smeg 
owing to the shared similarity of the responding genes from both strains to host conditions 
that trigger this phenomenon (Shiloh and Champion 2010). Therefore, the data 
extrapolation from infection model systems can serve as hypotheses of what occurs in situ 
and guide the process of drug discovery. 
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1.7 Aims and objectives 
It is hypothesized that proteases, such as MMP-1 and MMP-9, including their effectors are 
involved in the macrophage response to Mycobacterial infection. Thus, the aim of the study 
was to evaluate the role of MMP-1 and MMP-9 including their effectors during a time 
course infection with Mycobaterium smegmatis. 
This was achieved by: 
1. Harvesting at different time points the lysate and media from differentiated THP-
1 monocytes that are uninfected and infected with M. smeg.  
2. Comparing the extracellular and intracellular activity of MMP-1 and MMP-9 
between uninfected and infected, also between the different harvest time 
points.  
3. Identifying upstream and downstream effectors of MMPs that may be 
influencing their activity and expression through generating proteomic data by 
mass spectrometry. This will be accomplished by: 
o Quantifying (label free) differentially expressed proteins 
(uninfected versus infected proteome, and between different time 
points). 
o Characterise the differentially expressed and secreted proteins 
and those that are exclusively expressed/secreted using gene 
ontology terms. STRING will then be used to assess if any of these 
proteins interact with MMP-1 or MMP-9 directly/indirectly and 
pathways that may influence their dysregulation will be mapped 
out. 
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Chapter 2 
 Materials and methods 
 
2.1 Tissue culture 
 
2.1.1 Maintenance of the THP-1 human monocytic cell line in culture 
The THP-1 cells, first described by Tsuchiya and colleagues (Tsuchiya et al. 1980) were 
proliferated and cultured in suspension using RPMI-1640 media containing 10% FCS, 100 
U/ml penicillin and 100 µg/ml streptomycin and incubated at 37 °C in a humidified 
atmosphere of 5% CO2. Media change was done every second day. To ensure their viability, 
the cell density was kept between 2 x 105 and 2 x 106 cells/ml. If the cell density is above or 
below this density, clumping occurs, and cells grow very slowly or stop dividing. When the 
cells reached ~ 1 x 106 cells/ml, they were split, this was usually between 48 and 72 hours.  
 
2.1.2 Proliferation of THP-1 cells from frozen ampoules and preparation of 
stocks 
To proliferate cells from frozen ampoules, the vial containing cells was thawed and the 
contents were immediately dispensed into a falcon tube containing 10 ml of pre-warmed 
RPMI-1640 media. Centrifugation was carried out at 200 g for 3 minutes. After decanting 
the supernatant, the pellet was re-suspended to homogeneity in 5 ml of warm media by 
gently aspirating up-and-down with a pipette. This step was done to wash off the dimethyl 
sulfoxide (DMSO) used as an antifreeze agent. It has been documented that DMSO can 
induce monocyte differentiation and lysis by upregulating TNF (Depraetere et al. 1995).  
The cell suspension was then transferred into a T25 flask and incubated overnight in a 
humidified 37 ⁰C incubator with 5% CO2. After 24 hours, the media was changed by 
centrifuging at 200 g for 3 minutes and the re-suspended cells were left to proliferate to a 
cell density of 1 x 106 cells/ml. These were then split accordingly. 
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Preparation of freezer stocks entailed growing cells until a cell density of ~ 1 x 106 cells/ml in 
a T150 flask with media volume of 20 ml. Cells were spun down at 200 g for 3 minutes and 
the pellet was re-suspended in 4.75 ml of ice-cold 100% FCS. The falcon tube containing the 
cell suspension was kept on ice while gently aspirating the contents to ensure homogeneity. 
To preserve the cells from the harsh freezing conditions, 250 µl of DMSO was added in a 
drop wise manner to the cell suspension before dispensing 1 ml aliquots into five cryotubes. 
The ampoules were frozen slowly using a freezing container or “Mr Frosty” (NalGeneTM, 
Cryo 1 °C freezing container, Catalogue No: 5100-0001) and stored at – 80 °C for 48 hours 
before transferring to a liquid nitrogen tank. The ampoules were reconstituted to check for 
viability and mycoplasma infection before transferring to a liquid nitrogen tank. 
 
 
2.1.3 Differentiation of human THP-1 monocytes to macrophages using PMA 
and preparation for infection 
Macrophages are more potent MMP secretors than monocytes (Elkington et al. 2005a). To 
differentiate the cells, phorbol 12-myristate-13-acetate (PMA also known as TPA), which is a 
widely used differentiation agent was used throughout the experiments (Tominaga et al. 
1998). Once the macrophages are treated with PMA they stop growing and adhere to the 
culture plate. The cells were counted four times using a Neubauer haemocytometer before 
seeding at 2 x 106 cells/ml in a 10 cm dish. Cells were re-suspended in media containing 20 
nM PMA and left to differentiate for 72 hours. The cells were rested and starved with FCS-
free RPMI-1640 media for 6 hours prior infection or treatment. 
 
 
2.1.3.1 Evaluation of optimum PMA concentration on CD11b expression using 
fluorescence-activated cell sorting (FACS) 
The differentiation of monocytes to macrophages is accompanied by the expression of cell 
surface markers such as CD11b which is expressed at very low levels in monocytes. 
Therefore, THP-1 monocytes were treated with different concentrations of PMA and plated 
on six-well plates at 1 x 106 cells per well. The concentrations used included 0, 10, 20 and 
100 nM PMA where incubation was allowed for 72 hours. The PMA-containing media was 
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then discarded, and the cells were rested in RPMI media. Pre-warmed lidocaine (600 µl per 
well) was used to lift the adherent cells (a sterile syringe was used to scrape the cells off the 
plate as most of them were still adherent even after 5 minutes of incubation at 37 °C). 
Lidocaine is preferred over trypsin-EDTA for this experiment because it is thought that the 
CD11b receptor may be solubilised with trypsin-EDTA treatment. The cells were pelleted by 
centrifuging at 350 g for 5 minutes at 10 °C and re-suspended in FACS blocking buffer (5% 
BSA in PBS). These were incubated for an hour on ice. Following that, the cells were pelleted 
and re-suspended in FACS blocking buffer (100 µl per well), either containing CD11b (PE-Cy7 
conjugated) antibody (10 µl) or no antibody, for each PMA treatment. Since the fluorophore 
is light sensitive, the cell-antibody (or no antibody) suspension was incubated in the dark 
and on ice for an hour. Again, the cells were centrifuged and re-suspended in FACS wash 
buffer (0.5% BSA in PBS), this was done three times. Finally, the cells were re-suspended in 
FACS fix buffer (300 µl of 1% (v/v) formaldehyde in FACS WASH) and analysed using FACS 
Aria cell sorter. The BD FACSDIVA software, version 6.1.3 was used.  
To further ascertain the effects of PMA, the morphological changes were captured using 
phase contrast microscopy. THP-1 monocytes were plated in 35 mm dishes at 1 x 106 cells 
per well and incubated with 20 nM PMA or without PMA.  
 
 
2.2 Proliferation of Mycobacterial smegmatis (M. smeg)  
The non-pathogenic and fast growing, Mycobacterium smegmatis is a widely used model of 
Mycobacterium tuberculosis and was thus employed in this study. 
 
 
2.2.1 Proliferation of Mycobacterium smegmatis from freezer stocks 
To grow M. smeg, 7H9 media containing OADC and 0.05% Tween-80 was inoculated with 
M. smeg freezer stocks at a 1:100 ratio. The culture was incubated at 37 °C with shaking at 
225 rpm until OD580 between 0.6 and 1. It took between 22 and 30 hours to reach the 
respective OD580 reading 
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2.2.2 Glycerol stock preparation 
Glycerol stocks were prepared by growing M. smeg until OD580 between 0.6 and 1 in 7H9 
media. The culture was mixed 1:1 with 50% glycerol to make up 1 ml stocks and these were 
kept at -80 °C freezer.  
 
2.2.3 Infection of THP-1 macrophages with Mycobacterium smegmatis 
The infection of differentiated THP-1 macrophages was done at an MOI (multiplicity of 
infection) of 1:10 (i.e. macrophage: bacilli). The macrophage monolayer (1 x 106 cells) was 
prepared as explained in section 2.1.3 before adding the bacterial suspension. When the 
optical density of the growing bacteria reached between 0.6 and 1, 5 ml was pipetted into a 
falcon tube and centrifuged for 10 minutes at 4000 rpm. Two washes with PBS buffer 
containing 0.05% Tween-80 was performed, followed by another wash with FCS-free RPMI 
media. Ultimately, the macrophages were incubated in media containing bacilli (1 x 107 
cells) at 37 °C for an hour to allow phagocytosis. At this point the harvested media and 
lysate were referred to as the 1-hour time point. For the remainder of the non-harvested 
wells, the bacilli containing media was removed and extracellular bacteria was removed by 
washing three times with warmed FCS-free RPMI. Thereafter, the uninfected and infected 
cells and media were collected at different time points. Two biological replicates were 
carried out. The media was filter sterilised using a 0.2-µm syringe filters. The cells were 
lysed on ice using 500 µl of 1 X RIPA lysis buffer also containing a cocktail of protease 
inhibitors and DNase [3X RIPA lysis buffer recipe: 150 mM NaCl, 100 mM Tris HCl, 0.5% 
Sodium deoxycholate, 1% SDS, pH 7.6].  Lysis was facilitated by pipetting up and down until 
the lysate was less viscous. To remove cell debris, the lysate was spun down at 10 000 rpm 
for 20 minutes, the supernatant was then collected and kept at – 20 °C until further analysis. 
 
2.2.4 Treatment of macrophages with lipoarabinomannan (LAM) 
Differentiated THP-1 macrophages (1 x 106 cells) were serum starved for 6 hours before 
incubation in RPMI (FCS-free) containing 1 µg/ml LAM. For this experiment, the cell 
monolayer was rinsed once with warmed RPMI prior incubation with LAM containing media. 
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The cells and media were collected after 24 hours. Lysis was carried out as previously 
(section 2.2.3) and the media was not processed any further.  
 
2.3 Evaluating the activity of MMPs 
 
2.3.1 Activity of MMP-9 using a non-fluorogenic peptide substrate: Analysis 
by High Performance Liquid Chromatography (HPLC)  
HPLC was used to monitor substrate hydrolysis of the non-fluorogenic peptide with the 
sequence (GCREKGPRQITERCG) (Figure 2-1) (Bracher et al. 2013;Kridel et al. 2001). At the 
suggested scissile bond Q9/I10, the sequences and masses of the expected products are 
depicted in Figure 2-1, however, it is possible that cleavage can be at other sites (Kridel et al. 
2001).  The media and buffers were filtered before use. Thereafter the secreted MMP-9 was 
either activated or non-activated using APMA by incubation at 37 ˚C for 16 hours prior 
incubation with the substrate at 37 ˚C. The recombinant MMP-9 (recMMP-9) was included 
as a positive control to aid in identifying and confirming the cleavage products with analysis 
by mass spectrometry (MS). Incubation with substrate was performed at different periods 
for analytical reasons that will be stated. Samples were analysed with a Poroshell 120 EC-
C18 column on the Agilent 1260 infinity Hplc system and injected at volume of 10 μl unless 
stated differently. The peptides were eluted using 0 - 100% B (95% ACN, 0.1% TFA) over 12 
min; at a flow rate of 0.5 mL/min and monitored at wavelengths 214 nm; 280 nm and 
260 nm.  
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Figure 2-1: Schematic of non-fluorogenic substrate and expected MMP-9 cleavage site. 
The non-fluorogenic peptide is cleaved by MMP-9 at the indicated site. GPMAW was used to 
predict the HPLC elution profile and the masses of the cleavage products. The cleavage site 
has been previously described (Kridel et al. 2001). 
 
2.3.2 Evaluation of the cleavage products using mass spectrometry 
Analysis with MALDI-TOF 
The substrate was incubated at 37 C either with recombinant proMMP-9, APMA-activated 
recombinant proMMP-9 or with APMA for four hours before analysis with the HPLC and 
MALDI-TOF. Each peptide mixture was analysed using the HPLC with the method described 
in section 2.3.1 prior MALDI analysis. For the MALDI, the peptides were prepared by using 
the desalting method described in section. Thereafter, the samples were mixed with the 
matrix α-Cyano-4-hydroxyccinamic acid (α-CHCA) to a final concentration of 1 µg/µl. The 
sample spots were prepared by loading 1 µl of the sample-matrix mixtures on the stainless 
steel MALDI plate and left to dry for 15 minutes. This step was repeated twice by overlaying 
the sample spot with 1 µL of the same sample-matrix mixture. Thus, a final concentration of 
3 µg of peptide was loaded for each sample. For each experiment, three MALDI spots were 
evaluated. BSA and matrix were included in the analysis as controls. The peptide digests 
were analysed using MALDI laser desorption at a fixed laser frequency of 5107 Hz. The MS 
spectra was monitored between m/z 500 and m/z 2000, with a total of 400 laser shots per 
spectra.    
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Analysis using Q-Exactive and TSQ analysis 
The substrate was incubated at 37 C with APMA-activated recombinant proMMP-9 for 1, 2 
and 24 hours. Only the 2-hour experiment was analysed by mass spectrometry. Briefly, the 
30 µl of 2-hour sample was injected into the HPLC column and peptides were collected in 
glass vials as individual peaks eluting from the column. The HPLC conditions described in 
section 2.3.1 were applied for this experiment. For the Q-Exactive and TSQ mass 
spectrometry, the collected peptide solutions were concentrated using a vacuum 
concentrator and desalted using the method described in section.  
The samples were injected on a monolithic HPLC column with a 6 to 36-minute gradient. The 
peptides were eluted initially using a 31-minute constant flow rate of 100 µl/min as follows: 
3 to 8% solution B (95% acetonitrile, 0.1 formic acid) from 0 to 5 minutes, 8 to 60% 
solution B from 5 to 20 minutes, 60 to 80% solution B from 20 to 21 minutes and then 80% 
solution B from 21 to 31 minutes. Thereafter, the gradient was returned to 3% solution B at 
a flow rate of 200 µl/min for 5 minutes. Re-equilibration of the column was performed for 
20 minutes at 3% solution B. Analysis was performed using TSQ Vantage with Accela 600 
pump set for MS1 scan only at a range of 300 to 1500 m/z. Peptides collected from peak C 
and E (please see peak designation in Figure 3-4) were injected and analysed separately. 
Following that, peptide samples collected from peak A, B, C, D and E were mixed and 
analysed with the TSQ. 
Only peptides collected from peak A were evaluated using the Q-Exactive Quadrupole-
Orbitrap mass spectrometry (Thermo Scientific) which was coupled to the Dionex Ultimate 
3500 RSLC nano_LC system (Thermo Scientific). The sample injection volume was 10 µl. The 
sample was loaded on a 40 cm C18 analytical column (packed in- house with Aeris peptide 
3.6 µM beads, Phenomenex), thereafter elution was carried out using a linear gradient of 6 
– 35% solvent B (95% acetonitrile, 0.1 formic acid), at a constant flow rate of 300 nl/min. 
The acquisition of data was carried out using Xcalibur software (Thermo scientific, v2.2) in 
positive ion mode. MS1 scans were acquired with a resolution of 70 000, an automatic gain 
control  of 3 x 106 and an ion injection time of 250 ms. The MS/MS scans were acquired at a 
resolution of 17 500, AGC target of 2 x 105, ion injection of 120 ms. The peptide matching 
was set to ‘preferred’, isotopic exclusion and a dynamic exclusion of 30 s. 
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2.3.3 Investigation of MMP-1 and MMP-9 activity using gelatin, casein and 
collagen zymography 
Zymography is an electrophoretic technique that was developed in the 1980s (Heussen and 
Dowdle 1980) and it is still used to date for detecting protease activity especially of MMPs. 
This technique is based on their ability to hydrolyse substrate that has been incorporated by 
co-polymerisation with the separating gel. Discrimination between enzymes relies on 
migration and formation of clear bands indicative of hydrolysis of the substrate at the 
respective molecular weight of the enzymes. This technique has been widely used for 
analysis of the MMP’s active and zymogenic forms. The zymogenic form can be identified on 
the zymogram since the SDS perturbs the cysteine switch motif formed between the 
catalytic zinc and the prodomain’s cysteine residue while the prodomain itself remains 
uncleaved. In addition to that, both the covalent and non-covalent interactions between the 
MMP and TIMP is broken by SDS, these bonds can reform following refolding by exchange of 
the SDS with Triton X-100.  
The experiments were carried out as described by Gogly and colleagues (1998), with sample 
preparation under non-reducing conditions (Gogly et al. 1998). Briefly, total protein 
concentration was determined by the BCA method thereafter samples were adjusted so 
that equivalent total protein concentrations are loaded on the gels. The 1X nonreducing 
sample buffer was used for loading the samples. Electrophoresis was carried out using ice-
cold running buffer at a current of 15 mA until the sample front had reached the separating 
gel and then constantly at 35 mA. Following that, the denaturant i.e. SDS was washed by a 
two-step exchange with 2.5% Triton X-100 for 30 minutes each to allow renaturation of the 
proteins. For subsequent substrate hydrolysis, gels were placed in incubation buffer for 16 - 
20 hours at 37 ⁰C. Staining was carried out in 0.25% Coomassie Brilliant blue for about an 
hour and destained until clear bands indicating proteolytic activity were observed. Since 
zymograms differ, 10 ng of the positive control (recombinant MMP-9) was loaded on the 
gels. Bands were scanned in triplicate and for normalisation the scan units of the positive 
control were divided by each sample band, thereafter the quotients of uninfected or 
infected were plotted as bar graphs. 
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2.3.4 Assessing the activity of secreted MMP-1 using a fluorogenic substrate 
The activity of secreted MMP-1 was assessed by means of a fluorogenic Sensolyte® Plus 520 
MMP-1 assay kit according to the manufacturer’s instruction. These methods of assessing 
the activity of MMPs has been developed over the years and described (Menges et al. 
1997). Briefly, the secretome was incubated for 2 hours with the MMP-1 antibody (coated 
on the microplates) for selective binding to occur. This was done at room temperature with 
constant shaking of the microplate. After a series of washes to remove unbound molecules, 
the bound MMP-1 was either activated with APMA (ultimately measuring the active form 
and activated proMMP-1) for 4 hours or not activated to measure the endogenously 
secreted active form alone. Thereafter, substrate hydrolysis was monitored for 2 hours at a 
fluorescence excitation/emission wavelength of 490/520 nm dependent on the 5-
FAM/QXLTM520 FRET substrate. The Perkin Elmer fluorimeter (EnSpire) was used.  
 
2.4 Investigation of MMP-1 and MMP-9 expression by western blotting 
To assess alterations in the expression of MMP-1 and MMP-9 that may have been induced 
by infection of THP-1 macrophages, western blotting was used. SDS-PAGE was carried out 
with accordance to Laemmli’s conditions (see Appendix 1), this was followed by an hour of 
protein transfer (see Appendix 1). Membrane blocking was done for an hour in blocking 
buffer. After that, the membrane was probed with an anti-MMP1 or anti-MMP-9 primary 
antibody diluted 1:1000 in blocking buffer. The membrane was then incubated at 4 °C 
overnight with gentle shaking. Prior probing with secondary antibody, the membrane was 
rinsed six times with blocking buffer and then placed in blocking buffer containing anti-
mouse secondary antibody diluted a 1000-fold. Binding of secondary antibody was allowed 
to occur at room temperature for two hours. A series of rinsing steps were done, three 
times briefly with blocking buffer and three times with TBS-T buffer 15 minutes each time. 
To visualise the bound antibodies, BioRad Immuno-Star Western C kit which exploits the 
horseradish peroxidase (HRP) conjugated to the secondary antibody was used. 
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Chapter 3 
Matrix metalloprotease activity  
 
The function of MMP’s is pivotal in remodelling of the ECM and anomaly in their activity is 
implicated in pathology of diseases such as cancer and tuberculosis. In TB, the expression of 
MMP-9 is associated with granuloma formation and maturation, whilst the degradation of 
collagen is correlated with increased MMP-1 activity. These events have been documented 
to cause cavitation and dissemination which culminate in transmission (Elkington et al. 
2005a;Elkington et al. 2005b;Hrabec et al. 2002;Kubler et al. 2015;Salgame 2011). Inhibiting 
MMP’s is thus ideal but the similarities in the active site pocket poses a challenge in 
designing specific inhibitors and substrates for assaying them. Different methods of 
assessing their activity have been used including zymography, labelled and nonlabelled 
peptides.   
Therefore, the objectives of the study on analysing the effect of M. smeg infected 
macrophages on the activity of MMPs were as follows: 
1. Assessing the proliferation and differentiation of THP-1 macrophages. 
2. Harvesting at different time points the lysate and media from differentiated 
THP-1 monocytes that are uninfected and infected with M. smeg.  
Comparing the extracellular and intracellular activity of MMP-1 and MMP-9 between 
uninfected and infected, also between the different harvest time points. 
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3.1 Evaluation of THP-1 proliferation and differentiation 
Since macrophages are more potent secretors of MMPs than monocytes, the THP-1 cells 
were differentiated prior to infection. This also allows adherence of the cells to the plate 
and inhibits further growth of the cells. The optimum concentration of PMA that is required 
to induce differentiation without being toxic to the cells was assessed using FACS and the 
accompanying morphology was evaluated using phase contrast microscopy. Within 18 hours 
of incubation with PMA, the monocytes had adhered and were adopting a macrophage-like 
appearance that is more flattened, elongated and spindle-like shaped (Figure 3-1). This is a 
typical morphological transition also observed in other studies (Mehta and Lopez-Berestein 
1986;Tsuchiya et al. 1980). Another important marker of differentiation is CD11b which is 
almost exclusively expressed by differentiated macrophages.  
 
Figure 3-1: Morphology of undifferentiated and PMA-differentiated THP-1 cells. Phase 
contrast microscopy was used to visualise and compare (A) undifferentiated and (B) 
differentiated THP-1 monocytes treated with 20 nM PMA. Because the font for scale bar is so 
small, maybe you can indicate. The scale bar corresponds to 100 µm 
In cells treated with 20 nM PMA, 93% of the cells which were CD11b positive (Figure 3-2), 
this was comparable to other PMA concentrations used. The heterogeneity in the 
population is comparable to other studies (Mehta and Lopez-Berestein 1986;Qin 
2012;Tominaga et al. 1998). Since 20 nM of PMA was sufficient to induce differentiated and 
more adherent monocytes than the 10 nM, it was used for all experiments.  
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Figure 3-2: Assessing CD11b expression levels using different concentrations of PMA. FACS 
was used to analyse the expression of CD11b. Undifferentiated (without PMA) and 
differentiated THP-1 cells were either incubated with or without the CD11b antibody which 
is conjugated to the PE-Cy7 fluorescent dye. BD FACSDIVA version 1.6.3 was used to analyse 
the data. 
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3.2. MMP activity of Mycobacterium smegmatis infected THP-1 macrophages 
 
3.2.1 Assessing MMP-9 activity using a non-fluorogenic substrate and HPLC 
MMPs are similar in molecular weight and can act upon a large number of overlapping 
substrates due to the similar architecture of their active sites.  Specifically, the catlytic site 
of MMP9 is closely related to other MMPs emphasising the need for specific and 
quantitative assay for assessing its enzymatic activity. Thus, a synthetic peptide substrate 
that has a very high kcat/Km for MMP9 (Kridel et al. 2001) was used to quantify and compare 
the activity between the uninfected and infected secretome. 
 
3.2.1.1 Characterising the specificity of recombinant MMP9 using HPLC and 
mass spectrometry 
Briefly, the substrate GCREKGPRQITERCG was incubated with recombinant proMMP-9 with 
and without APMA activation. To characterise the cleavage products and the effect of APMA 
on the substrate, HPLC followed by MALDI-TOF mass spectrometry using the matrix 
α-cyano-4-hydroxyccinamic acid (α-CHCA) was carried out (Figure 3-3). Incubation of the 
non-activated recMMP-9 with substrate yielded a single peak that overlays with the 
substrate peak with lower peak area indicating partial substrate hydrolysis (Figure 3-3A). 
The products resulting from cleavage at the Q9/I10 bond were identified. Specifically peaks 
at m/z of 678.39 and 1030.60 were observed and these were in close agreement with the 
peptides ITERCG (677.77) and GCREKGPRQ (1030.54) (Table 3-1). It is important to note that 
the aforementioned products were not observed in the control where substrate was 
incubated with APMA (Figure 3-3C). Other cleavage sites that were identified included 
I10/T11 and E4/K5. Since the products could not be conclusively matched to the HPLC 
chromatograph peaks, further analysis of individually collected peaks was performed using 
the Q-Exactive and TSQ mass spectrometry (Described in Chapter 2, Section 2.3.2).  
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Figure 3-3: Analysis of MMP-9 cleavage products using MALDI. The MALDI spectra (left 
panel) and representative HPLC chromatograms (right) are depicted. (A) Recombinant 
MMP-9 non-activated (red chromatogram), (B) activated with APMA (blue chromatogram), 
and (C) APMA without MMP-9 (yellow chromatogram) were incubated with substrate at 37 
˚C for 4 hours. The MALDI identified the substrate 1687.9 (blue circle), and product peptides 
678.39 (green circle) and 1030.60 (black circle). The 1889.84 peptide (red circle) was only 
identified in the presence of APMA. 
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Table 3-1. Summary of the MALDI-TOF analysis of the MMP-9 substrate cleavage products 
                     
Non‑activated 
Rec_MMP-9 + 
Activated Rec_MMP-9 + 
substrate APMA + substrate Fragment sequence Theoretical mass (Da)  Cleavage site
m/z m/z m/z
**678.39 678.35 N/a ITERCG 677.70 Q9/I10
680.38 680.36 N/a KGPRQI 680.42 E4/K5 & I10/T11
**1030.60 1030.50 N/a GCREKGPRQ 1030.54 Q9/I10
1687.92 1687.91 1687.89 GCREKGPRQITERCG 1687.92 Intact substrate
1689.92 1689.91 1689.92 GCREKGPRQITERCG 1689.94 Intact substrate  
**Q9/I10 cleavage products. 
 
APMA-activated recMMP-9 was incubated with substrate for 1, 2 or 24 hours and peptides 
resolved by HPLC. The peaks from the 2-hour incubation were collected and MS analysis was 
carried out. The chromatogram (absorbance at 214 nm) shows that after an hour, there is 
some substrate hydrolysis with partial resolution of some peptides indicated by peaks with 
‘shoulders’ (Figure 3-4A). The recombinant MMP-9 elutes at 6.64 minutes (chromatogram 
not shown) which is after the elution of substrate and peak E3. Peak E1 disappears after 24 
hours whereas there is little change in E2 and E3 compared to the 2-hour incubation. The 
area under these peaks was computed as a single peak since they are not fully resolved. 
There was a 2-fold increase in products A, C and D after 24 hours (compared to after 
2 hours) and a decrease in B and E (Figure 3-4B). This suggests that there is sequential 
hydrolysis of the substrate. Assessment of the peaks by MS (Q-Exactive and TSQ) confirmed 
the co-elution and the sequential cleavage of the substrate, the data is summarised in Table 
3-2. Peaks at m/z of 677.95 and 695.85 observed and these were in agreement with the 
calculated masses of the peptides 677.78 and 696.37. These peptides correspond to 
cleavage at the Q9/I10 bond, and R3/E4 and Q9/I10 cleavage bonds, respectively. Other 
cleavage sites that were identified include G6/P7, R3/E4, E12/R13 and I10/T11. Although 
there were some cleavage products identified in peak A and E, the dominant molecules 
were APMA and substrate, respectively. 
Substrate hydrolysis was also evident when the substrate was incubated with APMA-
activated MMP-1 and chymotrypsin which yielded similarities in the peak pattern to 
hydrolysis by MMP-9 (Figure 3-5).     
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Figure 3-4: Determination of the product peaks by time course analysis. (A) The 
chromatogram of the substrate incubated with activated recombinant MMP-9 for 1 hour 
(Rec1), 2 hours (Rec2) and 24 hours (Rec3). The elution peaks are also indicated (A to E). (B) 
Bar graph representing peak ratios calculated from the area of the 24 to 2-hour period of 
hydrolysis. 
Table 3-2: Mass spectrometry analysis of cleavage products of MMP-9 substrate with 
APMA activated recombinant MMP-9.  
The peaks were collected after 2 hours of incubation with substrate and were assigned 
according the HPLC chromatogram in Figure 3-15. 
 
Peak m/z 
Charge 
state Instrument Fragment sequence Theoretical mass (Da) Cleavage site
A 333.28 MH+ QE (MS2) GCR/RCG 334.14 R3/E4 OR E12/R13
648.51 MH+ GCREKG 648.74 G6/P7
C 677.95 MH+  TSQ (MS1) ITERCG 677.78 Q9/I10
D 695.85 MH+ TSQ (MS1) EKGPRQ 696.37 R3/E4 & Q9/I10  
 
A 
B 
64 
 
 
 
Figure 3-5: HPLC chromatogram of MMP-9 substrate hydrolysis by other enzymes. The 
substrate was incubated with chymotrypsin, activated MMP-1 or chymotrypsin and MMP-9. 
The cleavage products were monitored by HPLC at a wavelength of 214 nm.  
 
3.2.1.2 Evaluating the substrate hydrolysis pattern of uninfected and infected 
secreted proteins   
The hydrolysis of the MMP9 substrate by the uninfected and infected secretome was 
assessed with and without APMA-activation. A representative chromatogram of the peaks 
generated with the APMA-activated secretome (Figure 3-6) corresponds to the peaks 
assigned in Figure 3-4. Differences between uninfected and infected secretome were 
analysed by computing the ratio of the individual peaks to the substrate (Figure 3-7 to 
Figure 3-13). Only peak C and D were compared since peak A and E mainly represent APMA 
and substrate peaks, respectively. B was ignored since the product concentrations from the 
secretome hydrolysis were too low.   
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Figure 3-6: Representative chromatogram of the secretome hydrolysis of the MMP9 
substrate. The peaks depicted are from incubation of the substrate and APMA-activated 
secretome and are assigned A to E similar to the hydrolysis pattern resulting from APMA-
activated recombinant MMP-9. 
 
 
For the 1-hour time point, there was no significant difference in products C and D between 
the infected and uninfected in both the 1-hour and 6-hour incubations (Figure 3-7). 
Similarly, following APMA-activation of the secretome there were no differences observed 
between uninfected and infected (Figure 3-8).  
For the 3-hour time point the area of the product peaks was only slightly higher in the 
uninfected (Figure 3-9). In contrast, APMA activation masked these differences between 
infected and uninfected (Figure 3-10). 
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Figure 3-7: Hydrolysis of substrate by the 1-hour time point media. The substrate was 
incubated with the uninfected (Uni) and infected (Inf) media for 1 hour (Uni_1Hr and 
Inf_1Hr) or 6 hours (Uni_6Hrs and Inf_6Hrs).  
 
 
 
 
 
 
 
Figure 3-8: Effect of APMA on substrate hydrolysis of the 1-hour time point. Prior to 
hydrolysis the media was incubated with APMA for 16 hours. Thereafter the substrate was 
incubated with the uninfected (Uni) and infected (Inf) media for 1 hour (Uni_1Hr and 
Inf_1Hr) or 20 hours (Uni_20Hrs and Inf_20Hrs).  
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Figure 3-9: Substrate hydrolysis with the 3-hour time point. The substrate was incubated 
with the uninfected (Uni) and infected (Inf) media for 1 hour (Uni_1Hr and Inf_1Hr) or 
6 hours (Uni_6Hrs and Inf_6Hrs).  
 
 
 
 
 
 
Figure 3-10: Substrate hydrolysis with the APMA-treated 3-hour time point. Prior to 
hydrolysis the media was incubated with APMA for 16 hours. Thereafter the substrate was 
incubated with the uninfected (Uni) and infected (Inf) media for 1 hour (Uni-1Hr and 
Inf_1Hr) or 20 hours (Uni_20Hrs and Inf_20Hrs).  
At the 6-hour time point, there is a 2-fold increase in D in the infected media after 1 hour of 
incubation with the substrate. However, incubating the media with the substrate for 6 hours 
abolished this difference (Figure 3-11). For the 18-hour time point, there were no significant 
differences between the uninfected and infected after 1 and 6 hours of incubation with 
substrate (Figure 3-13). Overall, there were no significant differences observed induced by 
the M. smeg infection and the results were not conclusive.  
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Figure 3-11: Product formation from the 6-hour time point substrate digestion. The 
substrate was incubated with the uninfected (Uni) and infected (Inf) media for 1 hour 
(Uni_1Hr) or 6 hours (6_Hrs).  
 
 
 
 
 
 
Figure 3-12: Product elution profile from APMA-treated 6-hour time point substrate 
digestion. Prior hydrolysis the media was incubated with APMA for 16 hours. Thereafter the 
substrate was incubated with the uninfected (Uni) and infected (Inf) media for 1 hour 
(Uni_1Hr and Inf_1Hr) or 6 hours (Uni_20Hrs and Inf_20Hrs). 
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Figure 3-13: Evaluation of substrate hydrolysis with the 18-hour time point in the absence 
of APMA. The substrate was incubated with the uninfected (Uni) and infected (Inf) media 
for 1 hour (Uni_1Hr and Inf_1Hr) or 6 hours (Uni_6Hrs and Inf_6Hrs).  
 
 
3.2.2 Evaluation of MMP-9 and MMP-1 activity using zymography 
Owing to the challenges associated with the HPLC-based enzyme assay, zymography was 
employed to assess the effect of M. smeg infection on the activity of secreted and 
intracellular MMPs. Substrates including gelatin, casein and collagen were used to evaluate 
any differential hydrolysis due to the infection or type of substrate. The activation of 
proMMP-9 and proMMP-1 are stepwise processes summarised below (Figure 3-14) and in 
more detail in Section 1.3.2. 
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Figure 3-14 Schematic migration pattern of different MMP-9 and MMP-1 forms on 
zymograms.  In lane 1 are the expected bands with respect to the molecular weight marker 
(Mw). Also illustrated are the steps involved in conversion of the proMMP-9 and proMMP-1 
to their different forms.      
In the secretome, the difference in enzymatic activity of MMP9 between infected and 
uninfected macrophages was most pronounced at 6 and 18-hour time points as indicated by 
the zone of clearing at 82-kDa (Figure 3-15A and B). This was clearly indicated by 
densitometric analysis (Figure 3-15D). There was an approximate 5- and 11-fold increase in 
MMP activity at 6 and 18 hours, respectively. Thereafter the fold difference in activity 
between uninfected and infected declined at 24 hours, and at the 72-hour time point the 
uninfected was slightly higher versus the infected. Interestingly, in the 72-hour infected 
macrophages the 82 kDa band migrates more slowly than that observed in the uninfected 
(Figure 3-15B). In addition, the infected secretome had a larger molecular weight band (113 
kDa) that was absent in the uninfected. This band was also present in the 6-hour time point 
of the infected secretome. This may represent proMMP-9 or the formation of multimeric 
complexes. This will be discussed later in Chapter 4. The band observed at 57 kDa in the 24- 
and 72-hour time points in the uninfected secretome corresponds to proMMP-1 hydrolysis 
(Figure 3-15C).  
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Additionally, at higher protein concentrations the uninfected secretome at 72 hours showed 
a 47 kDa band that is likely the active form of MMP-1 (Appendix Figure 6-1). This suggests 
that at higher protein concentrations proMMP-1 undergoes autolysis. In summary, there is 
an overall increase in the gelatinase activity of secreted MMP-9 in the secretome of infected 
macrophages. In contrast, secreted proMMP-1/MMP-1 activity was observed only in the 24 
and 72-hour uninfected harvests.  
 
Figure 3-15: Gelatinase activity of the secretome from M. smeg infected versus uninfected 
macrophages. The different harvest time points post infection are indicated. The uninfected 
and infected samples are depicted as (-) and (+), respectively. As a control, recombinant 
proMMP-9 was loaded in lanes 2 and 1, in gel (A) and (B), respectively. (C) Loading higher 
concentrations of the same samples results in appearance of other bands as indicated by 
the arrows. (D) Bands were scanned in triplicate and quantified using ImageJ, and data was 
represented as mean ± SEM.  
Collagen hydrolysis by the 82 kDa form was higher for the infected secretome compared to 
the uninfected between the 1 and 18-hours (Figure 3-16A and C). In contrast to the other 
time points the activity for the uninfected secretome at 6 hours was almost undetectable. It 
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is important to note that the highest differential activity observed between the time points 
was substrate dependent, where collagenase activity is about 13-fold higher for the infected 
at the 6-hour time point versus 11-fold higher at the 18-hour time point. In the later time 
points, i.e. 24 and 72 hours, collagen hydrolysis was similar for both infected and 
uninfected, and slightly higher for the uninfected at 24 hours post-infection (Figure 3-16B). 
The band corresponding to the 76 kDa form of MMP-9 had collagenolytic activity that was 
higher in the infected versus uninfected especially at the 18-hour time point, and in contrast 
the uninfected was 2.5-fold higher at 72 hours. Intriguingly, this band was absent in the 
6-hour time point.  
Elastin which is a primary substrate for MMP-12 was also used. No enzymatic activity was 
detected for both infected and uninfected macrophages, implying that MMP-12 might not 
be expressed and secreted by the THP-1 macrophages (results not shown).  
 
Figure 3-16: Analysis of collagen I hydrolysis by M. smeg infected and uninfected 
secretome. The secretome collected for the (A) earlier and (B) later time points were loaded 
as defined. Lanes 1 and 2 represent recombinant proMMP‑9 and proMMP-1, respectively, in 
both gels. The bands corresponding to the (C) 82 kDa and (D) 76 kDa bands, and 
recombinant proMMP-9 (lane 1) were quantified using ImageJ. Bands were scanned in 
triplicate and data represented as mean ± SEM.  
When casein was used as a substrate, the secretome from the earlier time points (1 to 
6-hours) showed no enzyme activity for both uninfected and infected cells (Figure 3-17A) in 
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contrast to the later time points (Figure 3-17B). This trend, and the discrepancy in the 
highest differential activity observed between time points when gelatin and collagen were 
used, suggests that there is a switch in substrate specificity of MMP-9 between the 6- and 
18-hour time points. This will be discussed further in Chapter 4. At 24 hours the casein 
hydrolysis was slightly higher in the uninfected compared to the infected secretome; 
however, at 72 hours the uninfected shows 2.2-fold increase in activity (Figure 3-17B and C). 
Casein is typically used to determine the activity of MMP-3 and MMP-1, which have similar 
molecular weights; however, zymography did not show any bands at the corresponding 
lower molecular weights that correspond to these enzymes (Figure 3-17A and B).  
 
Figure 3-17: Caseinolytic activity of the uninfected and infected secretome. Casein was 
used as a substrate to evaluate MMP activity of harvested media. (A) The recombinant 
proMMP-9 (lane 1) and proMMP-1 (lane 3) were also loaded as controls. (B) Positive 
controls proMMP-9 and proMMP-1 were loaded in lanes 2 and 3, respectively. (C) The 
bands corresponding to the 82 kDa band and recombinant proMMP-9 were scanned and 
quantified using ImageJ. Bands were scanned in triplicate and data represented as mean ± 
SEM.  
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At the intracellular level, the activity for the 82 kDa form of MMP-9 was comparable 
between the infected and uninfected samples at all the time points (Figure 3-18 (A and C). 
The gelatinolytic banding pattern of the 72-hour time point (Figure 3-18B) was similar to 
that of its secretome where the presumed MMP-9 band (82 kDa) in the uninfected migrated 
more rapidly. In addition, a 57kDa-band corresponding to proMMP-1 was observed in the 
uninfected but was absent in the infected lysate. The band corresponding to the active form 
of MMP-1 (47 kDa) migrated more slowly in the infected samples of the 18 and 24-hour 
time points and was not observed in the infected cells at 72 hours (Figure 3-18B). Like the 
secretome, this highlights the contrasting effects that the M. smeg has on the expression 
and activity of MMP-1 versus MMP-9 in the THP-1 macrophages. The gelatinase activity 
corresponding to MMP-9 (67 kDa band) was higher in the uninfected lysates for the earlier 
time points (1 to 6 hours) as well as 72 hours (Figure 3-18 B and D). The proMMP-1 (57kDa) 
which was only observed in the 72-hour time point migrated slightly more quickly in the 
uninfected and showed higher activity than in the infected (Figure 3-18D). Unlike the 
secretome, the intracellular samples did not hydrolyse casein (Figure 3-19A and B). 
proMMP-9 contains 19 cysteine residues, some of which have been shown to be important 
for its secretion and/or activity. Therefore, gelatin zymography was used to assess the 
activity of secreted and lysate MMP-9 when exposed to the reducing agent β- 
mercaptoethanol (Figure 3-20). The recombinant MMP-9 loaded as a control was also 
reduced using β- mercaptoethanol. Under these conditions the activity of secreted MMP-9 
was abrogated in the 3 and 6-hour time points, and greatly decreased for the later time 
points when compared to non-reducing conditions (Figure 3-15). The bands showing 
hydrolytic activity including the control migrated more slowly (closer to 100 kDa), compared 
to non-reducing conditions. 
Similarly, the activity of intracellular MMP-9 was abolished in the presence of β-
mercaptoethanol (Figure 3-21) in all the time points except for the 24-hour cells which had 
some residual bands of activity (Figure 3-21). This contrasts with the lysates under non-
reducing conditions (Figure 3-18). The band corresponding to the proMMP-1 at 47 kDa 
maintained activity under reducing conditions. 
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Figure 3-18: Effect of M. smeg infection on gelatin hydrolysis by the lysate. (A and B) 
Lysate harvests from uninfected and infected cells were loaded on the respective lanes. The 
recombinant proMMP-9 (lane 7) was loaded as a positive control. (C & D) The bands 
corresponding to the MMP-9 82 kDa (black arrow) and 67 kDa (red arrow) were scanned 
and quantified using ImageJ. Also, quantified in the 72-hour time point is the proMMP-1 
band (purple arrow) represented by the purple and pink bars (D). The active form of MMP-1 
is also indicated (yellow arrow). The bands were scanned in triplicate and data represented 
as mean ± SEM.  
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Figure 3-19: Hydrolysis of casein by uninfected and infected intracellular proteome. The 
harvested lysate (A) from hour 1, 3 and 6 hours post-infection are represented by lanes 1-2, 
3-4 and 5-6, respectively and (B) lanes 4-5, lanes 6-7 and lanes 8-9 represent the later time 
point harvests 18, 24 and 72 hours, respectively. 
 
 
  
A 
B 
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Figure 3-20:  Analysis of gelatinase activity of the secretome under reducing conditions. 
The media samples from the indicated time points were prepared with sample buffer 
containing 10% β-mercaptoethanol prior electrophoresis. Recombinant proMMP-9 was also 
prepared under reducing conditions and loaded (lane 1) as a control. 
 
 
Figure 3-21: Effect of reducing conditions on the gelatinase activity of the lysate. The 
lysate samples were prepared using buffer containing 10% β-mercaptoethanol including 
recombinant proMMP-9 loaded (lane 1) as a control. Representative samples from the 
earlier and later time points are indicated. 
 
3.3 Evaluation of APMA activated media using gelatin zymography 
The presence of the prodomain inhibits MMP activity by co-ordination of its cysteine 
residue with the active site catalytic zinc thus preventing the acquisition of the water 
molecule essential for catalysis. Non-proteolytic activation of MMPs can be carried out using 
APMA which interacts directly with the prodomain cysteine inducing a conformational 
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change that allows for hydrolysis but still retaining the prodomain. This form corresponds to 
a molecular weight of 92 kDa as observed by zymography and SDS-PAGE (Shapiro et al. 
1995). Cleavage of the prodomain yields an 82 kDa active form of MMP-9 apparently via 
autoproteolysis or hydrolysis by other proteases.  
Zymography was used to assess the effects of APMA-activation of the secretome on gelatin 
hydrolysis. The uninfected and infected secretomes from the 6 and 72-hour time points 
were incubated at 37 ˚C for 16 hours with or without APMA. In the zymogram there is a 
distinct difference in the banding pattern between the APMA activated and non-activated 
secretome (Figure 3-22A). Activation with APMA results in the disappearance of the band at 
120 kDa (Figure 3-22A) and the conversion of the 82 kDa MMP-9 to its 67 kDa form which 
occurs more slowly with non-activated. This 67 kDa active form of MMP-9 lacking the C-
terminal hemopexin domain is more prominent in the APMA activated samples. At 6 hours, 
APMA activation results in faster conversion to the 67 kDa form in the uninfected compared 
to the infected media. In the absence of APMA, this time point harvest depicts a hydrolytic 
band at 57 kDa corresponding to proMMP-1 and the 120 kDa form in both infected and 
uninfected that is absent with the APMA activation. The 120 kDa band is higher in intensity 
in the uninfected secretome. Interestingly, in the absence of APMA the 72-hour uninfected 
secretome shows increased activity of the 67 kDa fragment including bands of activity for 
proMMP-1 (57 kDa), active MMP-1 (47 kDa) and the 32 kDa MMP-1 autocatalytic fragment 
which were not visualised in the infected secretome (Figure 3-22A). In contrast, the infected 
secretome shows almost no activity at 67 kDa but elicits comparable activity at 82 kDa and 
120 kDa to the uninfected. Overall, treatment with APMA results in a more rapid conversion 
from the 82 kDa to the 67 kDa form of MMP-9 with the absence of proMMP-1/MMP-1 and 
120 kDa multimer activity.  
When the 6-hour time point media was incubated for 2 hours with and without APMA at 
37 ˚C, there was no difference between APMA and non-activated (Figure 3-22B). For 
instance, the uninfected depicted equal activity for the 82 and 67 kDa form. In contrast, the 
corresponding infected secretome samples showed much lower activity for the 67 kDa 
versus the 82 kDa form and increased activity of the 120 kDa multimer.  
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Figure 3-22: The effect of APMA-activation and heat-activation on the gelatinase activity 
of infected and uninfected secretome. (A) The secretome harvested from the 6 and 72-hour 
time points were incubated with (+) or without (-) APMA for 16 hours at 37 ˚C. (B) The 6-
hour time point secretome (Lanes 1 to 4) and recombinant proMMP-9 (Lanes 5 and 6) were 
incubated for 2 hours with (+) or without (-) APMA at 37 ˚C. 
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3.4 The effect of Mycobacterium smegmatis infection on the specific activity 
of secreted MMP-1 
Due to the limited sensitivity and specificity of the zymography assay for MMP-1, an assay 
where a specific anti-MMP-1 monoclonal antibody is used in combination with an MMP 
fluorogenic substrate was used for further comparative analysis. Analysing the secreted 
MMP-1 without prior activation with APMA resulted in no measurable activity (data not 
shown). Therefore, APMA was used to activate MMP-1, meaning the endogenously active 
and pro-forms were measured. The enzyme activity was only detectable at the 24 and 72-
hour time points suggesting that MMP-1 is secreted after 24 hours incubation with the 
macrophages. This delayed secretion when compared to that of MMP-9 was also observed 
in other studies where THP-1 monocytic cells were used (Friedland et al. 2002). The activity 
was higher in the uninfected versus infected, especially after 72 hours where there was a 
4.9-fold increase in activity (p <0,008) (Figure 3-23). This agrees with the gelatin zymography 
of the secretome from M. smeg infected versus uninfected macrophages (Figure 3-15C).  
 
Figure 3-23: Effect of M. smeg infection on activity of secreted MMP-1. The activity of 
secreted MMP-1 post-treatment with APMA (proMMP-1 and MMP-1) was compared 
between uninfected and infected for harvested time points at 24 and 72 hours post-
infection. The experiments were done in triplicate for each of the two biological replicates.  
No significant difference was observed after 24 hours (p = 0,381), the only significant 
difference (p = 0,008) was observed for the 72-hour time point. 
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Matrix metalloprotease expression 
 
3.5 Comparing the expression pattern of MMP-1 and MMP-9 in infected and 
uninfected THP-1 macrophages 
To investigate whether there is any correlation between the expression and activity of 
MMP-1 and MMP-9, western blotting was carried out with a polyclonal anti proMMP-1 
antibody (Figure 3-24). Under non-reducing conditions the active form of MMP-1 (47 kDa) 
was visible only in the uninfected 72-hour harvest, again supporting the zymography data 
(Figure 3-15C). Under reducing conditions, the pro-form (57 kDa) was present in both 
uninfected and infected; however, there was more of the active form (47 kDa) in the 
infected lysate. Other bands were also detected at 25 and 32 kDa in the uninfected and 
infected samples, respectively. These may be active degradation products generated by 
other proteases or autolysis products of MMP-1. 
 
 
 
 
 
 
 
 
 
 
 
82 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3-24: The migration pattern of expressed MMP-1 under reducing and non-reducing 
conditions. (A) Lysate harvested from uninfected and infected THP-1 macrophages after 
72 hours post infection was prepared with or without β-mecarptoethanol before 
electrophoresis. The MMP-1 antibody was used to probe and compare the expression 
pattern. (B) The reduced MMP-1 bands in lanes 1 and 2 were scanned in triplicate and 
represented as mean ± SEM. (C) The non-reduced bands in lanes 3 and 4 were scanned in 
triplicate and represented as mean ± SEM. 
The monoclonal proMMP-9 antibody did not detect any proMMP-9 in the lysate (both 
reducing and non-reducing sample buffer), which implies that the THP-1 macrophages 
express the active form of the enzyme. This corroborates the zymography results (Figure 3-
15) where the 82 kDa active form is detected.   
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Discussion 
Implication of MMP-1 and MMP-9 in the macrophage 
response against M. smeg infection 
 
Mycobacterium smegmatis is used to model its virulent counterpart Mycobacterium 
tuberculosis because of its fast-growing and less laborious nature. Both MMP-1 and MMP-9 
have been documented to be upregulated in patients with tuberculosis and in primary 
monocytes infected with M. tb (Elkington et al. 2007;Elkington et al. 2005a;Elkington et al. 
2005b;Ordonez et al. 2016). In all the cases there was no counterbalance by the TIMPs. This 
led to the conclusion that M. tb deliberately drives this tissue degrading phenotype that 
causes cavitation culminating in transmission (Elkington et al. 2007;Elkington et al. 
2005a;Elkington et al. 2005b;Ordonez et al. 2016). Analysing the expression and activity of 
MMPs in response to M. smeg infection is an important comparative study. 
 
3.6 Hydrolysis of the MMP-9 synthetic substrate 
The overlap in substrates cleaved by MMPs poses a challenge in designing drugs that are 
specific for different MMPs. Novel ways of inhibiting or regulating MMPs have been 
described including targeting their activation (Scannevin et al. 2017). Variability in the 
sequences of their Hx domain (Piccard et al. 2007) makes it another potential target for 
rational drug design. The selectivity of MMP-9 to the synthetic substrate has been mainly 
attributed to Arg at P2 and Ser/Thr at the P2´ site of the substrate (Kridel et al. 2001). 
However, the substrate has a consensus sequence (SGKGPPRQITA) that can be cleaved by 
MMP-7 and MMP-13 at a catalytic efficiency about 10-fold lower than that of MMP-9. 
MMP-7 is a matrilysin that lacks the C-terminal Hx domain and like MMP-1, MMP-13 is a 
collagenase. The derivation of the MMP-9 substrate was mainly based on collagen and 
gelatin cleavage sites (Kridel et al. 2001). In the current study the expected Q9/I10 cleavage 
site described by Kridel and colleagues was confirmed with the identified proteolytic 
products (GCREKGPRQ) with the molecular weight 1030.54 Da (Table 3-1) and ITERCG with a 
molecular weight of 677.78 Da (peak C) (Table 3-1 and Table 3-2) by mass spectrometry. 
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Unbound APMA reacts with the substrate at the cysteine and possibly arginine residues 
(Galazka et al. 1996), resulting in the deamination of APMA or of the substrates amino acid 
residues. Thus, the shoulder peaks eluting with substrate in presence of APMA suggests 
some interaction between APMA and substrate. Other cleavage sites that were identified 
include the I10/T11, E4/K5, R3/E4, G6/P7 and E12/R13. The findings of the current study 
suggest that MMP-9 cleaves the substrate at multiple sites mainly via gelatinolytic, 
collagenolytic and serine protease activity. The postulated serine protease activity has not 
been investigated exhaustively in the current study, but since MMPs can activate each other 
and/or undergo autolysis, thus they could be mimicking the serine proteases; plasmin and 
trypsin which are well-known MMP-activating proteases (Duncan et al. 1998). The simulated 
cleavage sites for the serine proteinases trypsin and proteinase K that overlap with the 
postulated cleavage sites by MMP-9 are R3/K4; and E4/K5, I10/T11 and E12/R13, 
respectively. To further support the postulated serine protease activity of MMP-9, the 
crystallised structure of proMMP-1 illustrates intermolecular interactions between the Hx 
domain and the prodomain (Piccard et al. 2007) advocating for the auto-activation of MMPs 
occurring via the serine protease cleavage of their Hx domain. Besides its role in 
sequestering heme, other functions have been described for hemopexin namely its serine 
protease activity and suppression of lymphocyte necrosis amongst others (Mauk et al. 
2011). Although it lacks the typical catalytic triad ascribed to serine proteinases, there is 
enough evidence to suggest that it has serine protease activity, for example it is inhibited by 
serine protease inhibitors (Mauk et al. 2011). A study by Mecham and colleagues showed 
that glycine and alanine were more preferred at the P1 site of elastin over leucine and 
isoleucine by MMP-9 (Mecham et al. 1997). This supports the G6/P7 cleavage site that was 
identified in the current study.  
The difference in the hydrolysis of the synthetic substrate between infected and uninfected 
macrophages was insignificant for all the time points. There are some limiting factors in the 
activity assays. The presence of MMP inhibitors and other proteinases in the media with the 
potential of cleaving the substrate add a layer of complexity in analysis. The use of the 
synthetic substrate cannot discern whether the lack or reduced activity is due to inhibition 
by TIMPs or secretion of proMMPs.  
85 
 
The study confirmed the Q9/I10 cleavage site described by Kridel and colleagues (Kridel et 
al. 2001) and identified other cleavage sites, but additional supporting data is required. 
Identification of the scissile amino acids by mass spectrometry could have benefitted from 
labelling, for example, with Edmans reagent (Lombard et al. 2005). This would also enhance 
the signal of low abundant product peptides. The limitations of using the non-labelled 
synthetic substrate was identifying the product peaks on the HPLC with confidence making 
quantitation inconclusive. Identification and quantitation of the peptides could have been 
done by mass spectrometry given its high-resolution power and sensitivity over the HPLC 
but due to limited availability of the instrument the activity experiments were carried out 
using the HPLC. In future, optimisation of the gradient could be performed for example 
using a longer gradient for separating the product peaks further and enhancing the 
quantitation. 
3.7 Analysis of MMP-1 and MMP-9 activity by zymography  
 
Activity of secreted MMP-9 and MMP-1 
Zymography was used for further of the activity and has the advantage of discerning the 
activity of different forms of MMPs including their pro-forms. M. smeg induced an increase 
in MMP-9 activity which was maintained until 18 hours. Thereafter, a decline in the 
differential activity is observed in the 24-hour time point. Although the 18-hour time point 
shows the highest difference in activity (11-fold higher in the infected) there is an observed 
drop in gelatinolysis for both uninfected and infected compared to the 6-hour time point. 
This is important to note as it is indicative of a switch in the proteolytic phenotype, 
specifically, in the MMP repertoire of the macrophages between the 6 and 18-hour time 
point. It is well-documented that MMP-9 is responsible for recruiting macrophages to the 
site of infection and for granuloma maturation, therefore its enhanced activity is not 
surprising as it is imperative for degradation of the basal membrane and migration of cells 
to the site of infection.  
The secreted 113 kDa gelatinolytic band observed in the 6 and 72-hour infected harvests 
could represent heterodimerisation of the 82 kDa form of MMP-9 for regulating its activity 
and/or that of its interacting partner. There is a plethora of plausible interacting proteins 
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(discussed in the Proteomics Chapter 5) including sideroflexin and the 32 kDa form of 
MMP-1. Absence of the 32 kDa MMP-1 form in the infected lysate compared to the 
uninfected (Western blotting) supports the heterodimerisation of the 82 kDa MMP-9 and 32 
kDa MMP-1 in the infected secretome. Other studies have reported that dimerization of the 
proMMP-9 (TIMP free) and MMP-1 yields an active complex that functions synergistically in 
the hydrolysis of gelatin and collagen (Goldberg et al. 1992). It is therefore possible that 
MMP-1 and MMP-9 interact to regulate their ECM degrading function. The presence of the 
57 kDa gelatinolytic band presumed to be proMMP-1 in the uninfected secretome and its 
absence in the infected at 72 hours could be evidence of the postulated proMMP-9.TIMP-1 
dimer forming a ternary complex with proMMP-1 and inhibiting its activity in the infected 
secretome (Ogata et al. 1995). Neutrophil gelatinase-associated lipocalin is a 25 KDa protein 
that can form disulphide bonds with the C-terminal hemopexin domain of proMMP-9 
(Bouchet and Bauvois 2014). This complex has been detected in urine, blood, tissue and 
brain tumours and has been documented to indicate severity of disease in cancer (Bouchet 
and Bauvois 2014;Yan et al. 2001). In addition to neutrophils, NGAL is also expressed by 
other cells either than neutrophils, including macrophages, kidney cells (Jung et al. 
2016;Miharada et al. 2008) and adipocytes (Zhao et al. 2014). In the case of M. smeg 
infection the presence of NGAL in the infected and not the uninfected secretome may be to 
regulate the activity of MMP-9 with the aim of controlling substrate binding and recognition 
via the C-terminal hemopexin domain. Its binding to MMP-9 has also been reported to 
prevent its own degradation (Yan et al. 2001). Another important and relevant function of 
NGAL is its ability to scavenge bacterial siderophores and prevent egress of intracellular iron 
to the extracellular matrix starving bacteria thereby preventing their growth (Flo et al. 
2004;Zughaier et al. 2014). Thus, this interaction implies a dual role, that is a balance in the 
antimicrobial activity of NGAL and the tissue degrading activity of MMP-9. There was no 
evidence of the expression of proMMP-9 when the lysate and media (results not shown) 
were probed with the proMMP-9 monoclonal antibody (Appendix 2, Figure 6-11) suggesting 
that 82 kDa form of MMP-9 and not proMMP-9 is expressed and secreted by the THP-1 
macrophages. However, zymography is a more sensitive technique than western blotting 
thus the 113 kDa band could represent proMMP-9. Other possibilities include post-
translational modifications such as glycosylation and disulfide modification (Khan et al. 
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2012). In a previous study the upper band has been attributed  to activity of  proMMP-9 or 
the fully glycosylated form (Ashley et al. 2017).  
When comparing the hydrolysis pattern between gelatin and collagen, collagenolysis 
between uninfected and infected is not significantly different, except in the 6-hour time 
point where collagen hydrolysis is significantly higher in the infected versus uninfected. 
Similar results were evident when the second biological replicate was analysed (Appendix 2, 
Figure 6-3). Even so, the fact that the infected at 6 hours still shows similar hydrolytic 
activity to the uninfected at 3 hours validates the postulated substrate switch at the 6-hour 
time point with the objective of minimising the breakdown of gelatin and especially collagen 
type I. Thus, infection with M. smeg, results in the host restricting extracellular degradation 
especially of the lung collagen given its primary role in providing tensile strength to the lung 
possibly by balancing the pro- and anti-inflammatory responses. This is indicated by the 
regulation of MMPs which are also secreted as a response to inflammation. Additionally, 
collagen degradation has been associated with dissemination of M. tb, this rationalizes the 
tight regulation of collagen hydrolysis observed with zymography. Also, the 24 and 72-hour 
uninfected time point harvests show activity of proMMP-1 but not its active form even 
under serum starvation. The absence of proMMP-1 activity when either casein or collagen 
were used as substrates indicates that it is secreted at levels lower than the detection 
minima of the respective zymograms or largely in its pro-form to regulate its activity. Due to 
its narrower collagen binding site and the steric hindrance conferred by the propeptide 
(Nagase et al. 2006), cleavage of collagen in its native triple helical state and detection of 
proMMP-1 by collagen zymography is difficult.  
Elastin is a primary substrate for elastases such as MMP-12 but can also be cleaved by 
MMP-9 (Mecham et al. 1997;Senior et al. 1991) which was loaded as a positive control in 
elastin zymography. There was no enzymatic activity when elastin was used as a substrate, 
this could be attributed to the insolubility of the elastin (Mecham et al. 1997) making it 
difficult for cross-linking and polymerisation with acrylamide. This would hinder the 
retention of the Coomasie-blue background by the gel rendering the clear zones of 
hydrolysis undefined and invisible. 
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Another possibility is that the elastases were either not secreted by the macrophages or 
were secreted at concentrations lower than the detection limit of elastin zymography.   
To contain M. tb infection, well-formed granulomas and recruiting macrophages to the site 
of infection is important and is associated with the upregulation of MMP-9. The pronounced 
increase in the gelatinase activity of MMP-9 which declined in the later time points suggests 
that factors that are expressed and secreted as the macrophage response system (including 
resident macrophages) are sufficient in killing M. smeg. Thus, an alternate mechanism is 
employed by the host in sterilizing M. smeg without causing irreparable tissue damage. In 
this case by switching the substrate specificity of secreted MMP-9 as was evident in the 
later time points having caseinolytic activity in contrast to the earlier time points. The switch 
is postulated to occur between the 6 and 18-hour time point. The mutation of the 
propeptide cysteine residues in proMMP-3 to serine or histidine (C75S and C57H) resulted in 
proteins that were only able to hydrolyse casein when activated with APMA (Galazka et al. 
1996) and that the R74/D79 salt bridge of the propeptide are important for APMA activation 
suggesting direct interaction with these residues. The R74 (R106 in proMMP-9) has also 
been shown to be important for the small inhibitor JNJ0966 binding and inhibiting activation 
of MMP-9 from the 86 kDa to the fully active 82 kDa form. Since both the uninfected and 
infected secretome had caseinolytic activity only in the later time points and none in the 
lysate, this indicates that to generate the fully activated form of MMP-9 (82 kDa) requires 
that it be secreted together with other factors that destabilise the propeptide such as 
temperature, oxidation and other proteins that accompany prolonged incubation. It is 
possible that the earlier time points secrete the 86 kDa form while the later ones secrete 
the 82 kDa form, which would be indistinguishable by zymography given the small 
difference in molecular weight. Another explanation is that these differences reflect the 
effects of alternative splicing or posttranslational modifications of proMMP-9 that are 
ultimately processed differently in the ECM. These may be strategies employed by the host 
in preventing chronic gelatinase activity resulting in severe tissue damage and repurposing 
the function of MMP-9 toward regulation of processes such as angiogenesis and wound 
healing amongst others.  
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Activity of intracellular MMP-9 and MMP-1 
The intracellular gelatinase activity of MMP-9 (82 kDa) was not significantly altered by the 
M. smeg infection, in fact the activity was only slightly higher in the uninfected in the 18 and 
24-hour time points (Figure 3-18), suggesting that the activity of secreted MMP-9 is 
controlled in the ECM. The gelatinolytic band corresponding to the 67 kDa molecular weight 
shows higher activity in the uninfected during the 3, 6 and 72-hour time points suggesting 
that its presence in the infected is suppressed by minimising activation of the 82 kDa form. 
There is appearance of the band corresponding to proMMP-1 at 72 hours which had higher 
activity in the uninfected versus infected, a pattern observed in the secretome and 
expression levels as evident from the western blotting. This contrasts with M. tb infection 
which is characterised by an increase in the expression and activity of MMP-1 (Elkington et 
al. 2011a;Elkington et al. 2005a). The absence of caseinolysis in the cell lysates, despite 
eliciting gelatinase activity and with the later time points of the secretome showing 
caseinolysis, indicates that the proteolytic phenotype does not favour casein as a substrate. 
Substrate preference could be dictated by the presence of other proteins or by 
posttranslational modifications which ultimately conferred caseinolytic activity to the 
secreted MMP-9 at the later time points. It is also important to note that the structure of 
casein is more complex than that of gelatin with O-glycan linked sites, disulfides and 
phosphorylation sites (Ecroyd et al. 2010;Lasa et al. 1997). Processes such as invadopodia 
formation, phagocytosis, exo- and endocytosis require cytoskeletal remodelling and 
consume energy (Kolonko et al. 2014;Ressad et al. 1999;Thomas et al. 2006), therefore 
intracellular energy could be reserved for these processes and diverged from breakdown of 
complex substrates hence the absence of casein hydrolysis by intracellular proteases. 
Maintenance of the microtubular structure has also been reported to be highly important 
for the secretion of MMP-9 and facilitating endocytosis (Chintala et al. 1998;Hanania et al. 
2012). Regulation via modification of cysteine residues could also alter the secretion and 
substrate specificity of MMP-9 given the location of these cysteines as alluded to earlier. 
Protein disulphide isomerase (PDI) is one of the enzymes that has been shown to regulate 
the activity of MMP-9, not only does it increase the secretion of MMP-9 but was also able to 
reactivate and renature reduced and denatured MMP-9 (Ali Khan and Mutus 2014;Khan et 
al. 2012).  
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In the uninfected lysate, MMP-9 migrated more slowly than in the infected lysate at 18 and 
24-hour time points, unlike the 72-hour time point. This could be attributed to a difference 
in posttranslational modification and/or alternative splicing of MMP-9. These modifications 
may be impacting the secretion and activity of MMP-9. For example, the activity of the 82 
kDa form of MMP-9 was higher in the infected secretome at 18 and 24 hours unlike in the 
72-hour time point where activity of the infected is lower than the uninfected secretome. 
The differential migration pattern may be influenced by two important factors, that is, 
glycosylation and redox modification of the disulfide bonds possibly located at the cysteine 
switch, fibronectin and/or Hx domain. Khan and colleagues have demonstrated that the 
cysteine to serine mutations in the cysteine switch, fibronectin repeats and to a lesser 
extent the Hx domain resulted in underglycosylated forms. Interestingly, these mutations 
abrogated the secretion of MMP-9 while the ones located in the Hx domain only decreased 
its secretion (Khan et al. 2012). With regards to redox control, the reduction of MMP-9 
resulted in slower migration and significant decrease in activity (Figure 3-20 and 3-21). In 
the current study the faster migration of MMP-9 in the infected at the 18 and 24-hour time 
points is indicative of a drop in pH and an oxidative burst that accompany phagolysosomal 
fusion and bacterial killing an environment that could have resulted in modification of the 
cysteines redox state. These alterations would in turn lead to underglycosylation in the 
infected cells, a strategy employed to decrease its secretion and activation in the ECM 
where the differential activity declines in the 24 and 72-hour time points. The drop in pH is 
associated with the acidification steps during phagolysosomal fusion facilitated by vATPase 
which has been shown to decrease and increase the activity of MMP-9 and MMP-2, 
respectively, when inhibited with concanamycin in pancreatic cancer cells (Chung et al. 
2010;Chung et al. 2011). Although PDI has been shown to rescue denatured and reduced 
MMP-9 its role during the acidification steps is ambiguous and may be acquired to minimise 
its secretion and activation. In contrast to the 18 and 24-hour time points, the faster 
migration of MMP-9 in the uninfected at the 72-hour time point is intriguing and may depict 
the ability of the macrophages to restore homeostatic conditions as indicated by the higher 
activity of secreted MMP-9 in the uninfected versus the infected.    
The migration of MMP-1 is contrary to that of MMP-9. The active 47 kDa form of MMP-1 
migrates more quickly in the infected lysate versus uninfected in the 18 and 24-hour 
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harvests. Whereas in the 72-hour lysate, like the secretome, this band disappears in the 
presence of M. smeg. Western blotting of reduced MMP-1 migrates more slowly than non-
reduced (Appendix 2, Figure 6-10) implying that discrepancies in the redox conditions may 
be responsible for different migration patterns. Reduction of the lysate with β-
mercaptoethanol abrogated gelatinolysis of MMP-9 while the MMP-1 was resistant with the 
band of activity migrating more slowly for all the time points. Thus, it is possible that the 
113 kDa band in the ECM is indeed a heterodimer of MMP-9 and MMP-1 that is induced by 
changes in their redox and glycosylation states, a synergy that serves to control degradation 
of the ECM. In relation to TB cavitary granulomas, a study reported that the outermost 
environment of the necrotic centre is reducing (Marakalala et al. 2016) this suggests that at 
this site the activity of MMP-9 is abrogated allowing the release of MMP-1 from the 
heterodimer to degrade collagen causing severe tissue damage and dissemination of M. tb.  
Although zymography is an inexpensive and sensitive technique, quantitation by 
densitometry can be limited by the overlap in molecular weight making the discernibility of 
the bands a challenge. The difficulty in solubilizing substrates such as collagen can affect the 
sensitivity of the technique hence a positive control was also loaded with the gels. Working 
with unknown concentrations of MMPs makes it difficult to load concentrations that are 
within linear detection limit. The use of a purified MMP control curbs this problem as 
normalisation methods can be used during densitometric analysis like in the current study. 
Loading equal amounts of total protein for the uninfected and infected also minimises 
biases. These methods are widely applied in zymography (Gogly et al. 1998;Ren et al. 
2017;Scannevin et al. 2017).   
 
3.8 Hydrolysis of the MMP-1 fluorogenic substrate   
The higher level of MMP-1 activity secreted by uninfected macrophages compared to 
infected in the 24-hour time point and with significance in the 72-hour time point supports 
the zymography data. As mentioned earlier MMPs are regulated at different levels, this is 
important to note since they perform various other functions besides ECM degradation. The 
MMP-1 fluorescence activity assays suggest that the activity of secreted MMP-1 is regulated 
at different levels in the uninfected and infected macrophages. For the uninfected the 
regulation is implied at the level of activation where cleavage of the propeptide is either 
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inhibited or occurring at a very slow rate post-secretion. This is also indicated by gelatin 
zymography where the observed hydrolysis band corresponds to the proMMP-1 rather than 
its active form. Loading higher protein concentrations resulted in 47 kDa active form also 
observed only in the uninfected (Appendix 2, Figure 6-1), suggesting that at higher 
concentrations proMMP-1 autoproteolysis and activation occurs. Interestingly, in the 
infected cells the significantly lower levels of activity at 72 hours implied that the secretion 
of proMMP-1 is tightly regulated compared to the uninfected (also depicted by absence of 
secreted proMMP-1 band of activity in Figure 3-15C) and/or the expression levels are lower 
compared to the infected. Further investigation was carried using western blotting and 
discussed in section 3.9. 
Although, this high-throughput method is expensive it is specific as it involves capturing 
MMP-1 with a specific antibody coated on the plate prior assaying the activity. This 
minimises substrate hydrolysis by other MMPs, a well-known challenge when using 
synthetic MMP substrate (Bracher et al. 2013;Kridel et al. 2001). Although quantitation was 
carried out with the use of a standard curve the nonlinear relationship between substrate 
concentration and fluorescence changes because of ‘inner filter effects’ which is common 
with use of fluorogenic substrates (Lombard et al. 2005) should be considered. Unlike 
zymography the concentration of proMMP-1 could not be quantified as the change in 
fluorescence was very minute hence APMA activation of the secretome was done prior 
assaying the activity.  
3.9 Expression levels of MMP-1  
When examining the expression pattern of MMP-1 from lysate samples prepared under 
non-reducing versus reducing conditions, only a faint band of active form of MMP-1 (46 
kDa) was detected in the uninfected 72-hour time point under non-reducing conditions 
(Figure 3-24). Under reducing conditions multiple bands of the pro- and active forms were 
detected. The amount of proMMP-1 detected in the uninfected was elevated by about 
1.6-fold compared to the infected lysate. This implies that the infected cells also expressed 
proMMP-1 but at a slightly slower rate, thus regulating MMP-1 activity in the ECM by mainly 
controlling its secretion, whereas in the uninfected cells the activity is regulated by 
controlling its activation in the ECM.  The 32 and 25 kDa bands that were detected in the 
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uninfected and infected, respectively, could potentially be due to autolysis and degradation, 
respectively. This is substantiated by the absence of the intracellular 32 kDa gelatinolytic 
band for the infected versus uninfected in the lysate of the 72-hour time point. Autolysis is 
concentration dependent again suggesting that the expression of MMP-1 may be slightly 
higher in the uninfected. The MMP-1 catalytic domain (32 kDa) alone has been shown to be 
capable of hydrolysing non-collagenous substrates only, such as gelatin (Chung et al. 2004). 
Truncation of the MMP-1 C-terminal hemopexin domain caused inhibition of collagen 
hydrolysis by compromising its binding and unwinding ability to the collagen triple helical 
structure (Chung et al. 2004). Therefore, M. smeg alters the pathways which govern the 
secretion and/or expression of MMP-1. These pathways/mechanisms are also implied to be 
different from those induced by stress conditions. This is because the differential activity 
induced by M. smeg was not markedly masked by the potential stress that might have been 
caused by the serum-free conditions in which the macrophages were cultured.   
 
3.10 Effect of APMA- and heat-activation on gelatin hydrolysis 
The differences in the gelatinolytic pattern between heat-activated and APMA-activated 
secretome suggests that the concentration of the 67, 82 and 120 kDa forms, in the 
physiological context may result in different hydrolysis products of the same biological 
substrates. The Hx domain contributes to substrate binding and selectivity (Chung et al. 
2004;Eckhard et al. 2014;Overall 2002;Piccard et al. 2007) thus it is possible that the 82 kDa 
and 67 kDa forms have different substrate cleavage sites. The Hx domain is also responsible 
for the interaction of MMPs with other proteins and multimerization to higher molecular 
weight proteins which exhibit gelatinolysis such as the 120 kDa form. The findings also 
highlighted the importance in the period of activation since the 2-hour and 16-hour 
activation generated different concentrations of the MMP-9 forms. Therefore, under 
physiological conditions during infection with M. tb, the activation of MMPs may either be 
beneficial or detrimental to the host as a result from masked differences in MMPs secreted 
by uninfected and infected macrophages. In turn, factors such as inflammation and ECM 
destruction would be perpetuated. This also highlights the importance of TIMP-1 in 
minimising the activation and conversion of MMP-9 through binding and stabilising the Hx 
domain.  
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Summary  
In the current study, M. smeg-induced an increase and decrease in the activity of MMP-9 
and MMP-1 respectively in macrophages in contrast to M. tb infection. This supports the 
postulation that upregulation of MMP-1 is specific for M. tb infection (Elkington et al. 
2005a). The ability of macrophages to clear the M. smeg infection without causing 
irreparable tissue damage is by inducing a switch in the proteolytic repertoire of the 
macrophages to one that generates the same degradation products as the uninfected 
macrophages. This switch is induced between the 6-hour and 18-hour time point and could 
be facilitated and regulated by oxidoreductases and isomerases. These enzymes may alter 
the specificity of the MMPs by acting on the substrate and/or the MMPs. Therefore, the 
challenge in designing specific MMP inhibitors is also due to their activation which is 
accompanied by dissociation of the Hx domain resulting in loss of substrate specificity. 
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 Chapter 4 
Proteomics: Introduction and literature review 
 
Since homeostasis is essential for normal functioning of the body, studying physiological 
processes at the protein level provides a broader scope of knowledge in context of their 
molecular function. Proteomics, particularly mass spectrometry-based proteomics, allows 
for monitoring of the dynamic function of proteins in complex systems such as tissue 
samples, whole cell lysates, the secretome and blood/plasma samples. It is a powerful tool 
employed in deciphering protein networks in context to their spatial and temporal 
expression, including their dysregulation in diseased compared to non-diseased states, 
hence its significance in the discovery of biomarkers, diagnostics and drug discovery.  
 
4.1.1 Bottom-up proteomics: A simplified work flow 
In principle, gel-based techniques such as western blotting and 2D-PAGE are aimed at 
analysing intact proteins, with the latter profiling larger numbers of proteins as opposed to 
a single protein. Although generating greater information content than western blotting, 
2D-PAGE still falls short in terms of high-throughput screening, which has evolved and 
advanced the field of science. Comparing data between different samples by 2D-PAGE can 
be complex requiring expertise in pattern-matching thus limiting the number of samples and 
data output that could be analysed (Aebersold and Mann 2003). The other limitation of the 
technique is that only highly abundant proteins are profiled and the limited dynamic range 
(Aebersold and Mann 2003). However, with 2D-PAGE isoforms can be clearly separated and 
identified on the gels, which is difficult with mass spectrometry where cleavage of proteins 
causes loss of the isoform defining features. Bottom-up proteomics involves the analysis of 
peptides, ultimately matching them to their respective proteins, whereas top-down 
proteomics deals foremost with intact proteins (Aebersold and Mann 2016). Mass 
spectrometers are instruments exploited largely for bottom-up proteomics and utilise the 
ionisation of peptides to generate spectra of mass to charge ratio (m/z) versus intensity. 
This is termed the total ion chromatogram (TIC) produced by the first mass analyser (MS1) 
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and correlates with the relative abundance of peptides. The second mass analyser (MS2), 
which is relevant in the case of tandem mass spectrometry (MS/MS) used in this study, 
deconvolutes the peptide sequence, allowing for matching to the respective proteins 
(Aebersold and Mann 2003;Aebersold and Mann 2016). Briefly, a typical work flow (Figure 
4-1) commences with tryptic digest of the proteins followed by in-line chromatographic 
separation of the tryptic digest by reverse phase HPLC. The peptides are then ionised by 
either matrix assisted laser desorption and ionisation (MALDI) or electrospray ionisation 
(ESI) and enter the mass spectrometer where they are sequentially subjected to MS1, 
fragmentation, and MS2 scans. The acquired spectra are then matched to theoretical 
spectra, which are produced in silico from predicting tryptic fragments of the database 
protein sequences (Aebersold and Mann 2003;Aebersold and Mann 2016).  
 
Figure 4-1: illustration of a typical proteomics experiment workflow. [adapted from 
(Aebersold and Mann 2003;Aebersold and Mann 2016)] 
4.1.2 Tandem mass spectrometry (LC-MS/MS) 
Given that this technique relies mainly on the measurement of the mass of molecules 
residing in complex systems, accuracy, reproducibility, resolution and sensitivity are 
inherently important to a mass analyser. There are four mass analysers currently in use for 
proteomics which includes the time-of-flight (TOF), Fourier transform ion cyclotron (FT-
MS/FT-ICR), linear quadrupole ion trap (LIT) and the orbitrap mass analyser. These mass 
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analysers have been further developed in combination/hybrid with respect to their 
individual capabilities to produce high-performing instruments (Aebersold and Mann 
2003;Eliuk and Makarov 2015). 
In the current study, discovery proteomics was performed by employing a Q-Exactive 
instrument which has a built in Orbitrap mass analyser (Michalski et al. 2011) (Figure 4-2). 
This type of mass analyser exploits the electrostatic field generated axially by the inner 
spindle-like electrode forcing the axial acceleration of the ions upon injection, which are 
then trapped in orbital motion by the outer-barrel electrode. Detection of the current 
produced by the oscillating ions is through the differential amplifier situated in the outer-
barrel electrode of the orbitrap. The spectrum of the m/z charge ratio is extrapolated from 
the image current by using Fourier transformation (Eliuk and Makarov 2015). 
 
Figure 4-2: Schematic diagram of the Q-Exactive instrument. 
[adapted from (Eliuk and Makarov 2015)] 
 
 
4.1.3 Mass spectrometry as a tool for proteomic studies 
There are several factors that contribute to a successful proteomics experiment, including 
sample preparation, the ion source, mass analyser, and for data output and analysis, the 
software and algorithms used. The MALDI and ESI are commonly used for ionizing peptides 
and/or intact proteins for the earlier. The electron spray ionisation (ESI) is employed for 
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analysis of more complex material since it is easily coupled to ion traps or triple quadrupole 
analysers which allow further fractionation by either collision induced dissociation (Quesada 
et al. 1997) and/or electron induced dissociation (ETD) of pre-selected ions (Aebersold and 
Mann 2003). In the current study high-energy collision dissociation (HCD), a type of CID, was 
coupled to ESI. 
Fragmentation by ETD generates the c and z ion fragments by cleaving the bond between 
the R-group primary carbon and the N-terminal side of the amide bond. ETD induces 
fragmentation only by transfer of electrons to this bond hence preserving post-translational 
modifications such as sulfonation, phosphorylation and glycosylation (Figure 4-3). Regarding 
fragmentation by CID, once ions are in the gaseous phase they are allowed to collide with 
neutral molecules such as helium, cleaving the peptide bond thus producing b and y ions 
(Mikesh et al. 2006). 
 
Figure 4-3: Illustration of the nomenclature of fragmented ions. 
[adapted from (Mikesh et al. 2006)  
 
Since ESI requires the sample to be in liquid form, it is often coupled to liquid 
chromatography (LC). Once the sample is ionised it is ultimately introduced into the first 
mass analyser (MS1) where the generated m/z versus intensity spectra of the measured 
peptide is relatively correlated to its abundance (Aebersold and Mann 2003). To acquire 
MS2 data and sequence coverage, a round of fragmentation is performed by preselection of 
ions for further fragmentation, usually the ‘top 10’ ions with the highest intensity in a given 
window are selected for fragmentation. Here, the intensity of the peptide is dependent on 
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the experimental preparation, hence referred to as data-dependent acquisition. Bias in 
identification of high abundant peptides over less abundant peptides is minimised by setting 
the dynamic exclusion. Dynamic exclusion refers to the exclusion of peptides with the use of 
precursor masses of peptides to be excluded within a set period during MS/MS analyses 
(Domon and Aebersold 2010;Hodge et al. 2013;Zhang et al. 2016). This eliminates selecting 
the same peptides, usually high abundant proteins thereby broadening the peptide 
sequences covered.   
4.1.3.1 Methods of quantitative data analysis 
The methods used for quantifying peptides are mostly relative however absolute 
quantitation can be applied by spiking a peptide sample with a labelled peptide as a 
reference standard with a known absolute value. This would allow for extrapolation using a 
standard curve. With relative quantitation both labelled, or label-free approaches can be 
used. Addition of tags/labels can be achieved through metabolic, chemical or enzymatic 
methods yielding isotopes that can be differentiated by mass shifts. These include SILAC, 
iCAT, iTRAQ amongst others, however these methods are more expensive, and can 
therefore be limiting in terms of the number of comparative samples that can be analysed 
(Cox et al. 2014;Tate et al. 2013). For the purposes of this study a label-free approach was 
used.  
 
Label-free quantitation 
The use of high-resolution mass analysers allows label-free quantitation (LFQ) at the MS1 
level where the m/z elution profile of a peptide is quantified as a function of the LC 
retention time. This is different from other methods that utilise spectral counting and 
extraction ion chromatograms (Cox et al. 2014;Tate et al. 2013). Since the Orbitrap meets 
the high mass resolution requisite, label-free quantitation was used in the current study. 
MaxQuant has two built-in algorithms that can be used for label-free quantitation namely 
LFQ and iBAQ. Given that the LFQ depends on the m/z elution profile of a peptide, 
compared across samples, this poses limitations since a protein group can be reported as 
unidentified based on the reproducibility of the selected peptide across samples especially 
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for low abundant proteins (Cox et al. 2014). To compound this, the MaxLFQ algorithm uses 
stringent normalisation formulas for a peptide to be reported quantifiable thus undermining 
the biological significance that can be learned from the proteomics data. In contrast, iBAQ 
uses the inferred total intensity of the protein divided by the number of observed tryptic 
peptides with a length between 6 to 30 amino acids (Krey et al. 2014). The recently 
developing data independent acquisition method (DIA), SWATH (Sequential Window 
Acquisition of ALL Theoretical Fragment Ion Spectra) is performed on fast scanning hybrid 
MS usually a quadrupole mass analyser in conjunction with a TOF or Orbitrap (Ludwig et al. 
2018). It entails the recording of a single precursor ion (MS1) followed by a series of MS2 
scans over a defined wide precursor isolation windows. Thus, information is generated from 
extracting ion chromatographs at the MS1 and MS2 level (Ludwig et al. 2018). Peptide-
centric scoring can be used to analyse SWATH-MS generated data. 
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Materials and methods 
 
4.2.1 Filter aided sample preparation (FASP) 
FASP was first described by Wisniewski and colleagues (Wisniewski et al. 2009) and was 
used to prepare all the samples for discovery proteomics. 30 kDa MWCO filters (Merck) 
were used, and both the 18-hour time-point media (also referred to as the secretome) and 
lysate samples were centrifuged at 15 000 rpm until the dead volume is reached. 
Thereafter, protein denaturation was performed using 200 µl of UA solution [8 M Urea; 0.1 
M Tris; pH 8.5] which was added to the filters and spun at 15 000 rpm for 15 minutes. This 
step was repeated twice for the lysate samples. Sample reduction was carried out by 
incubation with 0.1 M DTT in 50 mM NH4CO3 buffer for 30 minutes. To prevent disulphide 
bond re-formation, 0.05 M of iodoacetamide (prepared in 50 mM NH4CO3) was incubated 
with protein samples for 20 minutes in the dark. After the flow-through was discarded the 
samples were washed twice with urea solution and three times with 50 mM NH4CO3 buffer 
containing 20 mM calcium chloride (CaCl2), with pH 8 (optimum trypsin activity). Digestion 
with trypsin, which was prepared in 50 mM NH4CO3 buffer containing 20 mM CaCl2 was 
carried out at a ratio of 1:100 with respect to protein concentration. Finally, the samples 
were incubated at 37 °C for 16 hours in a humidified chamber. To prevent further digestion, 
formic acid was added to a final concentration of 0.1% to the peptide solution.  About 80 µl 
of the peptide digest was eluted from the filter into new collection tubes by centrifuging at 
15 000 rpm for 10 minutes. To elute the peptides further, the filter was washed with 40 µl 
with ammonium bicarbonate buffer.  
The eluent was desalted using an in-house packed C18 stage tip. Prior to loading the sample 
on the C18 stage tip, the C18 was activated by washing three times, first with solution B 
(80% Acetonitrile; 0.1% Trifluoroacetic acid), then with solution A (2% Acetonitrile; 0.1% 
Trifluoroacetic acid). The acidified tryptic peptides were loaded onto the stage tip, followed 
by washing three times with solution A.  Peptides were eluted using 50 µl of solvent C (60% 
Acetonitrile; 0.1% Trifluoroacetic acid) and collected in glass vials. A vacuum concentrator 
was used to evaporate solution C by centrifuging the samples for 30 minutes at 30 °C. Once 
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the peptide pellet had dried, it was re-suspended in 50 µl of solution A for mass 
spectrometry analysis. 
4.2.2 Liquid chromatography mass spectrometry (LC-MS/MS) analysis 
parameters 
All the discovery proteomics experiments were performed on a Q-Exactive Quadrupole-
Orbitrap mass spectrometry (Thermo Scientific) which was coupled to the Dionex Ultimate 
3500 RSLC nano_LC system (Thermo Scientific). It should be noted that three technical 
replicates (i.e. three injections per experiment) were analysed for both lysate and media. 
The sample injection volume was optimised to give comparable MS intensity levels between 
the samples, with a minimum intensity of 3E9. Peptide samples were loaded on a 40 cm C18 
analytical column (packed in- house with Aeris peptide 3.6 µM beads, Phenomenex), 
thereafter elution was carried out using a linear gradient of 6 – 35% solvent B (95% 
acetonitrile, 0.1 formic acid), at a constant flow rate of 300 nl/min. The gradient was 
45 mins and 120 mins long for the secretome and lysate, respectively. The acquisition of 
data was carried out using Xcalibur software (Thermo scientific, v2.2) in positive ion mode. 
MS1 scans were acquired with a resolution of 70 000, an automatic gain control  of 3 x 106 
and an ion injection time of 250 ms. The MS/MS scans were acquired at a resolution of 
17 500, AGC target of 2 x 105, ion injection of 120 ms and the normalised collision energy 
(NCE) of 25. The peptide matching was set to ‘preferred’, isotopic exclusion and a dynamic 
exclusion of 30 s. 
 
4.3 Raw data analysis and processing 
Analysis of the raw data files was performed by MaxQuant (version 1.5.3.12) using 
Andromeda search engine in the Blackburn Lab, searching against the Human Uniprot 
database (2018) and Mycobacterium smegmatis EC122 database (2018) to generate protein 
quantification and identification data. The raw files were run simultaneously, and each 
technical replicate was set as a separate experiment on MaxQuant. The majority of the 
MaxQuant settings used were default, with the false discovery rate (FDR) set at 1% against a 
reverse decoy of the database, with variable modifications of oxidation (M), and Acetyl 
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(Protein N-term), and a fixed modification of carbamidomethyl (C). A maximum of two 
missed cleavages was allowed. To quantify proteins, only unique peptides were used to 
increase the confidence of identified protein groups and iBAQ was selected and used 
downstream for further analysis. Thereafter the generated quantitative data were further 
analysed with Perseus (version 1.6.1.3).  
The peptides that were identified as contaminants, reverse/decoy, or identified only by site 
were excluded. To compare between uninfected and infected samples, peptides that were 
identified in at least two of the replicates were used in the two-sample t-test (p-value < 
0.05) to identify differentially expressed proteins. A p-value < 0.05 was used as a cut-off and 
any proteins that had a p-value less 0.05 were considered significantly differentially 
regulated. Since the p-value considers the variances between samples this also justifies 
using these proteins for downstream analysis and biological interpretation. Additionally, 
interference from false positives is less likely since the FDR was set at 1% in MaxQuant to 
exclude them. The gene/protein IDs that were found to be significantly different were 
assessed for biological relevance and function using FunRich 3.1.3 tool and STRING for 
analysing protein-protein interactions. The same assessment tools were used for proteins 
that were found to be uniquely expressed in either uninfected or infected samples (for both 
lysate and media). For a protein group to be considered as exclusively identified, a minimum 
of 2 peptides were required  to be identified in the uninfected and 0 in the infected, or visce 
versa. This builds stronger evidence for differences induced by the infection. 
The GO terms that had p-values < 0.05 were considered significantly enriched, and for 
STRING analyses the level of confidence was set at high confidence and medium confidence 
for the lysate and secretome, respectively. This reason being that the secretome had a 
smaller data set compared to the lysate. The thicker the line between the proteins the 
stronger the confidence of interaction between the proteins. Non-interacting proteins were 
removed. 
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Results 
 Modification of the THP-1 macrophage proteome and 
secretome by infection with M. smeg 
The inherent function and tight regulation of matrix metalloproteinases (MMPs) for tissue 
homeostasis and remodelling has already been emphasised, including their dysregulation in 
diseased states. It is thus important to understand the factors that regulate them upstream 
and downstream. This is essential because the overlap in the substrates they degrade and 
close similarity in their catalytic and substrate binding sites still poses challenges in 
developing specific inhibitors, therefore, targeting factors that regulate MMPs and their 
regulatory/binding sites is an option still to be explored. Briefly, THP-1 macrophages were 
infected with M. smeg, followed by harvesting of the media and lysate at different time 
points. The 18-hour time point was prepared using the FASP protocol and analysed by the 
Q-Exactive.  
There was a clear difference in chromatographs of the secretome (Figure 4-4), where the 
uninfected samples had peptides eluting between 16 and 26 minutes that were not visible 
in the infected samples. The chromatographs from the lysate showed no obvious 
differences (Figure 4-5) and the TIC intensities were comparable. The trypsin digestion was 
efficient, with 89.6% of identified peptides containing no missed cleavages (Figure 4-6). 
Between the media and lysate samples, 2878 protein groups were identified, with 24 and 29 
identified as contaminants and decoy hits, respectively.  
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Figure 4-4. Representative chromatograph of the uninfected and infected secretome. 
 
 
  
Figure 4-5: Representative chromatograph of the uninfected and infected lysate. 
Uninfected 
Infected 
Uninfected 
Infected 
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Figure 4-6: Efficiency of trypsin digestion. All The identified peptides are presented 
according to the number of missed trypsin cleavage.  
All the 238 protein groups that were identified in the secretome overlapped with the 2107 
protein groups in the lysate. Out of the 202048 spectra submitted, 36.98% were identified. 
The ion injection times and percentage of MS/MS identified (Figure 4-7) are similar between 
the triplicates, except for the infected secretome. This is corroborated by the multi-
scatterplots, which show good correlation coefficients, between 0.763 and 0.929, for the 
lysate samples, while the secretome had correlation coefficients of 0.101 and 0.951 (Figure 
4-8). This may be due to the low abundance of secreted proteins, and the high sample-
sample variation observed in the secretome samples in this dataset. The loss of proteins 
during FASP preparation could also explain the variability since a dilute sample 
concentration, that is, media can lead to low abundance during the concentration steps. 
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Figure 4-7: Reproducibility of data from technical injection replicates. (A) The ion injection 
times and (B) percentage of MS/MS identifications were used to analyse differences 
between the three technical replicates. Inf_Lys1 and Inf_Med1 represent infected lysate and 
media, respectively, followed by the number of the technical replicate. Similarly, Uni_Lys1 
and Med_Lys1 represent uninfected lysate and media, respectively, followed by the number 
of the technical replicate. 
 
A 
B 
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Figure 4-8: Scatterplot of the technical replicates. (A) The lysate and (B) secretome 
injection replicates were compared using the correlation co-efficient (R2). The R2 values are 
indicated (blue). Three technical replicates were analysed for each experiment. 
4.4 Characterisation of differentially expressed and secreted proteins 
As mentioned earlier, iBAQ was used for quantification and for qualitative analysis of the 
data. The three technical triplicates of the secretome and lysate each clustered together as 
well as the infected and uninfected (Figure 4-9). Differential expression of proteins is 
depicted in the heat map. There are 295 (Appendix 3, Table 6-4) and 18 (Appendix 3, Table 
6-5) significantly differentially regulated protein groups between M. smeg infected and 
uninfected lysate and secretome samples, respectively. Interestingly, out of these, there 
were only two overlapping proteins between the secretome and lysate (Figure 4-10), and 
these were MMP-9 and Beta-hexosaminidase subunit beta (HEXB) (Accession IDs: P14780 
and P07686, respectively). Differential expression of the protein groups was visualised by 
volcano plots (Figure 4-10B and C) which indicate fewer protein groups (Appendix 3, Table 
6-6) are significantly differentially regulated than indicated by two-sample t test as expected 
since volcano plots are FDR corrected. The significantly different proteins groups calculated 
by the two-sample t test were used for downstream analysis and for biological 
interpretation. This is because p-values take into account variation between samples, 
peptides that were identified in at least two of the replicates were used in the two-sample 
t-test, FDR of 1% was used to filter false positives in MaxQuant and most of the false 
A B 
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positives would be outliers and excluded in STRING and GO analysis. Thus, the volcano plots 
were used to validate the highly significantly differentially expressed and secreted proteins.  
 
Figure 4-9: Hierarchal cluster analysis of intracellular and secreted proteins. The iBAQ 
intensity was used and k-means were selected for data analysis and processing of the three 
technical replicates of each experiment.  
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Figure 4-10: Representation of the computed dysregulated proteins. (A) The Venn diagram 
represents and compares the significantly different protein groups between infected versus 
uninfected in the media and the lysate as calculated by the two-sample test. (B) Volcano 
plots of the lysate and (C) media indicated the upregulated and downregulated protein 
groups. The significantly different ones are depicted by red dots.  
The iBAQ intensities of MMP-1, MMP-3, MMP-14 and tissue inhibitors TIMP-1 and TIMP-3 
were compared between infected and uninfected samples prior to normalisation using bar 
graphs (Figure 4-11). MMP-1 was only identified in the secretome and was only 2-fold 
higher in the infected samples, while MMP-9 was upregulated in both the lysate and 
secretome. The expression of MMP-14 in the secretome was comparable between 
uninfected and infected. While TIMP-1 was only identified in the infected lysate and 
secretome, TIMP-3 was only identified in the uninfected secretome. These were identified in 
the three replicates excluding the possibility of an artefact. 
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Figure 4-11: iBAQ intensity of identified MMPs in infected versus uninfected in the lysate 
and secretome. MMP-9 was significantly dysregulated with a p-value < 0.0001.  
 
Functional annotation: Dysregulated lysate proteome 
GO enrichment terms that were considered significantly enriched were those with p-values 
≤ 0.05. The differentially expressed proteins in the lysate proteome indicate enrichment of 
GO terms for exosomes, lysosomes, mitochondrion, centrosomes and cytoplasm. The 
disregulated proteins are also associated with GO terms that indicate enzyme activity from 
different classes of enzymes (including ligases, GTPases, oxidoreductases) (Figure 4-12). The 
infection enriched biological processes in energy pathways and metabolism (Figure 4-13). 
With respect to RNA binding, the tRNA aminoacylation was the biological pathway that was 
mostly represented. Purine nucleotide de novo biosynthesis II which conincides with the 
ligase activity that is increased in the molecular function classification was another 
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biological pathway present (Figure 4-12). Another valuable classification was the site of 
expression which yielded the ascites cancer cells and monocyte in the top two (Figure 4-13).  
 
 
Protein-protein interactions of MMP-9 and dysregulated lysate proteome 
The significantly dysregulated proteins were analysed for protein-protein interaction by 
STRING database (STRING-DB) (Figure 4-14). MMP-9 has direct interactions with ILB-1 
(Interleukein-1β), ICAM (Intercellular adhesion molecule 1), IL-1RN (Interleukin-1 receptor 
antagonist protein), PYCARD (Apoptosis-associated speck-like protein containing a CARD) 
and indirectly with PSAP (Prosaposin), PLAUR (Urokinase plasminogen activator surface 
receptor), MYLK (Myosin light chain kinase, smooth muscle), VCP (Transitional endoplasmic 
reticulum ATPase), DARS (Aspartate--tRNA ligase, cytoplasmic) and FSCN1 (Fascin). MMP-9 
together with IL-1RN, ICAM-1, PLAUR and PSAP were also found to be significantly 
dysregulated when volcano plots were used. The Rab-related proteins also form an 
important part of this network.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12: Functional annotation of dysregulated proteins from the lysate harvest.  
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Figure 4-13: Further classification of dysregulated proteins harvested from the lysate. 
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Figure 4-14: MMP-9 protein-protein interactions with other dysregulated intracellular 
proteins. MMP-9 (arrow) and its interacting proteins are illustrated. Rab-related proteins 
are also depicted (black circle). The proteins are colour coded according to their biological 
function (colour key) and FDR values are indicated as predicted by STRING. 
Functional annotation: Dysregulated proteins in the secretome 
The 18 protein groups that were differentially regulated were mostly associated with the 
nucleosome, centrosome, nucleoplasm, exosomes and nucleolus, with the p-value for 
enrichment less than 0.001 (Figure 4-15).  It is interesting to note that proteins that are part 
of the nuclear component are more enhanced in the secretome compared to the lysate. 
Therefore, it is not surprising that the major molecular function and biological process 
signatures were DNA binding and regulation of nucleobase, nucleoside, nucleotide and 
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nucleic acid metabolism, respectively (Results not shown). The H4 (histone H4) domain (p-
value < 0.001) was the enriched protein domains (Results not shown). This is interesting 
since H4 was shown to be dysregulated by volcano plots and two sample t-test and indicates 
the presence of chromatin in the secretome. It is also possible that some cell lysis could 
have occurred during sample harvest or preparation. However, this will be discussed further 
with respect to extracellular traps. The biological pathways that are depicted were mainly 
focused on packaging of telomere ends, RNA polymerase I promoter opening, deposition of 
New CENPA-containing nucleosomes at the centromere, nucleosome assembly, meiotic 
recombination and meiotic synapsis (Figure 4-15). These findings are captivating and make 
for interesting discussions and hypothesis generation.  
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Figure 4-15: Analysis of the functional representation of the secretome.  
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Figure 4-16: Functional representation of the secretome. 
 
Protein-protein interactions of MMP-9 and other dysregulated proteins of 
the secretome 
The protein-protein interactions that were formed by the dysregulated proteins were 
analysed using STRING-DB as before, and are portrayed in Figure 4-17. MMP-9 formed 
direct interactions with PPIA (Peptidyl-prolyl cis-trans isomerase A), A2M (α-2-
macroglobulin), VIM (vimentin), COL6A1 (Collagen alpha-1(VI)), ANXA2 (Annexin A2) and 
CHI3L1 (Chitinase-3-like protein 1). STRING analysis also suggested that glycosaminoglycan 
degradation, extracellular matrix organization and chondroitin sufate metabolic process 
were enhanced in the secretome. Given that MMP-9 is the most glycosylated MMP and that 
glycosylation has a role in protein-protein interactions (section 1.3.3) this is an important 
discovery that also validates its earlier mention in the zymography discussion (Chapter 3).  
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Figure 4-17: MMP-9 interacting protein with other significantly different proteins in the 
secretome. The proteins are colour coded according to their functions as computed by 
STRING. The FDR values are also given. 
 
4.5 Description of uninfected and infected phenotypes using exclusively 
expressed and secreted proteins   
Understanding the phenotypic changes induced by M. smeg is central to better our 
knowledge of its avirulent nature to the host in comparisons to M. tb. Thus, protein groups 
that were exclusively identified in the unifected and not in the infected lysate and 
secretome were analysed. A minimum of 2 peptides were required  to be identified in the 
uninfected and 0 in the infected (and vise versa) to be considered exclusively identified  for 
that protein group. Three technical replicates were considered for each experiment. This 
builds stronger evidence for phenotypic differences induced by the infection. The 
overlapping proteins between the infected lysate and secretome were insulin-like growth 
factor binding protein 3 isoform b (IGFBP3) and between uninfected lysate and secretome 
was apolipoprotein C-I (APOC1), while ADAM DEC1 was expressed in the infected lysate and 
uninfected media (Figure 4-18). 
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Figure 4-18: Overlap pattern of exclusively intracellular and secreted proteins. The 
overlapping protein groups in the uninfected (Uni) and Infected (Inf) were compared 
between the media and lysate. 
 
Functional annotation of the exclusively expressed protein groups: Lysate 
The protein groups that were exclusively expressed in the infected and uninfected lysate did 
not show any significantly enriched GO terms at least as analysed using FunRich (Results not 
shown).  
 
Analysis of protein-protein interactions: Uninfected versus infected lysate 
The interactions that were observed in the infected lysate was the clustering of the nuclear 
factors NF-kappa-B subunits NFKB1 and NFKB2 forming direct interactions with interleukin-8 
(CXCL8) which in turn interacts with prostaglandin G/H synthase 2 (PTGS2) (Figure 4-19). The 
latter also forms interactions with STAT6 (Signal transducer and activator of transcription 6). 
These predicted contacts are important and relevant in Mycobacterial infections. On the 
other hand, the protein groups in the uninfected formed fewer interactions (Appendix 3, 
Figure 6-12).  
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Functional annotation of the exclusively expressed protein groups: 
Secretome 
Both the uninfected and infected secretome depicted GO enrichment in exosomes and 
lysosomes which had comparable number of genes. In contrast the enriched mitochondrion 
and cytoplasmic proteins had a higher percentage of representative genes in the infected 
than the uninfected (Figure 4-20). The signature biological pathways that were enriched and 
only observed in the infected media were aspartate degradation II, FOxO family signalling, 
insulin-mediated glucose transport and p38 signalling mediated by MAPKAP kinases (Figure 
4-21). Also interesting was the conserved 14-3-3 protein domain enrichment in the infected 
whereas the uninfected was enriched with the calcium binding domains ANX (Figure 4-21). 
This implies that signal transduction pathways are modified by the infection from being 
dominantly calcium-dependent to phosphorylation-dependent ones. 
 
 
Figure 4-19: Protein-protein interaction of NFkB1 in infected lysate. The KEGG pathways 
are indicated by the colour keys and FDR values are also included. 
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Figure 4-20: Illustration of the GO enrichment of the secretome. 
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Figure 4-21: Illustration of the biological pathways and protein domain enrichment of the 
secretome.   
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Analysis of protein-protein interactions: Uninfected versus infected 
secretome 
The STRING-DB predicted protein network of the infected secretome displayed interactions 
with TIMP-1 which is relevant in the study of MMPs (Figure 4-22). This MMP inhibitor 
interacted directly with Amyloid-like protein 2 (APLP2), Nucleobindin-1 (NUCB1), Calumenin 
(CALU), Glucosidase 2 subunit beta (PRKCSH), insulin-like growth factor binding protein 3 
isoform b (IGFBP3). It forms indirect contact with cation-independent mannose-6-
phosphate receptor (IGF2R), intercellular adhesion molecule 1 (ICAM1), urokinase 
plasminogen activator surface receptor (PLAUR) and alpha-actinin-4 (ACTN4). The IGF2R 
makes contact with the actin-related proteins 2 (ACTR2) and 3 (ACTR3). Another exciting 
discovery within this network was the 14-3-3 proteins which are conserved in eukaryotic 
cells and regulate signalling molecules. These make direct interactions with Tubulin beta-4B 
chain (TUBB4B).  
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Figure 4-22: Protein-protein interactions of TIMP-1 in the infected secretome. TIMP-1 is 
indicated with an arrow (black) and the 14-3-3 conserved proteins are depicted (black 
circle).  
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Discussion 
 
4.6.1 The upstream and downstream regulation of MMPs  
The tight regulation of MMPs is inherent to the homeostasis of the ECM and regulation of 
other cellular processes such as angiogenesis, cell proliferation and immune system 
amongst others. Understanding pathways that are responsible for their dysregulation in 
disease pathologies is essential for strategic therapeutic development. These include 
pathways that control their expression, secretion and activation. The current study 
postulates that the significant expression of MMP-9 induced by M. smeg infection is 
cytokine driven. With respect to exclusively expressed protein groups the pro-form of IL-16 
and the IFN-γ receptor were present in the uninfected lysate in contrast to IL-8 and IL-27B in 
the infected lysate. IL-1β was the second most upregulated protein intracellularly. It is a 
potent inducer of MMP-9 which only induces the overexpression of MMP-1 when in 
combination with GM-CSF and TNF-α (Elkington et al. 2011b;Zhang et al. 1998b). The effects 
of IL1-β may in turn be regulated upstream via phosphorylation/dephosphorylation by 
interaction with LYN (Tyrosine-protein kinase Lyn), a non-receptor tyrosine kinase and 
negatively by the interleukin-1 receptor antagonist protein (IL1RN) which were both also 
significantly dysregulated. The pathways that were enriched in the lysate were mostly 
concerned with RNA processing and metabolism.  
The COX reaction pathways were also enriched, with prostaglandin E synthase 3 (PTGES3) 
being significantly different and prostaglandin G/H synthase 2 (PGH2) only identified in the 
infected lysate.  Thus, the cytokines may be driving the expression of MMP-9 in response to 
M. smeg and due to inflammation. The inflammation could also be caused by serum-
starvation however the comparison with the uninfected validates that it did not mask the 
differences induced by the infection.  
The significant dysregulation of intracellular and secreted MMP-9 was accompanied by the 
presence of TIMP-1 which was only identified in the infected secretome. This suggests that 
TIMP-1 is deliberately secreted to inhibit the activity of MMP-9 and/or control its secretion, 
given its documented role of complexing with MMP-9 prior to secretion (Roderfeld et al. 
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2007;Shapiro et al. 1995). Thus, the study validates the non-destructive ECM phenotype 
induced by M. smeg contrasting that of M. tb. Coinciding with this was the observed 
decrease in MMP-1 activity observed by zymography and MMP-1 activity assays.  
MMP-9 was upregulated intracellularly and in the secretome, while β-hexosaminidase 
subunit beta (HEXB) was upregulated intracellularly but downregulated in the secretome. 
This indicates another regulatory mechanism of MMP-9 via recycling, possibly via exosomes 
in turn preventing chronic inflammation and degradation of the ECM. This exosome 
compartmentalisation could be a strategy to control its secretion, and to prevent its 
degradation and denaturation from the acidic environment induced by serum-starvation 
and acidification steps during phagosomal processing.  
Since tRNA aminoacylation was induced by the infection, it is possible that the multiple 
bands observed by zymography are splice variants of MMP-9 possibly arising from the WHE-
TRS protein domain that was enriched by dysregulated intracellular proteome. It is a helix-
turn-helix domain which is found abundantly in glutamyl-prolyl tRNA synthetase (EPRS). It is 
essential for the interaction of protein-protein interaction of synthetases and has also been 
observed in alternative splicing of proteins such as the angiogenic factor VEGFA (Halawani et 
al. 2018;Mthembu et al. 2017;Ray and Fox 2014). Interestingly MMP-9 has glutamic acid-
proline repeats (EPEP) repeats at the C-terminal domain implying that tRNA glutamyl-prolyl 
tRNA synthetase may be binding to it and generating alternative splicing. Since most of the 
RNA binding proteins were also exosome proteins, it is possible that MMP-9 interacts with 
WHE-TRS and glutamyl-prolyl tRNA synthetase and aspartate--tRNA ligase which has been 
shown to interact with MMP-9 by STRING, supporting its transportation through exosomes.  
Therefore, the expression of MMP-9 may be regulated by IL-1β in a COX-prostaglandin 
synthase-dependent manner, and also via alternative splicing. To compare, the THP-1 and 
primary monocytes that were infected with M. tb upregulated the expression of MMP-1 and 
MMP-9 which was protein kinase C (PKC), PKA and protein tyrosine kinase (PTK) dependent 
which was not the case for TIMP-1 (Friedland et al. 2002). This implies that the secretion of 
MMP-9 is not TIMP-1-dependent as is the case with M. smeg infections.  Thus, the upstream 
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regulatory mechanisms exploited by M. smeg and M. tb in controlling MMPs/TIMPs are 
distinct.  
proMMP-9 is composed of 19 cysteine residues and is sensitive to changes in redox 
conditions which in this case could be induced by the acidification processing of the 
phagosome. Thus, the host might respond by preserving and counteracting these effects to 
control the expression, secretion and activation of MMP-9 including other redox sensitive 
proteins required for clearing the infection. Protein disulfide-isomerase (PDI) has been 
shown not only to be able to rescue and restore the gelatinase activity of denatured and 
reduced MMP-9 but also control its secretion (Ali Khan and Mutus 2014). Another study 
observed that inhibiting the gelatinase activity of MMP-9 (and MMP-2) caused an increase 
in the cell-surface of PDIA3 with a decrease in its secreted form (Rosewell et al. 2011). 
PDIA3 was significantly dysregulated in the lysate and was also identified together with its 
isoform PDIA4 only in the infected secretome suggesting a regulatory loop mechanism 
between it and MMP-9, also highlighting the relevance of PDI secretion due to infection. 
Like MMPs, the function of the high mobility group protein-1 (HMGB1) is redox controlled 
for instance when its fully reduced it acts as a chemoattractant for proinflammatory cells, 
acts as a cytokine when its partially reduced/oxidised and finally in its oxidised form it has 
neither activities (Antoine et al. 2014). HGMB1 and HMGB2 were identified in the infected 
secretome while HMGA1 (high mobility group protein HMG-I/HMG-Y) was significantly 
dysregulated in the lysate. Ribonuclease T2 (RNASET2) which was dysregulated in the 
secretome has optimum activity under acidic conditions and may degrade the lysosomal 
ribosomal RNA (Luhtala and Parker 2010). Therefore, its dysregulation is not coincidental 
but together with the RNA binding proteins, PDIs and HMGBs amongst other proteins may 
be employed during M. smeg infection to localise, maintain some expression and activity of 
MMPs and other matrix degrading proteins such as cathepsins.  
Cathepsins L1 and S (CTSL and CTSS) which are lysosomal cysteine proteases able to activate 
MMPs were identified in the infected lysate while cathepsin Z (CTSZ) was downregulated in 
the media. This implies that secreted proMMP-9 may be activated by cathepsins 
(Christensen and Shastri 2015;Shamamian et al. 2001). The generation of reactive oxygen 
species (ROS) is not only essential for antimicrobial activity and apoptosis but also for 
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activation of MMPs (Fu et al. 2001;Gu et al. 2002). The upregulation of superoxide 
dismutase (SOD (Mn)) in the lysate may be to control the activity of MMPs via its ability to 
convert oxygen to hydrogen peroxide ultimately forming hypochlorous acid (HOCl) that 
activates proMMPs (Fu et al. 2001).  
The overrepresentation of the purine nucleotide de novo biosynthesis II pathway (infected 
intracellular proteome), purine ribonucleoside degradation to ribose-1-phosphate 
(dysregulated intracellular proteome) and nucleotide metabolic (dysregulated secretome) 
pathways could be essential for generating NADPH which retains the reduced state of 
glutathione (GSH) for scavenging ROS and also for generating NADP required for scavenging 
superoxides which would lead to further activation of the MMPs (Banki et al. 
1996;Flannagan et al. 2009). Purine catabolism is essential in that the enzyme adenosine 
deaminase has been widely used as a marker for TB diagnosis (Atta et al. 2015;Baba et al. 
2008) even in pleural fluid of patients co-infected with HIV having a CD4 count less than 50 
cells/µL however this is not the case in TB pericarditis fluid (Baba et al. 2008). Adenosine 
deaminase catalyses the deamination of adenosine to inosine and it is also a marker of 
monocyte differentiation to macrophages (Atta et al. 2015;Baba et al. 2008). It was only in 
the infected lysate that this enzyme was expressed, and it depicts further differentiation of 
the macrophages with an active immune response. Interestingly the uninfected secretome 
was enriched with the transaminase molecular function highlighting the importance of 
deamination in Mycobacterial infection. The presence of calcium-binding and calcium 
channel proteins annexin A1 and A4, in the uninfected secretome suggests that in the 
absence of infection the calcium-dependent MMP-9 activity is regulated by controlling 
extracellular levels of calcium. 
Another way of controlling the activity of MMPs besides through activation is by regulating 
their secretion. As mentioned earlier TIMP-1 is reported to do this by complexing to 
proMMP-9 and controlling its secretion. The secretion of MMP-9 has also been shown to 
rely on the maintenance of actin polymerisation and intact microtubules (Bildyug 
2016;Hanania et al. 2012) which could explain the intracellular upregulation of the 
cytoskeletal structural proteins such as tubulin β-chain (TUBB), tubulin β6 chain (TUBB6), 
tubulin α-1 chain (TUBA1C) and  tubulin-8 (TUBB8), adenylyl cyclase-associated protein 1 
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(CAP1) in the infected lysate. To corroborate this, CAP-1 which is involved in the recycling of 
G-actin monomers from ADF/cofilins was expressed in the infected lysate. The identified 
alpha-actinin-4 (ACTN4), actin-related proteins 2 and 3 (ARP2 and ARP3) in the infected 
secretome could also facilitate the secretion and or re-internalisation of MMP-9 (Chintala et 
al. 1998). In a review by Bildyug, one of the insightful conclusions was that the 
polymerisation of actin was more likely to upregulate MMP-9 and downregulate MMP-2 
(Bildyug 2016), suggesting that the gelatinase activity of MMP-9 is only one of the reasons 
for its upregulation in Mycobacterial infections which will be discussed below. Alterations in 
redox and glycosylation state, together with alternate splicing would also modify the TIMP-1 
binding to MMP-9 advocating for other functions of MMP-9 and TIMP-1 either than ECM 
remodelling.   
 
4.6.2 The function of MMPs in the internalisation of M. smeg and phagosome 
maturation  
The role of MMPs in cancer metastasis and invasion has been widely documented and is still 
an exciting area of research. Remodelling of the cytoskeleton is a dynamic event entailing 
the assembling, disassembling and recycling of actin and microtubule filaments. This 
phenomenon is true not only in tumour progression but also in phagocytosis of microbes 
and in subsequent events of phagosomal processing. The localisation of MMPs to cell 
membranes and lipid rafts is essential for invadopodia formation (Jacob and Prekeris 
2015;Poincloux et al. 2009;Watanabe et al. 2013;Yamaguchi et al. 2009). Analysis of protein-
protein interactions with STRING showed MMP-9 forming direct interactions with ILB-1 
(Interleukein-1β), ICAM (Intercellular adhesion molecule 1), IL-1RN (Interleukin-1 receptor 
antagonist protein), PYCARD (Apoptosis-associated speck-like protein containing a CARD) 
and indirectly with PSAP (Prosaposin), PLAUR also uPAR (Urokinase plasminogen activator 
surface receptor), MYLK (Myosin light chain kinase, smooth muscle), VCP (Transitional 
endoplasmic reticulum ATPase), DARS (Aspartate--tRNA ligase, cytoplasmic) and FSCN1 
(Fascin).  
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Fascin is an actin binding protein, like MMPs it can localise to filopodia and invadopodia (Li 
et al. 2010). MYLK is involved in muscle contraction through the phosphorylation of myosin 
light chain (Gao et al. 2013). The interaction network between MMP-9 with fascin, MYLK, 
ICAM1 and uPAR taken together with its ability to colocalise to cell membranes and lipid 
rafts suggests that it may be important in the uptake of M. smeg. The urokinase 
plasminogen family of proteins are not only able to activate MMPs, specifically plasmin has 
been shown to have a direct interaction but also plays a direct role in collagen turnover. 
Urokinase plasminogen activator receptor-associated protein (uPARAP) also known as 
ENDO180 is a 180 kDa protein and a homolog of the C-type mannose receptor protein that 
can recognise and bind various types of carbohydrates making it relevant in the current 
study. It is well-known for its ability to bind and internalise collagen or gelatin localising it to 
the lysosomal compartment where it is degraded (Melander et al. 2015;Paracuellos et al. 
2015). It comprises the fibronectin repeats which are collagen-binding domains similar to 
that of MMP-9 and MMP-2. This protein is stable at low pH and low calcium concentrations, 
which do not affect collagen binding or release (Paracuellos et al. 2015). Thus, it is possible 
that uPARAP (although not identified in our data), uPAR and MMP-9 may be interacting on 
the cell surface facilitating M. smeg recognition, binding and internalisation. Since MMP-9 
can form multimers, it is also possible that it localises to the cell membrane via uPAR.  
The presence of extracellular actin, enrichment of glycosaminoglycans (GAGs) and 
plasminogen have been reported to be essential receptors for Mycoplasma hyopneumoniae 
(Raymond et al. 2018). Similarly, and as mentioned earlier the actin related proteins (ARP-2, 
ARP-3 and ACTN4) and uPAR identified in infected secretome, and enrichment of the 
glycosaminoglycan catabolic processes displayed by the dysregulated secretome suggests 
that these proteins together with MMP-9 may be forming a protein scaffold that is 
important in recognition and internalisation of M. smeg. Since MMP-9 has the most 
glycosylation sites amongst all the MMPs, it is possible that binding and internalisation of M. 
smeg is facilitated by the interaction of the mannose sugars on its cell wall with the 
glycosylated MMP-9. In addition, CD44 is a hyaluronan binding protein that was identified to 
be significantly dysregulated and to form direct interactions with MMP-9 when label free 
quantification (LFQ) was used. It is expressed in most cells and its interaction with F-actin is 
mediated by ezrin/radixin/moesin and/or akyrin. CD44 has been shown to dock MMP-9 into 
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the cell membrane (Zhang et al. 1998a) as well as bind the hemopexin domain of MMP-14 
localising it to lamellipodia (Mori et al. 2002). Moesin was one of the proteins identified to 
be exclusively identified in infected media when both LFQ and iBAQ are used. Also, the 
cytoskeletal proteins moesin, actin and tubulin are part of proteins making up exosomes 
(Atay and Godwin 2014) and could play a role in the morphological changes required by the 
cell during phagocytosis. The interaction of MMP-9 with the precursor protein prosaposin 
supports its role in M. smeg phagocytosis. Prosaposin is processed to saposins A-D which 
localise and function in the lysosomal compartments (Morimoto et al. 1990). It is also 
fascinating that genetic mutations found in prosaposin are associated with Tay Sachs a 
lysosomal storage disease which is associated with resistance of TB through deficiency of α-
hexosaminidase (Withrock et al. 2015). There was significant downregulation β-
hexosaminidase, both alpha (HEXA) and beta (HEXB) subunits in the secretome, whereas 
HEXB was significantly dysregulated in the intracellular. This means that its peptidoglycan 
hydrolase activity is not relevant in the ECM but rather the internalisation and localisation of 
M. smeg to the lysosome is required for exerting its hydrolase function.  
Another plausible internalisation mechanism could be via the already mentioned PDIs. 
Phagocytosis of the Leishmania chagasi promastigotes have been reported to be enhanced 
in the presence of PDI which colocalised with macrophage NADPH oxidase (Santos et al. 
2009). The role of PDI and redox conditions has also been documented to regulate positively 
the uptake of other bacteria such as Chlamydia (Abromaitis and Stephens 2009). Very 
interesting is its role in reducing the thiol groups of HIV gp120 preceding its uptake by 
lymphocytes (Santos et al. 2009). Like MMP-9, peptidyl-prolyl cis-trans isomerase A (PPIA) 
was also upregulated in the secretome by M. smeg infection and formed direct interactions 
with MMP-9 suggesting that it could also be important for phagocytosis. The binding and 
entry of HIV has been reported to be PPIA dependent (Gallina et al. 2002). To corroborate 
this further, PPIA is an MMP-14 substrate (Rodríguez et al. 2010) which was not identified in 
the secretome and was not dysregulated in the lysate. Therefore, the enrichment of PPIA, 
PDI and other proteins involved in oxidoreductase activity could alter the M. smeg 
phenotype directly and possibly facilitating its phagocytosis. Further investigation into the 
function and/or interaction of MMPs at the cell membrane and their possible role in 
facilitating phagocytosis and endosomolysis, a process whereby bacteria is released into the 
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cytoplasm may endorse the design of specific MMP inhibitors. Although there was no 
correlation between bacterial burden and upregulation of MMP-1 in M. tb-infected MMP-1 
transgenic mice (Elkington et al. 2011a), it is still possible that other MMPs such as MMP-14 
that are internalised via clathrin-dependent and caveolae mediated pathways (Remacle et 
al. 2003) are associated with the release and/or phagocytosis of M. tb into the cytoplasm.  
 
4.6.3 Clearance and bacteriostatic effects on M. smeg by THP-1 macrophages 
Mycobacterium smegmatis infections are cleared efficiently in non-immunocompromised 
individuals and its inability to progress to cavitary disease is relevant in this study since 
MMPs have been linked to progression of disease. In the current study, we postulate 
mechanisms by which bacterial growth may be slowed or halted, namely scavenging of ions 
like iron to prevent growth, phagosome and lysosome fusion, extracellular trapping of bacilli 
and finally apoptosis as a way of preventing excessive inflammation and necrosis.  
The role of β-hexosaminidase in controlling bacterial growth has been described in 
macrophage infections with Mycobacterium marinum (M. marinum). It was found to be 
active on the cell membrane surface during uptake suggesting that it is the first line of 
defence against the bacteria making direct interactions and modifying the bacterial cell wall 
(Koo et al. 2008). Its upregulation in the intracellular implies that it could be eliciting its 
bacteriostatic effects by localising the bacilli to the lysosome synergistically with MMP-9. 
Controlling bacterial growth by preventing the availability of ions such as Fe2+, Mn2+ and Zn2+ 
is a strategy also employed by the host (Flannagan et al. 2009). The intracellular survival of 
M. tb has been attributed to its ability to sequester the host iron for its own growth. 
Sideroflexin-1 (also known as tricarboxylate carrier protein) is essential in differentiation of 
erythrocytes and for iron ion homeostasis and transport across the mitochondria. Induction 
of its expression by M. smeg suggests that, like NGAL, it may function to scavenge iron 
resulting in a bacteriostatic effect. Amusingly, SOD (Zhou et al.) was one of the top five of 
the significantly upregulated proteins in the lysate. Since Mn2+  is required by pathogenic 
SOD as a protective enzyme (Flannagan et al. 2009) it is plausible that the SOD is expressed 
deliberately by macrophages to outcompete the bacterial SOD for Mn2+ thus eliciting its 
bacteriostatic effects. The current study has demonstrated that incubation of the secretome 
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with and without APMA at 37 ˚C results in conversion of MMP-9 (82 kDa) to its 67 kDa form 
which lacks the hemopexin domain (Hx), also showing that the conversion was faster when 
APMA was included (Section 3.3). Thus, the postulation that MMP-9 could be transported 
between the cytoplasm and the ECM through exosomes could be a strategy for preventing 
the degradation of its Hx domain possibly to iron, biliverdin and carbon monoxide by heme 
oxygenases (Vinchi et al. 2016). However other studies have shown a protective effect of 
the Hx domain by preventing iron toxicity (Kapojos et al. 2003). TIMP-1 in the infected 
secretome could be binding directly to the Hx and stabilising it, thus preventing its release. 
This is an important finding that suggests that the low levels of TIMP-1 in M. tb infected 
macrophages and TB patients could be an inherent factor in cavity formation and 
dissemination, hence TB-patients co-infected with HIV and children with TB rarely progress 
to cavity formation because of the upregulation of MMPs that is accompanied by TIMP-1 
increase.  
Another interesting function of the Hx domain is its ability to inhibit neutrophil infiltration, 
something that is also observed in the overexpression of tyrosine-protein kinase Lyn in OVA-
induced airway inflammation (Wang et al. 2017). The presence of iron has also been shown 
to polarise macrophages toward the M1 proinflammatory phenotype and the 
administration of the human hemopexin (Hx) to sickle mice rescued and attenuated this iron 
driven M1 phenotype (Vinchi et al. 2016). Therefore, attaining iron homeostasis by 
preventing the conversion of Hx might not only be essential for preventing the availability of 
iron for bacterial growth but for avoiding chronic inflammation which is vital for the process 
of wound healing, an inherent factor for efficient clearance of infection which may be time-
dependent. Again, this highlights the importance of TIMP-1 in preventing chronic 
inflammation by stabilising the MMP-9. Another mechanism that is employed to attenuate 
inflammation is apoptosis. It plays a crucial role in eradicating damaged or dead cells 
without eliciting an immune response thus preventing chronic tissue damage by proteases 
especially MMPs. An important function of HMGB-1 (identified in infected the secretome) is 
its role in attenuating the engulfment of apoptotic neutrophils by macrophages  (Friggeri et 
al. 2010;Velegraki et al. 2013). So, the exclusive identification of HMGB-1 and HMGB-2 in 
the infected secretome suggests that they have a role in regulating inflammation through 
engulfment of apoptotic cells. Both apoptotic and autophagic cells are reported to secrete 
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HMGB-1. The upregulation of isomerases which are essential in minimising protein 
aggregation could indicate that the cells are undergoing autophagy which facilitates 
clearance of protein aggregates and intracellular pathogens (Zeng and Carlin 2013).  
A study by Zeng and colleagues investigated the role of autophagy in adenovirus infected 
airway epithelial cells and suggested that autophagosomes can intercept endosomal 
processing by also preventing the exchange of Rab5a and Rab7 associated with early and 
late endosomes, respectively. This led to the conclusion that the host was unable to control 
the intracellular release and replication of adenovirus (Zeng and Carlin 2013). In the current 
study Rab7B and Rab10 were upregulated intracellularly meaning there is phagosomal 
processing of M. smeg.  Cathepsins are involved in direct killing of Mycobacteria and antigen 
presentation, and also in apoptosis (Pires et al. 2016). The upregulation of these lysosomal 
proteins, cathepsin B and D, and ribonuclease T2 in the secretome is an indication that there 
is phagolysosomal fusion, also plausible programmed cell death via the cathepsins.  
A very exciting discovery in our study was evidence of secreted histones, DNA, RNA, 
granulins and actin-like proteins induced by the infection. Extracellular traps have been 
described for neutrophils, namely neutrophil extracellular traps (NETs) and have been 
documented to immobilise and kill extracellular microbes (Schauer et al. 2014). NETs are 
characterised by secretion of chromatin, bactericidal protein and other proteins such as 
fibrils that trap bacilli. They are known to be induced by ROS and apoptosis, and depending 
on the cell density of neutrophils, it has been demonstrated that a high cell density induces 
formation of aggregates that can sequester and degrade proinflammatory molecules (Khan 
et al. 2017;Schauer et al. 2014). These NETs are referred to as aggNETS (this will also be 
referred to in Chapter 5).  Schauer and colleagues also showed that inhibiting proteinase 3, 
elastase and serine proteinases abolished the ability of these aggregates to degrade the 
inflammatory molecules. In contrast, EDTA or inhibitors of tissue transglutaminases did not 
prevent the degradation of inflammatory molecules but prevented formation of these 
aggregates. This suggests that zinc-dependent metalloproteases like MMP-9 may not be 
beneficial for mediating the degradation of these inflammatory molecules but for the 
formation of aggregates that release factors that sequester the pro-inflammatory cytokines. 
Although the cytokines were expressed, none of them were found in the secretome samples 
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implying that the extracellular traps are employed for degrading them. Given that MMPs 
have cytokines and chemokines as substrates (Morrison et al. 2009) for example MMP-9 can 
degrade the neutrophil attractant IL-8 (Rodríguez et al. 2010), MMP-9 could also be 
important for their intracellular degradation and regulation.  
IL-8 was identified in the infected lysate, while IL-1β was upregulated in the lysate in 
contrast only interleukin-1 receptor antagonist protein (ILRA) was identified in the infected 
secretome suggesting that other proteases could be degrading cytokines if they are 
secreted. Proteins such as PDIs, PPIA and HGMBs which regulate aggregation illustrate the 
presence of extracellular aggregates, the latter through inducing autophagy which clears 
toxic protein aggregates and the others by facilitating protein folding and renaturation. 
Thus, the host elicits multiple mechanisms that may be working collectively to clear 
bacteria.  
4.6.4 Role of extracellular exosomes, poly(A)RNA binding and 14-3-3 proteins 
in cell-to-cell communication 
The transmission of intercellular signalling is as vital as the cellular response to direct 
interaction with bacterial molecules. Analysis of the data lead to the hypothesis that cellular 
communication is delivered to neighbouring cells through exosomes carrying DNA, RNA, 
proteins and DNA/RNA binding proteins, and via signalling scaffolds formed by the 14-3-3 
proteins amongst others. In the secretome, the ‘deposition of new CENPA containing 
nucleosome at the centromere’ pathway was enhanced, in addition to that downregulation 
of deoxyribonuclease-2-alpha and ribonuclease T2 which has optimum activity under acidic 
conditions suggests that the DNA/RNA molecules are deliberately secreted and are 
protected from degradation.  
RNA binding proteins play a crucial role in the regulation of gene expression especially in 
splicing and capping (Chennathukuzhi et al. 2001). Poly(A) RNA binding proteins (Pabs) bind 
to polyadenosile RNA (poly (A) RNA) and function to stabilize, localise and enhance 
translation of the poly(A) RNA. Since most of the Pabs were also exosome proteins this 
implies that they could be protected from degradation by ECM proteases thus allowing their 
delivery to neighbouring cells. The transporting of genetic and/or epigenetic material as a 
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means of crosstalk between cells is interesting in infectious disease as a strategy in acquiring 
adaptive immunity and/or resistance against pathogens. RNA contained in vesicles can act 
as protein carriers that could alter the epigenetic of neighbouring cells by acting on 
chromatin structures thus modifying gene expression (Di Liegro et al. 2017). The multiple 
bands that were observed by western blotting of MMP-1 (Figure 3-24) and MMP-9 by 
zymography (Figure 3-18) and western blotting of MMP-9 (Appendix 2, Figure 6-11) may be 
splice variants resulting from tRNA/RNA binding proteins delivered to nearby cells through 
exosomes. As alluded to earlier, the splice variants may be inactive forms of the MMPs that 
could be performing other functions.  
CENPA is an H3-like centromeric protein A that is responsible for kinetochore assembling 
ensuring proper chromosome segregation (Carroll and Straight 2007;Niikura et al. 2016). 
Centromeric DNA is not well-conserved, however CENPA is required and conserved in 
centromeric nucleosomes thus being accepted as an epigenetic mark of centromere 
function (Carroll and Straight 2007;Niikura et al. 2016). The 14-3-3 proteins which were 
identified in the infected secretome are highly conserved acidic proteins in eukaryotes and 
are involved in signal transduction, apoptosis, cell proliferation, adhesion, differentiation 
and survival (Mhawech 2005). Very interesting is that they are mostly phosphoserine-
binding proteins and could be acting to relay intercellular signalling. These 14-3-3 proteins 
form a network of interactions with clathrin light chain A (CLTA) which is anchored to the 
IGF2R (Cation-independent mannose-6-phosphate receptor) a receptor that binds and 
transports phosphomannosyl substrates from the cell-surface and Golgi apparatus to the 
lysosome. Therefore, the above implies that the phenotypic changes that are acquired 
during M. smeg infection are not induced by mutations in DNA sequences but rather 
through modification of gene expression in neighbouring cells by delivery of genetic 
material and proteins via exosomes. On the other hand, the protein groups uniquely 
expressed in the uninfected formed fewer interactions where the main cluster comprised of 
interactions between PP4R2 (Serine/threonine-protein phosphatase 4 regulatory subunit 2) 
and PPP1CC (Serine/threonine-protein phosphatase PP1-gamma catalytic subunit) which are 
anchored to the cleavage and polyadenylation specific factor 3, 73kDa, isoform CRA_b 
(CPSF3) and Nuclear pore complex protein Nup205 (NUP205). These suggest that 
phosphatases in particular GTPases may be regulating proteins involved in the translocation 
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of macromolecules between the nucleus and cytoplasm, facilitating the processing and 
maturation of mRNA. 
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Chapter 5 
Proteomics of THP-1 macrophages in response to 
treatment with lipoarabinomannan (H37Rv) 
 
Lipoarabinomannan (LAM) upregulates the expression of MMP-1 and MMP-9 genes in 
THP-1 macrophages. Also, MMP-9 depicted an increase in gelatinase activity with increasing 
LAM concentrations (Chang et al. 1996). Since the composition of the glycolipids in the cell 
wall of M. tb differ from that of M. smeg, these discrepancies could result in major 
differences in the macrophage response. Thus, the exposure of the THP-1 macrophages to 
LAM (H37Rv) for a 24-hour incubation period was assessed for differences in the expression 
and secretion of proteins. Although there was no increase in the gelatinase activity of 
intracellular and secreted MMP-9 (Section 5.4), the resultant phenotypic changes studied by 
discovery proteomics will give an insight into the effects of this virulent factor in isolation on 
the host’s response.   
 
5.1 Raw data analysis and processing 
Three technical (injections) replicates were analysed. The processing of the raw data files 
was performed using MaxQuant (1.5.3.12) and the human Uniprot database to generate 
protein quantification and identification data. The raw files were run simultaneously, and 
each technical replicate was set as a separate experiment on MaxQuant. The analytic 
parameters used were as described in Chapter 4. 
The representative ion chromatograph of the media (Figure 5-1) and lysate (Figure 5-2) 
were from infected and uninfected samples had comparable intensities. The efficiency of 
trypsin digestion was 89% (Figure 5-3). The media and lysate samples generated a combined 
total of 2646 protein groups, with 38 and 26 identified as contaminants and decoy hits, 
respectively. Out of the 198613 spectra submitted, 41.7% were identified. The ion injection 
times and percentage of MS/MS identified (Figure 5-4) were similar between triplicate 
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repeats. Further analysis using histograms showed that the data were normally distributed 
(Figure 5-5), except for the LAM-treated media sample (L_Med3). This was confirmed by the 
scatterplots (Figure 5-6) which gave a correlation co-efficient (R2) between 0.771 and 0.915 
for the lysate and 0.796 and 0.933 for the secretome.  
 
 
Figure 5-1. Representative chromatogram of the secretome from untreated and LAM-
treated macrophages. 
 
Untreated 
Treated 
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Figure 5-2. Representative chromatogram of the lysate from untreated and LAM-treated 
macrophages  
 
Figure 5-3: Number of missed cleavages. The number of peptides generated are depicted 
by the bar graphs as a function of missed cleavages by trypsin. 
Untreated 
Treated 
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Figure 5-4: Analysis of the injection replicates. The injection times (A) and the (B) Ms/Ms 
percentage for each of the three technical replicates. LAM_Lys1 and LAM_Med1 represent 
lysate and media samples from LAM-treated macrophages, followed by the number of the 
technical replicate. Similarly, NLAM_Lys1 and NLAM_Med1 represent lysate and media 
samples from macrophages not treated with LAM, followed by the number of the technical 
replicate. 
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Figure 5-5: Description of the data distribution by histograms. (A) The lysate and (B) media 
were plotted using the counts as a function of the iBAQ intensities. Three technical 
replicates were analysed. 
 
 
Figure 5-6: Assessment of data reproducibility of the technical replicates. The scatter plots 
represent the computed correlation co-efficient (R2) between the three technical replicates 
of the lysate (A) and media (B).   
B A 
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5.2 Quantitative and qualitative data analysis of the LAM (H37Rv) treated 
macrophages 
The same data processing and analysis that was used for the M. smeg infected and 
uninfected macrophages was carried out for the LAM stimulated and non-stimulated 
macrophages. All the quantifiable protein groups found in the media were also found in the 
lysate (Figure 5-7).  A set of 264 of the lysate protein groups (Appendix 3, Table 6-7) were 
significantly different between uninfected and infected, and the secretome had 28 
significantly different protein groups (Appendix 3, Table 6-8) between uninfected and 
infected of which none were overlapping with the lysate (Figure 5-7). These were computed 
using the two-sample t-test without multiple hypothesis testing. According to volcano plots, 
six and three protein groups (Appendix 3, Table 6-9) were significantly dysregulated in the 
lysate and secretome, respectively (Figure 5-8). For biological analyses and interpretation, 
the differentially regulated proteins computed using the two-sample t-test was used. To 
compare between uninfected and infected samples, peptides that were identified in at least 
two of the replicates were used in the two-sample t-test (p-value < 0.05) to identify 
differentially expressed proteins. A p-value < 0.05 was used as a cut-off and any proteins 
that had a p-value less 0.05 were considered significantly differentially regulated. Since the 
p-value considers the variances between samples this also justifies using these proteins for 
downstream analysis and biological interpretation. Additionally, interference from false 
positives is less likely since the FDR was set at 1% in MaxQuant to exclude them. None of the 
MMPs were differentially regulated following LAM stimulation except TIMP-1, which was 
significantly dysregulated in the intracellular proteome and secretome (Figure 5-9). This 
coincides with the zymography results and explains the lack of a difference in the gelatinase 
activity between LAM treated and untreated samples (Section 5.5).  
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Figure 5-7: Visualisation of overlapping protein groups between the lysate and secretome. 
The protein groups calculated to be significantly different in the lysate and secretome did 
not overlap.  
 
  
Figure 5-8: Visualisation of computed differentially regulated protein groups induced by 
LAM treatment. Volcano plots from Perseus 1.6.1.3 were used to compare the differences 
in iBAQ intensity between treated (L_) and untreated (NL_) samples as well as the 
significantly different protein groups (red spheres).  
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Figure 5-9: iBAQ intensity of identified MMPs in LAM-treated and untreated in the lysate 
and secretome. Only TIMP-1 in the secretome was found to be significantly upregulated 
with a p-value <0.001. 
 
 
Biological function and classification of dysregulated protein groups: Lysate 
LAM treatment caused dysregulation of proteins of the lysosome, exosome, cytoplasm, 
cytosol and centrosome cellular components which were observed with a GO enrichment p-
values less than 0.001 (Figure 5-10). The expressed molecular function signatures with a p-
value less than 0.05 are ubiquitin-specific protease activity and cytoskeletal protein binding 
(Results not shown). Protein metabolism was the most enriched biological process, and to a 
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lesser extent energy pathways and protein modification were also represented (Results not 
shown).  
 
The H4, coiled coil region, RAB, 14-3-3 and ANX were amongst the enriched protein domains 
(Figure 5-10). The main pathways depicted were mRNA/RNA metabolism, p38 signalling 
mediated by MAPKAP kinases, Trk receptor signalling mediated by PI3K and PLC-γ and host 
interactions of HIV factors (Figure 5-11). The site of expression classification indicated 
global-SCX-fractionated, CaOV3 (ovarian cancer cells) and dendritic cells in the top three 
(Figure 5-11). The former is a strong ion exchange (SCX) chromatographic method used to 
enrich phosphopeptides suggesting that the lysate is highly charged with phosphopeptides. 
None of the clinical phenotypes were observed with good confidence. 
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Figure 5-10: Biological function classification of dysregulated protein groups in the lysate. 
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Figure 5-11: Annotation of the biological function of dysregulated protein groups in the 
lysate. 
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Protein-protein interactions: Dysregulated intracellular proteome 
Most of the dysregulated protein groups are known to form protein-protein interactions 
displaying clusters including ones associated with the 14-3-3 proteins and the calcium 
binding proteins (Figure 5-12). Most of the proteins were protein binding proteins and 
involved in intracellular transport. Also, of note was the clustering of proteins involved in 
‘symbiosis encompassing mutualism through parasitism’ which were mostly the proteasome 
subunit proteins and the Rab/Rap proteins.  
 
Figure 5-12: Protein interactions of dysregulated intracellular proteome induced by LAM. 
The 14-3-3 conserved proteins (black circle), calcium binding proteins (blue circle), Rab 
related proteins (orange) and proteasome subunits (red circle) are indicated. The GO 
protein classification terms (biological process and molecular function) were also 
determined by STRING and are colour coded (colour key). The FDR values are indicated. 
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Biological function of dysregulated protein groups: Secretome 
The secretome had differentially regulated proteins with GO classification in the 
nucleosome, nucleus, centrosome, exosome and ribonucleoprotein complex (Figure 5-13). 
Proteins that form part of the nucleic acid metabolic processes were mainly DNA binding 
(results not shown). Coinciding with that was H4 as the main protein domain enrichment 
and the GO metabolic process representing regulation of nucleoside, nucleotide and nucleic 
acid, suggesting the presence of chromatin in the secretome. The overrepresented GO 
biological processes were packaging of telomere ends, RNA polymerase I promoter opening, 
deposition of new CENPA containing nucleosome at the centromere, signalling events 
mediated by HDAC class III and meiotic recombination and synapsis (Figure 5-13).  
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Figure 5-13: Dysregulated protein groups of the secretome were classified with 
accordance to GO terms.  
 
Protein-protein interactions: Dysregulated proteins in the secretome 
Following analysis using STRING-DB, all but one of the dysregulated proteins in the 
secretome formed an interaction network (Figure 5-14).  
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Most of these proteins were classified as protein-containing complexes. The presence of 
kinase binding proteins implies possible effects on intercellular signalling. The integrins 
ITGB2 and ITGB5 formed interactions with fibronectin (FN1) and myosin regulatory light 
chain 12A (MYL12A). The actin-related protein 3 (ACTR3), actin-related protein 2/3 complex 
subunit 5 (ARPC5), clathrin heavy chain 1 (CLTC) and GAPDH (Glyceraldehyde-3-phosphate 
dehydrogenase) network anchor to the FN1 via ILF3 (Interleukin enhancer-binding factor 3). 
This is important to note because ARPC5, ACTR3 and ITGB2 are involved in phagocytosis 
(Figure 5-14) and ARPC5, CLTC and FN1 were classified as ‘bacterial invasion of epithelial 
cells’ (Results not shown). These are relevant in postulating the transportation of LAM or 
intact M. tb across the glomerular epithelial layer and ultimately secreted in urine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-14: Visualisation of dysregulated proteins in the secretome. The GO terms were 
also represented by the different colour coding with their computed FDR values. 
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5.3 Evaluation of LAM treatment on the THP-1 macrophage phenotype using 
exclusively expressed and secreted proteins 
The protein groups that were exclusively identified in the unifected and not in the infected 
lysate and secretome were analysed. A minimum of 2 peptides was required to be identified 
in the uninfected and 0 in the infected (and vice versa) to be considered exclusively 
identified  for that protein group. This would in turn build stronger evidence for differences 
induced by the LAM-treatment. The number of proteins for each category are illustrated 
with a Venn diagram (Figure 5-15), including the overlapping proteins between the LAM-
treated media and lysate, untreated media and lysate, finally between LAM-treated lysate 
and untreated media. These proteins were density-regulated protein (DENR), v-type proton 
ATPase subunit G 1 (VATG1) and copper transport protein ATOX1 (ATOX1), respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-15: Visualisation of the exclusively expressed proteins. 
 
 
Biological function of the LAM treated versus untreated THP-1 macrophages 
The protein groups exclusively expressed by the LAM treated and untreated lysate depicted 
enrichment in the GO classification of the lysosome. The percentage gene representation of 
the lysosome was higher in the untreated macrophages (Figure 5-16).  
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Figure 5-16: Classification of LAM-treated versus untreated lysate proteome.   
 
 
 
Protein-protein interactions of intracellular proteome: LAM-treated versus 
untreated macrophages 
 
In the LAM-treated proteome (Figure 5-17) the ribosome biogenesis protein (WDR12) was 
predicted by STRING database to form a cluster of networks directly with the WD repeat-
containing protein 3 (WDR3), Protein AATF (AATF), tetratricopeptide repeat protein 27 
(TTC27) and U3 small nucleolar RNA-associated protein 14 homolog A (UTP14C) which are 
mostly proteins associated with the ribonucleoprotein complexes. The cluster of the 
mitochondrial ribosomal proteins (MRPLs) with the pentatricopeptide repeat domain-
containing protein 3 (PTCD3) is also depicted (Figure 5-17). Most of the protein genes 
represent proteins involved in acetylation. 
 
 
LAM 
No LAM 
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Figure 5-17: Interactions between proteins exclusively expressed in LAM treated 
macrophages. Also represented were the GO classification terms of the proteins (colour 
coding) and their FDR values. 
In the uninfected intracellular proteome, Deoxyribonuclease-2-alpha (DNASE2) forms a triad 
with CTSZ (Cathepsin Z) and HSPA8 (Heat shock cognate 71 kDa protein) which forms part of 
the lysosome vesicle biogenesis together with CLTA (Clathrin light chain A). Another 
network was between Sec61 subunit alpha isoform 1 (SEC61A1) and the ribosomal proteins 
that form intracellular organelle part cellular compartments and function in macromolecule 
catabolic process (Figure 5-18). 
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Figure 5-18: depiction of protein-protein interactions expressed by untreated 
macrophages.  
Also represented were the GO classification terms (colour coding) and the FDR values are 
given. 
 
 
Biological function of LAM-treated versus untreated secretome 
The GO cellular component terms that had the highest percentage genes in the LAM-treated 
secretome versus untreated were the mitochondrion, centrosome, and mitochondrial 
nucleoid. The GO molecular function depicted higher percentage of genes representing the 
ribonucleoprotein and catalytic activity for the untreated and treated secretome, 
respectively (Figure 5-19).  
 
Protein-protein interactions in the secretome: LAM-treated versus untreated 
macrophages 
The LAM-treated macrophages specifically induced secretion of proteins that were 
predicted using STRING-DB to form protein-protein interactions around clustering of the 
ribosomal proteins (RPLS) which interacted with the early transcription factor, EIF2A and the 
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elongation factor 1-alpha 1 (EEF1A1). This network is anchored to the GTPase enzyme 
RAB7A and RHOG (Figure 5-20). This suggests that the GTPases may also be transporting 
these factors across cells via exosomes as a means of cell-cell communication. 
 
 
 
 
Figure 5-19: Cellular component, molecular function and biological process annotation of 
LAM-treated and untreated secretome. 
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Figure 5-20: Protein-protein interactions of proteins secreted from the LAM-treated 
macrophages. Also represented were the GO classification terms (colour coded) and FDR 
values are shown. Rab7a is indicate with an arrow. 
The uninfected secretome displayed protein interactions predicted by STRING-DB to form 
part of the spliceosome, and GRB2 (Growth factor receptor-bound protein 2), CRKL (Crk-like 
protein) and HNRNPK (Heterogeneous nuclear ribonucleoprotein K) are part of microRNAs 
in cancer. This suggests that gene silencing between cells is carried through exosomes and 
binding to the GTPase, RAB11B (Figure 5-21). 
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Figure 5-21: Interaction of the secreted proteins from untreated macrophages. Also 
represented are the GO classification terms (colour coding) and FDR values are shown. 
 
5.4 Effect of LAM on the gelatinase activity of secreted and expressed 
proteins in from THP-1 macrophages 
The lysate and media harvests from the 4 and 24-hour incubation with LAM were analysed 
by gelatin zymography for MMP activity (Figure 5-22). There was no significant difference in 
activity between stimulated and non-stimulated lysate and media, even after 24 hours in 
serum-free media. 
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Figure 5-22: Hydrolysis of gelatin by LAM stimulated and unstimulated macrophages. The 
lysate (lanes 1 to 5) and media (lanes 6 to 9) harvested from macrophages that were 
stimulated for 4 or 24 hours were run on gelatin zymography. The recombinant MMP-9 was 
loaded as a control (lane 1).  
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Discussion 
 
5.5.1 Implications of MMP-9 dysregulation and LAM (H37Rv) recognition  
Both the expression and secretion of MMP-9 were not significantly dysregulated, whilst its 
gelatinase activity was also not altered by the presence of LAM, implying that other factors, 
most probably Mycobacterial factors are required. However, significant upregulation of 
TIMP-1 in the media and lysate was observed. This also explains the lack of a difference in 
the gelatinase activity between the treated and untreated macrophages. The LAM 
component of M. smeg and M. tb are distinguished by the capping subunits where the latter 
comprises mono, di-, or tri- α(1→ 2) man units (man-LAM) whereas M. smeg contains 
phosphoinositol (PI-LAM) caps (Appelmelk et al. 2008;Fukuda et al. 2013). These differences 
in capping may result in some differences in the recognition pattern prerequisite and 
response from the host, thus eliciting unique proteomic phenotypes.  
The C-type mannose receptor 2 (MRC2) and C-type lectin domain family 11 (CLEC11A) were 
only expressed by the LAM-treated macrophages. The C-type lectin superfamily of proteins 
are part of the LAM recognition pattern expressed on the host cell membrane and are 
important sero-biomarkers associated with innate immunity (Alagarasu et al. 2007). This 
suggests that expression of these proteins is LAM-induced. As discussed with the M. smeg 
infections, the MRC2 and its homolog ENDO-180 (urokinase plasminogen activator receptor-
associated protein or uPARAP) act as the main route for the non-phagocytic uptake of 
collagen in cells for degradation in lysosomal compartments (Paracuellos et al. 2015). Like 
MMP-2 and -9, they contain the fibronectin-II repeats that bind collagen and gelatin. The 
overexpression of MRC2 or ENDO-180 caused the internalisation of labelled collagen, which 
was at a slower rate to that of gelatin. The authors also concluded that the collagen binding 
and release from this complex is neither pH- or calcium-dependent. Although others have 
reported that LAM induces an increase in MMP-1 and -9 genes and MMP-9 activity (Chang 
et al., 1996), however the induced expression of MRC2 observed in our study offers an 
alternate mechanism of gelatin and/or collagen degradation.  
Although MMP-9 is important for recruiting immune cells to the granuloma and for its 
maturation, MMP-9 knock-out mice infected with M. tb still resulted in albeit smaller 
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granulomas and less macrophages to the site of infection (Elkington et al. 2011a). Therefore, 
remodelling of the basal membrane and migration of immune cells may not be triggered by 
and solely dependent on MMP-9. This also suggests that the extracellular degradome of 
MMPs especially from collagen or gelatin may influence the phenotype that causes 
progression of disease to dissemination or cavitation. The LAM-treated macrophages depict 
a phenotype that implies preservation of collagen and/or gelatin breakdown hence the 
cathepsins which can breakdown ECM components were also not dysregulated. This further 
suggests that cathepsins regulate MMPs by activating them as discussed for the M. smeg 
infection (section 4.6.1). 
The immune response displayed by the treated macrophages supports that the contact 
between the bacterial cell-wall and host cell membrane triggers the initial immune 
response. In addition to that, LAM caused GO protein enrichment of the lysosome cellular 
compartment in dysregulated proteins of the lysate and the secretion of GTPases/RAB 
system including the late RAB7A that are crucial for phagolysosomal fusion and maturation. 
Thus, the aforementioned suggests that an increase in the levels and activity of MMP-9 may 
not be fundamental to granuloma formation and maturation, and phagolysosomal fusion. 
This endorses developing specific MMP-9 inhibitors as potential therapeutic drugs to 
alleviate chronic ECM degradation associated with cavity formation. 
 
5.5.2 LAM filtration in urine and its induction of proteinuria  
The detection of LAM in the urine of TB patients has been documented with research 
focused on development of diagnostic tools; however, the mechanism by which it is 
processed and excreted in the kidney remains to be elucidated. The presence of M. tb DNA 
in half of LAM-positive patients co-infected with HIV has been reported (Wood et al. 2015). 
Although there are several mechanisms that have been postulated which Cox and 
colleagues (Cox et al. 2015) have reviewed none has been fully investigated and accepted. 
These include 1) direct entry of intact M. tb through the glomerular basal membrane (GBM) 
from the bloodstream but was considered unlikely because of its size; 2) entry of LAM on its 
own or in an immune-complexed form but the latter would also be too large to cross the 
membrane; 3) finally the authors concluded that whilst GBM leakage and proteinuria would 
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allow passage of large molecules, their data demonstrated glomerulopathy in only 2 of the 5 
patients that were LAM-positive without renal TB, and 1 in 3 of LAM-negative in TB patients, 
whilst another study found only a weak correlation between LAM-positivity and proteinuria 
(Cox et al. 2015).  Thus, the likelihood of circulating LAM crossing the membrane is a 
possibility that remains to be explored. Importantly, co-infection with HIV (with CD4 less 
than 100 cells/mm3) enhanced the sensitivity of the urinary LAM diagnostic performance 
(Lawn and Gupta-Wright 2016;Pandie et al. 2016). Also, urine LAM detection in children has 
also been unsuccessful and according to Lawn and Gupta-Wright this is due to the 
paucibacillary nature of M. tb and inability to disseminate (Lawn and Gupta-Wright 2016).  
It is vital to note that patients co-infected with HIV rarely present with cavitary TB (Munthali 
et al. 2014) and the reduced tissue damage is associated with decreased concentrations of 
MMPs (Walker et al. 2012). In these patients and HIV negative controls MMP-1 was 
upregulated, however the concentration of TIMP-1 was lower in the latter (Elkington et al. 
2005a;Walker et al. 2012). Children rarely form cavities upon M. tb infection. Interestingly, 
like the HIV-positive adults co-infected with TB, the MMPs are upregulated, including MMP-
1, MMP-7 and MMP-8 but the TIMPs (TIMP-1 and TIMP-3) are also elevated (Pavan Kumar 
et al. 2013). As previously mentioned, dissemination and cavitation are associated with an 
upregulation and increased activity of MMP-1. 
The current study postulates that 1) LAM recognition and binding is through the interaction 
with MRC2 in conjunction with MMP-9, and/or uPA related receptors. 2) Thus, the number 
of macrophages and expression of MRC2 on the surface affects the concentration of LAM 
binding and circulating in the plasma. 3) The formation of extracellular traps causes ejection 
of chromatin into the secretome (plasma) facilitating the transport of LAM across the GBM 
through exosomes. 4) The inhibition of MMPs by binding to the catalytic Zn-binding site 
reduces the formation of aggNETS which may trap the LAM preventing its transportation 
across the GBM. Therefore, in patients who are HIV +ve and have lower CD4 cell counts, 
reduced MRC2 cell-surface expression may result in lower concentrations of bound LAM. 
The LAM still circulating in the blood may then be delivered and transported across the GBM 
through binding to chromatin via electrostatic interactions. This complex is then transported 
across the GBM via exosomes through fusion to the GTPases. Since formation of aggNETS 
was abolished by treatment with EDTA but not serine protease inhibitors (Schauer et al. 
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2014), inhibition of MMP activity by TIMPs could result in decreased aggregation that traps 
the LAM from being transported via the chromatin. Thus, patients who are HIV +ve and have 
high cell density may have lower urine concentrations of LAM because of aggNETs trapping 
the LAM and/or higher concentrations of MRC2-bound LAM. The paucibacillary phenotype 
in children could be due to the extracellular traps and aggNETS causing less transportation 
of bacteria and LAM across the GBM.  
The glomerular filtration barrier is made up of three layers including the endothelial cells, 
podocytes and the glomerular basal membrane (GBM). They are important in conferring 
selectivity to permeability of the membrane. The GBM is the ECM component that lies 
between the endothelial cells and podocytes and is initially synthesised by the endothelial 
cells and podocytes. The plasma that flows through the capillaries reaches the GBM through 
the highly fenestrated endothelial layer (Miner 2011;Miner 2012). The absence of increased 
MMP activity suggests that proteinuria may not be due to breakdown of the GBM, thus 
another mechanism may be more relevant.  
As mentioned earlier the significant overexpression and secretion of TIMP-1 is essential 
given its role in binding and stabilising the Hx domain. The intrarenal infusion of Hx domain 
into rats causes glomerular damage and proteinuria, which are both abolished by serine 
protease inhibitors rather than collagenase inhibitors (Bakker et al. 2005). That study 
suggested that this was partly due to the loss of glomerular ectoapyrase and 
sialoglycoproteins. Transgenic mice overexpressing heparanase resulted in decreased 
concentrations of heparan sulfate and presented minimal albuminuria which was however 
significantly different to the controls (van den Hoven et al. 2008). Removing the GBM 
glycosaminoglycans with bacterial glycosaminoglycan degrading enzymes has been 
associated with the presence of albumin and ferritin in urine (Kanwar et al. 1980). The 
dysregulated secretome from our M. smeg infections depicted enrichment of 
glycosaminoglycans, chondroitin sufate metabolic process and chondroitin sulfate 
proteoglycan metabolic process. Additionally, protein groups overexpressed by LAM-
stimulated macrophages depicted phosphatase activity and GO enrichment in global-SCX-
fraction. These imply that LAM alone, that is, without other Mycobacterial factors, might 
cause proteinuria and renal damage through the loss of negative charge derived from 
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phosphates. It is also plausible that during infection with M. tb, increased body 
temperatures cause the destabilisation of the MMP-9 leading to accumulation of the Hx 
domain in the plasma. This in turn could cause proteinuria when in direct contact with the 
kidney glomeruli through the loss of glomeruli glycoaminoglycans. This suggests that MMP 
substrate recognition and cleavage depends on the form of MMP. The specific targeting of 
their potential serine protease activity through inhibitors targeting the Hx domain rather 
than their collagenase or gelatinase activity could minimise proteinuria and the GBM 
filtration of LAM.  
 
5.5.3 Pathways enriched by LAM stimulation 
The LAM induced the GO enrichment in ubiquitin-specific protease activity molecular 
functions which is an essential post-translational modification (PTM) that regulates various 
biological processes including pathways that are involved in pathogenesis of Mycobacterial 
infections. Ubiquitination has been shown to be a vital regulatory PTM in the lysosomal 
localisation and macrophage apoptosis of Mycobacteria. Alonso and colleagues show that 
peptides derived from ubiquitin localise to the lysosome and are microbicidal against 
Mycobaterium tuberculosis and smegmatis. Transportation of these peptides to the 
lysosome was via multivesicular bodies (MVBs) and exert their effect by forming pores that 
cause permeability of the Mycobacterial cell wall and vulnerability to other antimicrobial 
molecules. This effect is enhanced by autophagy and is essential in early infection (Alonso et 
al. 2007). The implication of the antimicrobial properties of these peptides was attributed to 
histones and the ribosomal proteins L30, S30 and S19. Our data show GO enrichment of the 
lysosome cellular compartment and the dysregulation of the ribosomal proteins including 
RPL27A, RPL7, RPS8 amongst others in both secretome and intracellular protein. 
Interestingly these ribosomal proteins are predicted to form an interaction network with 
porin proteins (see Figure 5-12) in dysregulated intracellular proteins. It is possible that LAM 
alone causes ubiquitination generating ubiquitin-derived peptides that allow survival of the 
macrophage and bacteria.  
Most of these dysregulated proteins were predicted to form protein-protein interactions, in 
addition to being classified under the GO biological process ‘symbiosis process’. This 
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suggests that LAM induces phagolysosomal fusion but generates ubiquitin-derived peptides 
that culminates in escape and survival of the bacteria within the macrophages. The uniquely 
identified apoptosis regulating proteins BAK-1 and caspase-3 in the LAM-treated 
intracellular proteome are essential and in the same sample caspase-3 and DNA 
fragmentation factor subunit alpha (DFFA) were predicted to form protein-protein 
interactions. Caspase-3 causes the activation of DNA fragmentation factor (DFF) inducing 
the fragmentation of DNA during apoptosis by acting on DFFA (Wolf et al. 1999). The 
activation of ubiquitin-specific protease activity and 14-3-3 protein domain in the LAM 
treated macrophages suggests that the balance between pro-apoptosis and anti-apoptosis is 
mediated by ubiquitination and phosphorylation by kinases. Thus, the host may be 
protecting itself from the detrimental effects of necrosis by inducing a Bak and caspase-3 
dependent cell death.  
The Trk receptor signalling pathway is important to note and offers another mechanism by 
which the host is exploited for survival of the bacteria. Tropomyosin-related kinase (Trk) 
receptor tyrosine kinase are transmembrane glycoproteins with an extracellular domain 
containing multiple glycosylation sites, more specifically sialylation sites. Trypanosoma cruzi 
(T. cruzi) the causative agent of Chagasi disease is well-documented for its ability to exploit 
and evade the host system by transfer of the hosts sialic acid to the parasites mucin-like 
molecules of its cell surface and between the hosts glycoconjugates (Freire-de-Lima et al. 
2016;Freire-de-Lima et al. 2015). This is executed by the trans-sialidase (also known as 
parasite-derived neurotrophic factor) on the cell surface of T. cruzi. This enzyme interacts 
and activates TrkA and TrkC utilising TrkC for entry into the host (Weinkauf et al. 2011). This 
suggests that during M. tb infection LAM may be modified through interaction of Trk 
receptors and Mycobacterial factors that modify the cell-wall sugars resulting in the 
intracellular survival of M. tb. Methylthio-D-xylose (MTX) is a motif that’s been identified on 
the mannoside caps of LAM and is substituted via α-(1→4)-linkage (Angala et al. 2017). It is 
postulated to have a role in the host-Mycobacteria interaction and in conferring the 
antioxidative properties of LAM. Therefore, LAM can be modified to facilitate its survival in 
the host by redox- and glycosylation-dependent mechanisms.     
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5.6 Conclusions 
MMPs have been implicated in the pathophysiology of TB cavitation by causing irreparable 
tissue damage. The expression of MMP-9 is associated with granuloma formation and 
maturation, whilst the degradation of collagen is correlated with increased MMP-1 activity. 
These events have been documented to cause cavitation and dissemination which 
culminate in transmission (Elkington et al. 2005a;Elkington et al. 2005b;Hrabec et al. 
2002;Kubler et al. 2015;Salgame 2011).  Thus, MMPs are possible drug targets in combating 
tissue damage associated with cavitation but the major challenges include the similarity in 
their active site pockets, they perform important functions besides ECM degradation and 
remodelling, and their role as protective or detrimental agents has not been conclusively 
defined. Studying their upstream and downstream effectors in conjunction with their 
activity is essential and is the basis of this study. The avirulent M. smegmatis was used as 
the Mycobacterial model for monitoring the THP-1 macrophage response upon infection.  
An indirect but valuable comparison was carried out with the virulent H37Rv cell wall 
component LAM. 
The major findings of the activity assays were that M. smeg caused a general increase in the 
activity of MMP-9 and a decrease in MMP-1 activity. LAM did not cause any increase in the 
expression and activity of MMPs. This validates that MMP-1 activity is deliberately and 
specifically increased by M. tb (Elkington et al. 2005a;Elkington et al. 2005b;Hrabec et al. 
2002;Kubler et al. 2015;Salgame 2011). In addition to LAM, other Mycobacterial virulent 
factors are responsible for inducing the upregulation and increase in the activity of MMP-1 
and MMP-9. Similarly, M. smeg and LAM on its own, were able to activate an immune 
response. The C-type lectin superfamily of proteins are part of the LAM recognition pattern 
expressed on the host cell membrane and are important sero-biomarkers associated with 
innate immunity (Alagarasu et al. 2007). Interestingly, C-type mannose receptor 2 (MRC2) 
and C-type lectin domain family 11 (CLEC11A) were only expressed by the LAM-treated 
macrophages. It is possible that CLEC11A and MRC2 are specifically expressed for 
recognition of the M. tb cell wall rather than M. smeg however the signal does not induce 
dysregulation of MMPs. MRC2 and its homolog ENDO-180 (urokinase plasminogen activator 
receptor-associated protein or uPARAP) act as the main route for the non-phagocytic uptake 
of collagen in cells for degradation in lysosomal compartments (Paracuellos et al. 2015).  
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Thus, MRC2 offers an alternate mechanism of gelatin and/or collagen degradation 
suggesting that this may be an initial response that facilitates migration of immune cells to 
the site of infection.  
Survival of M. tb inside macrophages may be facilitated by two other mechanisms namely, 
ubiquitination and through interaction of Trk receptors and Mycobacterial factors. Trk 
receptors could be interacting with LAM, modifying the sugars of the M. tb cell-wall 
component such as the methylthio-D-xylose (MTX) motif that has been identified on the 
mannoside caps of LAM to be substituted via α-(1→4)-linkage (Angala et al. 2017). This 
substitution is postulated to have a role in the host-Mycobacteria interaction and in 
conferring the antioxidative properties of LAM. Therefore, LAM can be modified to facilitate 
M. tb survival in the host by redox- and glycosylation-dependent mechanisms.  
Ubiquitin-derived peptides localise to the lysosome where they elicit microbicidal activity 
against M. tb and M. smeg by forming pores that increase the permeability of the bacteria 
(Alonso et al. 2007). This is important in early infection and is facilitated by histones, the 
ribosomal proteins L30, S30 and S19. Both LAM and M. smeg caused the dysregulation of 
histone H4 in the secretome, and ribosomal L30 was upregulated by the M. smeg infection. 
Thus, M. tb may circumvent lysosomal killing by upregulating other ribosomal proteins 
rather than the aforementioned. 
Analysis of the time point harvests by zymography suggested that there is a switch in the 
proteolytic repertoire of the macrophages between the 6- and 18-hour time points to one 
that causes a decrease in the fold difference between infected and uninfected secretome. It 
is also possible that this leads to generation of the same degradation products between 
infected and uninfected macrophages minimising the positive loop mechanism that leads to 
chronic expression and activity of MMPs. Further investigation needs to be done to 
conclude. The postulated upstream factors that regulate MMPs during infection were not 
enhanced by LAM treatment somewhat validating their role in activating and/or inactivating 
MMPs. Expression of MMP-9 in M. smeg infected macrophages could be regulated by IL-1β 
in a COX-prostaglandin synthase-dependent manner, and also via alternative splicing which 
was also indicated by western blotting. Its secretion was possibly regulated and facilitated 
by exosomal compartmentalisation, TIMP-1 and cytoskeletal-related proteins including 
tubulins, actins and adenylyl cyclase-associated protein 1. Finally, the activation of MMP-9 
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may be regulated in the secretome by downregulating cathepsins and via redox control by 
secreting PDI, HMGB1 and ribonuclease T2. Also, by scavenging reactive oxygen species 
through the superoxide dismutase and nucleotide de novo biosynthesis II pathway in the 
lysate.  
The current study suggests that the potential serine protease activity of MMP-9 may have 
implications for drug design. For example, inhibiting its serine protease activity may lead to 
decreased degradation of pro-inflammatory cytokines, whilst chelating the active site zinc 
abolishes the formation of aggNETS only but does not prevent the degradation of the pro-
inflammatory cytokines. Reduced formation of aggNETS which may trap LAM preventing its 
transportation across the GBM, this could have potential implications for urine-LAM 
detection kits.  
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Appendix 1 
Western blotting 
 
SDS-PAGE  
The stacking and separating gels were prepared to final concentrations of 4% and 10% 
polyacrylamide gels, respectively. Samples were prepared by diluting in sample buffer which 
contained β-mercaptoethanol and then boiled for 5 minutes, unless otherwise stated. 
Electrophoresis was carried out at 40 mA for two gels using 1 X electrophoresis buffer. 
Following that, the protein bands were either visualised by using Coomassie-blue staining or 
transferred to a Hybond C nitrocellulose membrane as required for western blotting 
analysis.  
Table 6-1: SDS-PAGE buffer recipes 
  
  
Components 
Stacking gel 
4%   Acrylamide     
0.125 M Tris-HCL pH 6.8, 0.1% SDS and 150 µl of 10% ammonium 
persulfate (APS) and 20 µl TEMED      
Separating gel 
10% Acrylamide     
0.375 M Tris-HCL pH 8.8; 0.1% SDS, 150 µl of 10% ammonium 
persulfate (APS) and 15 µl TEMED      
Electrophoresis 
buffer 192 mM glycine, 1% (w/v) SDS and 25 mM Tris, pH 8.5     
3X Sample 
loading buffer 
10% glycerol, 0.01% bromophenol blue, 1% SDS and 50 mM Tris-
HCL, pH 6.8     
 
Protein transfer 
Transfer of protein to the Hybond C nitrocellulose membrane was done using the Biorad 
transfer apparatus. The Whatman papers, sponges and gel were soaked in ice-cold blotting 
buffer for 15 minutes prior assembling the transfer sandwich. This was done to minimise 
bubble formation during assembly and protein transfer. The transfer sandwich was 
assembled appropriately also ensuring exclusion of bubbles that may interfere with the 
blotting procedure. Blotting was carried out at 300 mA for about an hour with constant 
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stirring of the blotting buffer. To keep the buffer cool, an ice pack was placed in the slot 
provided in the apparatus. 
Table 6-2: Western blotting buffers 
 
 Buffer components 
Transfer 
buffer 0.025 M Tris-HCL, 0.192 M Glycine, 20% Methanol, pH 8.2     
Blocking 
buffer 
5% Skim milk, 0.1% Tween-20, 0.2 M NaCl, 0.05 M Tris-HCL, pH 
7.4     
10X TBS buffer 2 M NaCl, 0.5 M Tris-HCL, pH 7.4     
TBS-T buffer 0.1% Tween-20, 0.2 M NaCl, 0.05 M Tris-HCL, pH 7.4     
 
Zymography 
Table 6-3: Zymography buffer components  
 
  
Components 
Stacking buffer  
4%   Acrylamide   
0.125 M Tris-HCL pH 6.8, 0.1% SDS and 150 µl of 10% 
ammonium persulfate (APS) and 20 µl TEMED    
Separating buffer  
10% Acrylamide   
0.462 M Tris-HCL pH 8.8, 1.5 mg/ml substrate, 0.1% SDS, 150 
µl of 10% ammonium persulfate (APS) and 15 µl TEMED    
Substrate preparation 
(1.5 mg/ml) 
  
1.5 mg gelatin, 1 ml dH2O, dissolve at 60 ˚C    
1.5 mg casein, 1 ml dH2O   
1.5 mg collagen, 0.1 M Acetic acid, dissolve by agitation   
10X Electrophoresis 
buffer 1.92 M glycine, 1% (w/v) SDS and 0.25 M Tris, pH 8.5   
Renaturation buffer 2.5% TritonX-100 (make up with distilled water)   
Activation buffer 50 mM Tris-HCL pH 7.6, 0.2 NaCl, 5 mM CaCl2   
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Appendix 2 
 
Figure 6-1: Gelatinase activity of the 72-hour secretome at higher protein concentration. 
The uninfected (Lane 1) and infected (Lane 2) secretome was loaded at a higher total 
protein concentration. Clear bands representing MMP-9 (82 kDa) and MMP-1 (47 kDa) 
hydrolysis are indicated.    
 
Figure 6-2: Casein hydrolysis by the secretome. The secretome from the second biological 
replicate of the M. smeg infections was analysed. MMP-9 (Lane 1) and MMP-1 (Lane 2 in gel 
A and Lane 3 in gel B) were loaded as controls. 
B  
A  
191 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3: Collagenase activity of the secretome. The secretome samples from the second 
biological replicate of the M. smeg infection time point experiments were evaluated by 
collagen zymography. MMP-1 was loaded as a positive control in lanes 8 and 1 for gel A and 
B, respectively. 
A 
B 
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Figure 6-4: Gelatinase activity of the lysate. The lysate samples from the 2nd biological 
replicate of the M. smeg infection time point experiments. Recombinant MMP-9 (Lane 6) 
was loaded as a control. 
 
Figure 6-5: Analysis of casein hydrolysis by the lysate. The lysate from the second biological 
replicate of the M. smeg infection time point harvests were loaded in gels A and B. The 
recombinant MMP-9 and MMP-1 were loaded as controls in lanes 1 and 3 (A) and in lanes 9 
and 7 (B) , respectively. 
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Figure 6-6: HPLC trace of samples used for MALDI analysis. The full chromatograph is 
represented where the substrate was either incubated with non-activated recombinant 
MMP-9 (RecMMP-9), APMA-activated MMP-9 (Activated RecMMP-9) or APMA. 
 
Figure 6-7: Representative MALDI spectra of the matrix and BSA. The α-Cyano-4-
hydroxyccinamic acid (α-CHCA) and BSA were included as controls in the analysis of the 
MMP-9 cleavage products experiment.   
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Figure 6-8:  MMP-1 standard curve from activity assays. 
The R2 value of the linear regression curve was 0. 82, with standard deviation of ± 539 and  
y = 311.8x. 
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Figure 6-9: Densitometric analysis of the Intracellular MMP-1 western blot. The 72-hour 
time point lysate was loaded using non-reduced sample buffer. The 47 kDa form was then 
compared between infected and uninfected by densitometry.   
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Figure 6-10: Migration pattern of MMP-1 prepared under reducing versus no-reducing 
conditions. MMP-1 antibody was used to probe the recombinant MMP-1 prepared with 
reducing (Lane 1) and non-reducing (Lane 2) sample buffer.  
 
 
Figure 6-11: Western blot analysis of the intracellular expression of MMP-9. The lysate 
from the M. smeg uninfected and infected lysate time point harvests were prepared using 
non-reducing sample buffer. The blots were then probed using the proMMP-9 primary 
antibody. Different time points are indicated with proMMP-9 loaded as a positive control in 
lanes 1 and 2.   
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Appendix 3 
Proteomics 
 
 
 
 
 
 
Figure 6-12: The uninfected intracellular proteome forms fewer interactions. The colour 
coding indicates the different types of proteins. 
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Table 6-4: Dysregulated proteins secreted by M. smeg infected macrophages (two-sample 
t-test).  
These were computed using the two-sample t-test. 
Protein ID Protein Name 
Unique 
Peptides 
q-value 
Fold 
Change 
Sequence 
Coverage (%) 
O00115 Deoxyribonuclease-2-alpha 2 0 -3.07 6.4 
O00584 Ribonuclease T2 8 0 -1.09 38.3 
P01023 Alpha-2-macroglobulin 14 0 -1.97 11.1 
P06865 Beta-hexosaminidase 5 0 -3.77 9.6 
P07355 Annexin A2 11 0 -3.06 50.4 
P07686 Beta-hexosaminidase subunit 
beta 
10 0 -3.75 21.9 
P08670 Vimentin OS=Homo sapiens G 37 0 -4.25 65.5 
P11279 Lysosome-associated 
membrane glycoprotein 1 
1 0 -2.17 2.2 
P12109 Collagen alpha-1(VI) chain 14 0 -7.94 16.9 
P14780 Matrix metalloproteinase-9 18 0 3.41 28.1 
P34741 Syndecan-2 2 0 -4.23 10.9 
P36222 Chitinase-3-like protein 1 8 0 -2.83 41.3 
P62805 Histone H4 7 0 -6.08 49.5 
P62937 Peptidyl-prolyl cis-trans 
isomerase A 
12 0 3.06 70.9 
P63313 Thymosin beta-10 2 0 -3.15 63.6 
P68104 Putative elongation factor 1-
alpha-like 3 
22 0 -3.04 53 
Q9UBR2 Cathepsin Z 6 0 -2.35 21.8 
P06753 Tropomyosin alpha-3 chain 10 0 4.24 39.6 
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Table 6-5: Dysregulated proteins from the lysate of M. smeg infected macrophages (two-
sample t-test).  
These were computed using the two-sample t-test. 
Protein ID Protein Name 
Unique 
Peptide
s 
q-
value 
Fold 
change 
Sequence 
Coverage 
(%) 
P01584 Interleukin-1 beta  7 0 7.12 27.3 
P43490 Nicotinamide 
phosphoribosyltransferase  
11 0 5.04 12 
P11166 Solute carrier family 2. facilitated 
glucose transporter member 1  
6 0 5.01 3.2 
P04179 Superoxide dismutase [Mn]. 
mitochondrial 
4 0 4.50 66.8 
A8MVU1 Putative neutrophil cytosol factor 1C  7 0 3.92 21.8 
Q96RQ9 L-amino-acid oxidase  5 0 3.17 6.4 
B7Z5P7 Leupaxin  3 0 3.05 17.2 
B7Z3Z9 Long-chain-fatty-acid--CoA ligase 1  4 0 3.02 9.4 
P05362 Intercellular adhesion molecule 1 11 0 2.8 11.8 
E5RIJ3 Tumor necrosis factor alpha-induced 
protein 8 
1 0 2.75 23.5 
Q9ULC4 Malignant T-cell-amplified sequence 1 3 0 2.73 18.6 
P07948 Tyrosine-protein kinase Lyn 7 0 2.63 16.7 
P10124 Serglycin  3 0 2.56 35.4 
C9JRH2 Regulator of chromosome 
condensation  
3 0 2.55 20.3 
O00410 Importin-5 4 0 2.55 33.9 
Q9NY12 H/ACA ribonucleoprotein complex 
subunit 1 
3 0 2.54 34.5 
Q9NQR4 Omega-amidase NIT2 3 0 2.54 11.3 
Q9H4M9 EH domain-containing protein 1  12 0 2.3 3.8 
Q03405 Urokinase plasminogen activator 
surface receptor  
8 0 2.21 7.3 
A0A087X1W
8 
Cell adhesion molecule 1  2 0 2.20 35 
Q9Y512 Sorting and assembly machinery 4 0 2.17 11.3 
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component 50 homolog 
Q13303 Voltage-gated potassium channel 
subunit beta-2  
4 0 2.08 10.9 
E5RJ98 Protein NDRG1 OS 1 0 2.05 23.3 
P29966 Myristoylated alanine-rich C-kinase 
substrate  
5 0 2.04 47.4 
P61224 Ras-related protein Rap-1b  1 0 2.01 15.9 
P49915 GMP synthase [glutamine-hydrolyzing]  7 0 2.00 26.3 
P13674 Prolyl 4-hydroxylase subunit alpha-1  8 0 1.98 24.5 
G3XAJ6 Raft-linking protein. isoform CRA 7 0 1.97 32 
Q12913 Receptor-type tyrosine-protein 
phosphatase eta  
4 0 1.97 5.1 
S4R456 40S ribosomal protein S15  3 0 1.91 14.9 
Q99878 Histone H2A type 1-J  2 0 1.89 29.4 
Q8NBZ7 UDP-glucuronic acid decarboxylase 1  1 0 1.88 16.6 
O00303 Eukaryotic translation initiation factor 3 
subunit F  
6 0 1.87 34.6 
Q9Y5X1 Sorting nexin-9  6 0 1.86 58 
H3BTA2 Serine/threonine-protein phosphatase  3 0 1.85 30.1 
E9PEP6 Neuropilin  13 0 1.83 32 
Q96P48 Arf-GAP with Rho-GAP domain. ANK 
repeat and PH domain-containing 
protein 1  
2 0 1.82 28.1 
H0YDT8 ER membrane protein complex subunit 
7  
2 0 1.79 9.1 
P40306 Proteasome subunit beta type-10 2 0 1.65 23 
P06756 Integrin alpha-V  13 0 1.64 23 
P08240 Signal recognition particle receptor 
subunit alpha  
7 0 1.63 45.1 
P55795 Heterogeneous nuclear 
ribonucleoprotein H2 
4 0 1.62 12.7 
P28482 Mitogen-activated protein kinase 1 3 0 1.59 22.8 
Q92769 Histone deacetylase 2  4 0 1.58 15.8 
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Q96HE7 ERO1-like protein alpha  11 0 1.57 24.8 
H0Y4R1 Inosine-5-monophosphate 
dehydrogenase 2 
8 0 1.54 34.4 
D6RD47 40S ribosomal protein S23  2 0 1.54 66.9 
Q9P2J5 Leucine--tRNA ligase. cytoplasmic  7 0 1.52 18.5 
P09543 2.3-cyclic-nucleotide 3-
phosphodiesterase 
2 0 1.52 12.7 
P08754 Guanine nucleotide-binding protein 
G(k) subunit alpha  
3 0 1.50 45.2 
P18510 Interleukin-1 receptor antagonist 
protein  
3 0 1.50 21.9 
P17858 ATP-dependent 6-
phosphofructokinase. liver type  
5 0 1.47 23.5 
P10155 60 kDa SS-A/Ro ribonucleoprotein  5 0 1.44 15.8 
Q15393 Splicing factor 3B subunit 3  9 0 1.44 14.3 
P46778 60S ribosomal protein L21  4 0 1.44 37.1 
P21964 Catechol O-methyltransferase  4 0 1.43 21.1 
Q8WYA6 Beta-catenin-like protein 1 4 0 1.42 12 
P08567 Pleckstrin OS 7 0 1.41 15.5 
Q96JB2 Conserved oligomeric Golgi complex 
subunit 3 
1 0.0004 1.40 8.6 
P31150 Rab GDP dissociation inhibitor alpha  6 0 1.36 26.5 
P22102 Trifunctional purine biosynthetic 
protein adenosine-3  
7 0 1.34 23.4 
Q4KMQ2 Anoctamin-6  1 0 1.32 29.7 
Q96AH8 Ras-related protein Rab-7b  4 0 1.28 11.7 
P49354 Protein 
farnesyltransferase/geranylgeranyltran
sferase type-1 subunit alpha  
9 0 1.28 13 
P14780 Matrix metalloproteinase-9  18 0 1.28 14.6 
P27701 CD82 antigen  3 0 1.28 14.8 
P43034 Platelet-activating factor 
acetylhydrolase IB subunit alpha  
3 0 1.27 23 
H7C2R7 Spermine synthase (Fragment)  1 0 1.27 29.9 
201 
 
P07602 Prosaposin  19 0 1.26 19.1 
P46977 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A  
5 0 1.25 16.9 
P31949 Protein S100-A11  4 0 1.25 9.2 
P61020 Ras-related protein Rab-5B  3 0 1.25 28.1 
D6RD63 COP9 signalosome complex subunit 4 
(Fragment)  
3 0 1.24 30.5 
D6RFL4 Monocyte differentiation antigen CD14 
(Fragment)  
3 0 1.24 6.8 
O00116 Alkyldihydroxyacetonephosphate 
synthase. peroxisomal  
5 0 1.23 20.2 
O00743 Serine/threonine-protein phosphatase 
6 catalytic subunit  
3 0 1.23 29.5 
A0A0A0MR0
2 
Voltage-dependent anion-selective 
channel protein 2 (Fragment)  
12 0 1.21 40 
P16278 Beta-galactosidase  3 0 1.21 23.4 
Q9Y263 Phospholipase A-2-activating protein 
OS 
2 0 1.20 16.1 
Q9Y696 Chloride intracellular channel protein 4  10 0 1.20 8.8 
P13995 Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase. 
mitochondrial 
4 0 1.20 23.2 
O00442 RNA 3-terminal phosphate cyclase  4 0 1.20 22.2 
O43447 Peptidyl-prolyl cis-trans isomerase H  5 0 1.19 7 
P34897 Serine hydroxymethyltransferase. 
mitochondrial  
14 0 1.18 25.7 
O43598 2-deoxynucleoside 5-phosphate N-
hydrolase 1  
4 0 1.16 68.6 
A0A087WS
W9 
Thioredoxin reductase 1. cytoplasmic  11 0 1.16 25.1 
B0QYV8 ADP-ribosylation factor GTPase-
activating protein 3 (Fragment)  
2 0.0004 1.15 10.4 
E9PJK1 Tetraspanin OS 3 0 1.15 33.7 
E5RHW4 Erlin-2 (Fragment)  9 0 1.14 26.9 
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P55735 Protein SEC13 homolog  5 0 1.12 36.7 
O00186 Syntaxin-binding protein 3  2 0.0004 1.12 27 
Q8WX92 Negative elongation factor B  2 0.0004 1.11 7.4 
P05141 ADP/ATP translocase 2  4 0 1.11 43.6 
P21796 Voltage-dependent anion-selective 
channel protein 1  
16 0 1.11 44.2 
Q9HCC0 Methylcrotonoyl-CoA carboxylase beta 
chain. mitochondrial  
5 0 1.10 21.3 
O00560 Syntenin-1  2 0 1.09 13.5 
Q9BXD5 N-acetylneuraminate lyase 1 0.000 1.09 18 
X1WI28 60S ribosomal protein L10 (Fragment)  1 0 1.08 11.4 
Q99459 Cell division cycle 5-like protein  5 0 1.07 24.4 
Q14566 DNA replication licensing factor MCM6  6 0 1.06 30.4 
P56134 ATP synthase subunit f. mitochondrial  3 0 1.05 35.2 
Q13573 SNW domain-containing protein 1  4 0 1.05 48.9 
P00338 L-lactate dehydrogenase A chain  9 0 1.05 23.1 
Q9BUF5 Tubulin beta-6 chain  6 0 1.03604 17.8 
Q9Y277 Voltage-dependent anion-selective 
channel protein 3 
6 0 1.02 18.8 
H9KV28 Protein diaphanous homolog 1  10 0 1.02 32.9 
Q13423 NAD(P) transhydrogenase. 
mitochondrial  
9 0 1.01 40 
Q9H7D7 WD repeat-containing protein 26 11 0 1.00 41 
P40939 Trifunctional enzyme subunit alpha. 
mitochondrial  
17 0 1.00 7.6 
P62995 Transformer-2 protein homolog beta  2 0 0.99 32.1 
Q9BX68 Histidine triad nucleotide-binding 
protein 2. mitochondrial 
2 0 0.99 34.6 
P04150 Glucocorticoid receptor OS 5 0 0.97 22 
Q9UNM6 26S proteasome non-ATPase regulatory 
subunit 13  
10 0 0.97 13.6 
P51659 Peroxisomal multifunctional enzyme 
type 2  
16 0 0.97 35.4 
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P07814 Bifunctional glutamate/proline--tRNA 
ligase  
24 0 0.97 16 
A0A087WUD
3 
Oligosaccharyltransferase complex 
subunit OSTC  
1 0 0.96 11 
Q13501 Sequestosome-1  11 0 0.96 15 
P31939 Bifunctional purine biosynthesis protein 
PURH  
15 0 0.96 32.6 
Q9BW60 Elongation of very long chain fatty acids 
protein 1 
2 0 0.95 32.8 
P62081 40S ribosomal protein S7  6 0 0.95 61 
I3L1I0 Glyoxalase domain-containing protein 4 
(Fragment)  
1 0 0.94 25 
A0A1W2PN
M1 
Hydroxyacyl-coenzyme A 
dehydrogenase. mitochondrial 
4 0 0.94 6.5 
P07686 Beta-hexosaminidase subunit beta  10 0 0.94 16.2 
Q16186 Proteasomal ubiquitin receptor ADRM1  3 0 0.93 15.9 
Q15185 Prostaglandin E synthase 3  3 0 0.93 62.1 
P62304 Small nuclear ribonucleoprotein E 1 0 0.92 29 
K7EK60 Formin-like protein 1  1 0.0004 0.92 44.7 
Q8NBS9 Thioredoxin domain-containing protein 
5  
6 0 0.92 29.4 
P35232 Prohibitin  7 0 0.91 21.7 
Q13148 TAR DNA-binding protein 43  4 0 0.90 14.4 
P48147 Prolyl endopeptidase  8 0 0.90 30.6 
P43686 26S proteasome regulatory subunit 6B  11 0 0.89 33.8 
P14618 Pyruvate kinase PKM  3 0 0.88 21.2 
A6NLH6 Protein cornichon homolog 4  1 0 0.88 5.8 
P30520 Adenylosuccinate synthetase isozyme 2  5 0 0.88 7.6 
P51571 Translocon-associated protein subunit 
delta  
4 0 0.87 40.2 
P05091 Aldehyde dehydrogenase. 
mitochondrial  
8 0 0.87 26.6 
P22695 Cytochrome b-c1 complex subunit 2. 
mitochondrial  
8 0 0.87 52.7 
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E7EVZ5 Prenylcysteine oxidase-like  1 0 0.86 24.8 
J3KNF8 Cytochrome b5 type B  4 0 0.86 26.6 
Q16658 Fascin  14 0 0.86 13.8 
Q9UHA4 Regulator complex protein LAMTOR3  2 0.0004 0.85 36.4 
P01034 Cystatin-C  3 0 0.85 39.4 
E7EQJ3 HLA class II histocompatibility antigen 
gamma chain 
2 0 0.85 56.7 
O43312 Metastasis suppressor protein 1  9 0 0.85 12.6 
Q9Y265 RuvB-like 1  18 0 0.85 35.8 
H0YKT8 Proteasome subunit beta type 
(Fragment)  
5 0 0.84 18 
K7EJE8 Lon protease homolog. mitochondrial  13 0 0.84 39.4 
Q8NCW5 NAD(P)H-hydrate epimerase  3 0 0.83 21.9 
G3V4W0 Heterogeneous nuclear 
ribonucleoproteins C1/C2 (Fragment) 
4 0 0.82 20.5 
P49591 Serine--tRNA ligase. cytoplasmic  15 0 0.82 14.1 
P31930 Cytochrome b-c1 complex subunit 1. 
mitochondrial  
10 0 0.82 15.3 
M0QZS6 SUMO-activating enzyme subunit 1  7 0 0.82 47.4 
P61026 Ras-related protein Rab-10  4 0 0.82 28.4 
P25205 DNA replication licensing factor MCM3  5 0 0.81 12 
Q5T6H7 Xaa-Pro aminopeptidase 1  7 0 0.81 24.4 
P14868 Aspartate--tRNA ligase. cytoplasmic  12 0 0.81 47.1 
P30084 Enoyl-CoA hydratase. mitochondrial 7 0 0.81 51.8 
E9PMW2 Dr1-associated corepressor 2 0 0.80 10.4 
P62820 Ras-related protein Rab-1A  3 0 0.80 57.1 
P30101 Protein disulfide-isomerase A3  20 0 0.80 55.3 
Q9P0J0 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 13 
4 0 0.80 22.7 
Q9BXY0 Protein MAK16 homolog  1 0 0.80 14.4 
Q15029 116 kDa U5 small nuclear 
ribonucleoprotein component 
12 0 0.79 10.7 
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O15126 Secretory carrier-associated membrane 
protein 1  
4 0 0.79 39.1 
Q96JJ7 Protein disulfide-isomerase TMX3  6 0 0.79 44.6 
Q9BQE3 Tubulin alpha-1C chain  1 0 0.79 33.8 
Q86Y82 Syntaxin-12  5 0 0.79 5.9 
P30153 Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A alpha 
isoform 
9 0 0.78 4.5 
A0A286YF22 D-3-phosphoglycerate dehydrogenase  13 0 0.78 12.9 
Q9Y6M1 Insulin-like growth factor 2 mRNA-
binding protein 2 
5 0 0.77 12.1 
P55072 Transitional endoplasmic reticulum 
ATPase  
23 0 0.77 23.4 
B4DY09 Interleukin enhancer-binding factor 2  8 0 0.77 17.5 
O75487 Glypican-4  9 0 0.77 23.5 
A0A0A0MS4
1 
Sideroflexin  6 0 0.76 10.3 
P43304 Glycerol-3-phosphate dehydrogenase. 
mitochondrial  
8 0 0.76 53 
P12236 ADP/ATP translocase 3  4 0 0.75 12.1 
A0A087X1W
2 
Protein arginine N-methyltransferase 1  1 0 0.75 5 
Q13043 Serine/threonine-protein kinase 4 5 0 0.74 32.7 
O43615 Mitochondrial import inner membrane 
translocase subunit 
4 0 0.74 11.1 
Q5JP53 Tubulin beta chain  3 0 0.74 20 
P55084 Trifunctional enzyme subunit beta. 
mitochondrial  
10 0 0.74 8.5 
Q9BTV4 Transmembrane protein 43  5 0 0.74 2.8 
Q96HQ2 CDKN2AIP N-terminal-like protein  1 0 0.74 24 
P00558 Phosphoglycerate kinase 1  20 0 0.73 6.1 
P57737 Coronin-7  7 0 0.73 4.7 
F8VY35 Nucleosome assembly protein 1-like 1 
(Fragment)  
7 0 0.73 21.7 
206 
 
P16435 NADPH--cytochrome P450 reductase  9 0 0.73 19.9 
G3V126 ATPase. H+ transporting. lysosomal 
50/57kDa. V1 subunit 
2 0 0.72 34.1 
Q15758 Neutral amino acid transporter B(0)  4 0 0.72 16.2 
Q92598 Heat shock protein 105 kDa  23 0 0.72 23.8 
P42025 Beta-centractin  3 0 0.72 20.9 
E7EQ72 Transmembrane emp24 domain-
containing protein 2 (Fragment) 
2 0 0.71 16.9 
P49411 Elongation factor Tu. mitochondrial  15 0 0.71 13.7 
Q13405 39S ribosomal protein L49. 
mitochondrial  
3 0 0.71 11.3 
P55957 BH3-interacting domain death agonist  4 0 0.70 0.4 
P04899 Guanine nucleotide-binding protein G(i) 
subunit alpha 
3 0 0.70 10.5 
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase  
12 0 0.68 10.6 
Q15366 Poly(rC)-binding protein 2  3 0 0.68 42.8 
P16615 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
20 0 0.67 3.2 
F5H6X6 Neutral alpha-glucosidase AB  4 0 0.67 21.3 
P60900 Proteasome subunit alpha type-6  7 0 0.67 34.1 
P78371 T-complex protein 1 subunit beta 22 0 0.67 6.4 
P23381 Tryptophan--tRNA ligase. cytoplasmic  9 0 0.67 2.4 
E5RI99 60S ribosomal protein L30 (Fragment) 5 0 0.65 18.8 
O60506 Heterogeneous nuclear 
ribonucleoprotein Q  
13 0 0.65 14.9 
E9PBS1 Multifunctional protein ADE2 
(Fragment)  
10 0 0.65 24.6 
P05388 60S acidic ribosomal protein P0  7 0 0.65 26.4 
V9GY93 Transmembrane protein 165 
(Fragment)  
2 0 0.64 10.5 
O95373 Importin-7  11 0 0.64 5.3 
F5GZG1 Ras-related protein Rap-1b (Fragment)  1 0 0.64 5.9 
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P23141 Liver carboxylesterase 1  17 0 0.63 10.3 
Q9BS26 Endoplasmic reticulum resident protein 
44  
11 0 0.63 2.7 
Q15019 Septin-2  7 0 0.63 18.8 
Q96K17 Transcription factor BTF3 homolog 4  6 0 0.62 4 
P56537 Eukaryotic translation initiation factor 6  8 0 0.61 14.6 
P08648 Integrin alpha-5  9 0 0.60 3.4 
Q04837 Single-stranded DNA-binding protein. 
mitochondrial  
5 0 0.60 7.8 
Q16659 Mitogen-activated protein kinase 6  2 0.0003 0.60 16.8 
P06576 ATP synthase subunit beta. 
mitochondrial  
22 0 0.60 38.9 
O15355 Protein phosphatase 1G  7 0 0.59 11.9 
Q13595 Transformer-2 protein homolog alpha  1 0 0.59 8.8 
Q9Y6N5 Sulfide:quinone oxidoreductase. 
mitochondrial  
17 0 0.57 8.2 
P25705 ATP synthase subunit alpha. 
mitochondrial 
19 0 0.57 25.1 
P29350 Tyrosine-protein phosphatase non-
receptor type 6  
11 0 0.56 24.7 
F5H3X6 Prohibitin-2 (Fragment)  3 0 0.56 35.7 
P61225 Ras-related protein Rap-2b  2 0 0.56 15.5 
P13010 X-ray repair cross-complementing 
protein 5  
16 0 0.56 14.5 
O95831 Apoptosis-inducing factor 1. 
mitochondrial  
7 0 0.55 1.8 
Q53H82 Endoribonuclease LACTB2  4 0 0.55 18.3 
Q15746 Myosin light chain kinase. smooth 
muscle  
1 0.0022 0.54 41.1 
G5EA31 Protein transport protein Sec24C  5 0 0.53 1.7 
O00299 Chloride intracellular channel protein 1  12 0 0.53 12.2 
P26639 Threonine--tRNA ligase. cytoplasmic  12 0 0.53 9.7 
Q9H2U2 Inorganic pyrophosphatase 2. 
mitochondrial  
8 0 0.52 17.8 
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H0YL19 WD repeat-containing protein 61  3 0 0.49 15.6 
Q14012 Calcium/calmodulin-dependent protein 
kinase type 1  
9 0 0.49 5.3 
P48444 Coatomer subunit delta  7 0 0.46 37.7 
O75436 Vacuolar protein sorting-associated 
protein 26A  
6 0 0.42 15.3 
H0YE97 Phosphatidylinositol-binding clathrin 
assembly protein 
1 0 0.41 17.8 
Q9NR30 Nucleolar RNA helicase 2 OS 11 0 0.37 21.5 
P09960 Leukotriene A-4 hydrolase 
OSB228B227:B243B244B22B103 
11 0 0.36 9.7 
B0QY90 Eukaryotic translation initiation factor 3 
subunit L  
5 0 0.24 24.9 
Q92896 Golgi apparatus protein 1  7 0 -0.30 21.5 
Q15006 ER membrane protein complex subunit 
2  
4 0 -0.42 3.4 
Q8IVJ8 AP20 region protein 1  1 0.0037 -0.45 4.3 
Q13347  Eukaryotic translation initiation factor 
3 subunit I  
3 0 -0.45 11.9 
P52292 Importin subunit alpha-1  8 0 -0.51 22.6 
A0A0A0MRV
0 
Ribosome-binding protein 1  12 0 -0.58 37.4 
A0A087WW
C8 
Myelin expression factor 2  1 0.0004 -0.60 32 
Q9UJU6 Drebrin-like protein  8 0 -0.60 23.3 
O75312 Zinc finger protein ZPR1  7 0 -0.66 23.4 
A0A024R4E5 High density lipoprotein binding 
protein (Vigilin). isoform CRA 
11 0 -0.67 11.3 
M0QXH0 Thioredoxin. mitochondrial  1 0.0004 -0.72 13.7 
Q96I24 Far upstream element-binding protein 
3  
5 0 -0.73 11.8 
Q7Z5R6 Amyloid beta A4 precursor protein-
binding family B member 1-interacting 
protein 
11 0 -0.73 10.9 
Q92974 Rho guanine nucleotide exchange 6 0 -0.77 14.9 
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factor 2  
A0A087X0G7 NF-kappa-B essential modulator  2 0 -0.78 17.2 
E9PGC0 Ras GTPase-activating protein 1 5 0 -0.79 18 
Q8N573 Oxidation resistance protein 1 6 0 -0.81 14.5 
J3KS31 BUB3-interacting and GLEBS motif-
containing protein ZNF207 (Fragment)  
1 0.0003 -0.87 15.7 
F5GWX5 Chromodomain-helicase-DNA-binding 
protein 4  
7 0 -0.94 14.6 
Q12965 Unconventional myosin-Ie  4 0 -0.97 37.5 
F5H0W4 Bridging integrator 2  7 0 -0.98 13.8 
P49006 MARCKS-related protein 4 0 -0.99 8.6 
P67809 Nuclease-sensitive element-binding 
protein 1  
10 0 -1.0 19 
O60361 Putative nucleoside diphosphate kinase  1 0.0033 -1.05 41.1 
B5MCT7 Protein phosphatase 1F  4 0 -1.07 28.8 
Q3KQU3 MAP7 domain-containing protein 1  3 0 -1.10 21 
E9PKP7 Nucleolar transcription factor 1  9 0 -1.10 6.8 
O95104 Splicing factor. arginine/serine-rich 15  3 0 -1.12 27.4 
O75368 SH3 domain-binding glutamic acid-rich-
like protein  
5 0 -1.15 26.5 
P11234 Ras-related protein Ral-B  4 0 -1.16 27.7 
Q9Y3B9 RRP15-like protein  2 0 -1.20 35.6 
H3BRD2 Sulfhydryl oxidase (Fragment)  2 0.0044 -1.20 4.3 
Q96FJ2 Dynein light chain 2. cytoplasmic  1 0 -1.23 14.4 
H7C2F2 CD99 antigen (Fragment)  2 0 -1.28 4 
B0S8I6 Protein FAM50A  4 0 -1.28 59.2 
Q9ULZ3 Apoptosis-associated speck-like protein 
containing a CARD  
5 0 -1.32 31.8 
B0QYK0 RNA-binding protein EWS  4 0 -1.32 6.4 
A2A2D0 Stathmin (Fragment)  3 0 -1.41 9.8 
P98082 Disabled homolog 2  12 0 -1.42 15 
M0R088 Serine/arginine repetitive matrix 4 0 -1.44 59.7 
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protein 1 (Fragment)  
Q7L014 Probable ATP-dependent RNA helicase 
DDX46  
11 0 -1.55 5.4 
A0A0U1RQL
8 
Gelsolin (Fragment)  1 0 -1.56 10.9 
Q9UQ35 Serine/arginine repetitive matrix 
protein 2  
7 0 -1.59 40.2 
B1AMS2 Septin 6. isoform CRA 2 0 -1.61 10.9 
P21757 Macrophage scavenger receptor types I 
and II  
8 0 -1.65 6.5 
O75410 Transforming acidic coiled-coil-
containing protein 1  
7 0 -1.70 20.6 
E7ETA6 Pericentriolar material 1 protein  17 0 -1.76 13 
Q8IVD9 NudC domain-containing protein 3  2 0 -1.89 14 
H3BV80 RNA-binding protein with serine-rich 
domain 1  
4 0 -2.06 20.9 
J3QQK6 Myelin basic protein  3 0 -2.36 23.4 
Q14814 Myocyte-specific enhancer factor 2D 3 0 -2.43 53.3 
P17096 High mobility group protein HMG-
I/HMG-Y  
5 0 -4.03 1.8 
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Table 6-6: Dysregulated proteins from M. smeg infected macrophages (volcano plots).  
These were computed using volcano plots. 
M
e
d
ia
 Protein 
ID 
Protein Name 
Unique 
Peptides 
q-
value 
Fold 
Change 
Sequence 
Coverage (%) 
P62805 Histone H4 7 0 -6.08 49.5 
Ly
sa
te
 
Protein 
ID 
Protein Name 
Unique 
Peptides 
q-
value 
Fold 
Change 
Sequence 
Coverage (%) 
E9PEP6 Neuropilin  13 0 1.83 23.5 
P05362 
Intercellular adhesion 
molecule 1  
11 0 2.81 24.8 
P07602 Prosaposin  19 0 1.27 45.2 
P14780 
Matrix 
metalloproteinase-9  
18 0 1.28 28.1 
P18510 
Interleukin-1 receptor 
antagonist protein 
3 0 1.51 23.2 
Q03405 
Urokinase plasminogen 
activator surface 
receptor 
8 0 2.21 39.1 
 
Table 6-7: Dysregulated proteins secreted by LAM-stimulated macrophages (two-sample t 
test).  
These were computed using the two-sample t-test. 
Protein ID Protein Name 
Unique 
Peptides 
q-
value 
Fold 
Change 
Sequence 
Coverage (%) 
Q00610 Clathrin heavy chain 1 42 0 3.3 36.9 
P78527 DNA-dependent protein 
kinase catal 
76 0 2.55 24.4 
P25705 ATP synthase subunit 
alpha. mitochondrial 
21 0 2.54 49.2 
P62979 Ubiquitin-40S ribosomal 
protein S2 
6 0 2.2 40.4 
P04406 Glyceraldehyde-3-
phosphate dehydrogenase 
14 0 2.19 63.6 
P19105 Myosin regulatory light 
chain 12A 
3 0 2.09 24 
P05107 Integrin beta 26 0 1.67 48.5 
P62753 40S ribosomal protein S6 4 0 1.64 18.9 
Q99832 T-complex protein 1 
subunit eta 
21 0 1.42 56.2 
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P62241 40S ribosomal protein S8 7 0 1.29 41.3 
P13639 Elongation factor 2 38 0 1.2 55 
P61158 Actin-related protein 3 17 0 1.13 47.8 
Q09666 Neuroblast differentiation-
associated protein 
108 0 1.1 40.2 
P02751 Fibronectin 22 0 0.99 13.3 
P18084 Integrin beta-5 4 0 0.94 6.6 
A0A087WXM6 60S ribosomal protein L17 4 0 0.92 29.6 
P62805 Histone H4 9 0 0.83 49.5 
O15511 Actin-related protein 2/3 
complex 
5 0 0.81 52.3 
P11413 Glucose-6-phosphate 1-
dehydrogenase 
16 0 0.81 40 
O75367 Core histone macro-H2A.1 12 0 0.79 38.2 
P08238 Heat shock protein HSP 90-
beta 
21 0 0.77 33.3 
P38571 Lysosomal acid 
lipase/cholesteryl ester 
hydrolase 
3 0 0.76 14.1 
P52565 Rho GDP-dissociation 
inhibitor 1 
6 0 0.68 39.9 
E9PQQ4 Heat shock cognate 71 kDa 
protein 
1 0 0.48 6.6 
P00918 Carbonic anhydrase 2 13 0 0.46 55.8 
Q12906 Interleukin enhancer-
binding factor 3 
18 0 -0.76 27.4 
P06454 Prothymosin alpha 4 0 -0.91 26.2 
Q9BT09 Protein canopy homolog 3 5 0 -1.39 19.4 
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Table 6-8: Dysregulated lysate proteins harvested from LAM-stimulated macrophages 
(two-sample t-test).  
These were computed using the two-sample t-test. 
Protein ID Protein Name 
q-
value 
Fold 
Chang
e 
Unique 
Peptide
s 
Sequenc
e 
Coverag
e (%) 
Q6DKJ4 Nucleoredoxin 0 4.17 3 11 
Q9Y277 Voltage-dependent anion-selective 
channel protein 3 
0 3.72 8 43.5 
Q01970 1-phosphatidylinositol 4.5-bisphosphate 
phosphodiesterase beta-3 
0 3.67 3 4.6 
O60784 Target of Myb protein 1 0 3.50 8 32.1 
Q9C0H2 Protein tweety homolog 3 0 3.41 1 2.7 
Q99436 Proteasome subunit beta type-7 0 3.37 2 10.8 
O43592 Exportin-T 0 3.37 5 7.2 
P54725 UV excision repair protein RAD23 
homolog A 
0 3.32 2 15.2 
Q9HBI0 Gamma-parvin 0 3.31 5 20.2 
P61586 Transforming protein RhoA 0 3.26 2 18.7 
S4R456 40S ribosomal protein S15 (Fragment) 0 3.16 1 27.9 
K7EJ57 Mitochondrial import receptor subunit 
TOM40 homolog (Fragment) 
0 3.12 3 36 
Q9NRX4 14 kDa phosphohistidine phosphatase 0 3.11 2 25.6 
Q92890 Ubiquitin recognition factor in ER-
associated degradation protein 1 
0 3.09 3 16.9 
E9PJ81 UBX domain-containing protein 1 
(Fragment) 
0 3.06 3 22.1 
Q7L1Q6 Basic leucine zipper and W2 domain-
containing protein 1 
0 3.01 5 13.1 
P45880 Voltage-dependent anion-selective 
channel protein 2 
0 3.00 13 61.6 
E7ETC2 Serine/threonine-protein phosphatase 0 2.99 2 9 
Q8N6M0 OTU domain-containing protein 6B 0 2.94 2 10.2 
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P49721 Proteasome subunit beta type-2 0 2.86 7 41.3 
Q9NR31 GTP-binding protein SAR1a 0 2.86 3 27.8 
Q5T0R9 Adenylyl cyclase-associated protein 1 
(Fragment) 
0 2.81 1 8.4 
P61224 Ras-related protein Rap-1b 0 2.80 1 14.1 
D6RG39 OCIA domain-containing protein 1 
(Fragment) 
0 2.79 2 17.5 
Q96HQ2 CDKN2AIP N-terminal-like protein 0 2.79 1 15.5 
Q9H0U4 Ras-related protein Rab-1B 0 2.78 4 31.3 
Q9P0J7 E3 ubiquitin-protein ligase KCMF1 0 2.75 1 4.5 
Q9BW60 Elongation of very long chain fatty acids 
protein 1 
0 2.74 2 9.7 
F8W1W1 WASH complex subunit 4 (Fragment) 0 2.70 2 23.3 
P20645 Cation-dependent mannose-6-phosphate 
receptor 
0 2.69 2 11.6 
A0A087WU65 Vacuolar protein sorting-associated 
protein 45 
0 2.69 3 7.6 
Q96CN7 Isochorismatase domain-containing 
protein 1 
0 2.67 5 24.2 
P04632 Calpain small subunit 1 0 2.63 7 34.7 
P49407 Beta-arrestin-1 0 2.63 3 12.7 
Q99943 1-acyl-sn-glycerol-3-phosphate 
acyltransferase alpha 
0 2.63 1 7.4 
M0R1B5 Acetolactate synthase-like protein 
(Fragment) 
0 2.61 2 21.8 
Q9BRF8 Serine/threonine-protein phosphatase 
CPPED1 
0 2.59 6 26.8 
E9PKH6 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 8. mitochondrial 
0 2.59 2 19.6 
Q05639 Elongation factor 1-alpha 2 0 2.58 1 6 
Q96S44 TP53-regulating kinase 0 2.56 2 15.4 
P62314 Small nuclear ribonucleoprotein Sm D1 0 2.55 4 54.6 
E7EQ72 Transmembrane emp24 domain-
containing protein 2 (Fragment) 
0 2.53 2 16.9 
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E9PJ95 COMM domain-containing protein 9 0 2.51 1 8.6 
P35270 Sepiapterin reductase 0 2.48 2 13 
P30153 Serine/threonine-protein phosphatase 2A 
65 kDa regulator 
0 2.43 11 26.5 
Q9ULZ3 Apoptosis-associated speck-like protein 
containing a CAR 
0 2.42 6 28.2 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 0 2.42 9 16 
P48163 NADP-dependent malic enzyme 0 2.41 6 14.9 
A0A024RA52 Proteasome subunit alpha type 0 2.40 3 23.9 
F8VZN8 Protein phosphatase 1 regulatory subunit 
12A (Fragment) 
0 2.38 3 7.4 
Q05209 Tyrosine-protein phosphatase non-
receptor type 12 
0 2.37 5 11.9 
C9JDE9 3-ketoacyl-CoA thiolase. peroxisomal 0 2.37 4 18 
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 0 2.35 13 19.4 
P46821 Microtubule-associated protein 1B 0 2.35 11 7.1 
A0A1B0GWF8 Adenylosuccinate lyase (Fragment) 0 2.34 3 12.7 
D6RD69 GTP-binding protein SAR1b (Fragment) 0 2.33 2 25.3 
E7EMB1 Switch-associated protein 70 0 2.31 7 21.6 
P49354 Protein 
farnesyltransferase/geranylgeranyltransf
erase type-1 subunit alpha 
0 2.31 6 22.7 
P48059 LIM and senescent cell antigen-like-
containing domain protein 1 
0 2.30 5 18.8 
P47813 Eukaryotic translation initiation factor 1A. 
X-chromosome 
0 2.29 2 17.4 
A0A1B0GTK8 Tumor necrosis factor alpha-induced 
protein 8-like protein 3 
0 2.29 4 26.5 
P46734 Dual specificity mitogen-activated protein 
kinase kinase 
0 2.28 2 9.2 
P60953 Cell division control protein 42 homolog 0 2.27 2 14.7 
Q16762 Thiosulfate sulfur transferase 0 2.27 2 10.8 
Q96A33 Coiled-coil domain-containing protein 47 0 2.26 6 20.1 
D6RIZ4 Major facilitator superfamily domain- 0.000 2.26 1 3.7 
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containing protein 4 
P21796 Voltage-dependent anion-selective 
channel protein 1 
0 2.25 14 64 
F8VXI1 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 
0.002
1 
2.25 1 14.5 
J3KS22 L-xylulose reductase (Fragment) 0 2.24 6 39 
F5H6Y0 Vacuolar protein sorting-associated 
protein 33A 
0 2.23 1 8.6 
O43920 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5 
0 2.22 1 11.3 
E9PQX9 Dr1-associated corepressor 0 2.22 4 30.8 
P07204 Thrombomodulin 0 2.22 3 11.1 
Q13740 CD166 antigen 0 2.22 13 32.9 
Q96AQ6  Pre-B-cell leukemia transcription factor-
interacting protein 1 
0 2.21 3 5.1 
O94826 Mitochondrial import receptor subunit 
TOM70 
0 2.19 11 35.2 
Q5T196 FAD synthase 0 2.19 3 9.6 
H7C5S0 Actin-like protein 6A (Fragment) 0 2.18 4 39.8 
C9JP16 Cartilage-associated protein 0 2.18 3 10.6 
P62266 40S ribosomal protein S23 0 2.17 3 34.3 
P61758 Prefoldin subunit 3 0 2.17 3 21.3 
O60711 Leupaxin 0 2.15 3 11.4 
Q13185 Chromobox protein homolog 3 0 2.15 5 36.1 
A0A087X1K9 Acyl-protein thioesterase 1S 0 2.14 4 33.7 
P08758 Annexin A5 0 2.12 11 50 
P62081 40S ribosomal protein S7 0 2.11 6 46.9 
Q15121 Astrocytic phosphoprotein PEA-15 0 2.08 5 60 
J3QL26 Serine/threonine-protein phosphatase 4 
regulatory subuni 
0 2.07 2 18.5 
Q8TBQ9 Protein kish-A OS 0.001
3 
2.07 1 12.5 
P20701 Integrin alpha-L 0 2.07 5 6.8 
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P15289 Arylsulfatase A 0 2.05 4 12.6 
Q15555 Microtubule-associated protein RP/EB 
family member 2 
0 2.05 3 14.7 
P18031 Tyrosine-protein phosphatase non-
receptor type 1 
0 2.04 4 11 
Q13636 Ras-related protein Rab-31 0 2.02 4 32 
P31949 Protein S100-A11 0 2.01 3 32.4 
P43304 Glycerol-3-phosphate dehydrogenase. 
mitochondrial 
0 2.01 8 15 
O14933 Ubiquitin/ISG15-conjugating enzyme E2 
L6 
0 1.99 1 9.8 
C9J8R4 DCN1-like protein (Fragment) 0 1.99 2 26.6 
X6RDA4 Paraspeckle component 1 (Fragment) 0 1.99 3 21.8 
P61289 Proteasome activator complex subunit 3 0 1.99 4 22.8 
Q08J23 tRNA (cytosine(34)-C(Khan1 et al.))-
methyltransferase 
0 1.98 7 14.7 
O14617 AP-3 complex subunit delta-1 0 1.97 5 7.3 
Q10471 Polypeptide N-
acetylgalactosaminyltransferase 2 
0 1.96 5 15.4 
A6PVH9 Copine-1 0 1.94 6 19.1 
Q02750 Dual specificity mitogen-activated protein 
kinase kinase 
0 1.93 4 22.1 
P48960 CD97 antigen 0 1.92 7 16.2 
M0R0F0 40S ribosomal protein S5 (Fragment) 0 1.92 5 37 
Q86UP2 Kinectin 0 1.91 13 14.8 
B0QY91 MICAL-like protein 1 (Fragment) 0 1.90 1 7 
P47985 Cytochrome b-c1 complex subunit Rieske. 
mitochondrial 
0 1.90 3 21.5 
A0A087WUN7 SRA stem-loop-interacting RNA-binding 
protein. mitochondrial 
0 1.90 3 41.3 
P61026 Ras-related protein Rab-10 0 1.86 4 24.5 
O00264 Membrane-associated progesterone 
receptor component 1 
0 1.85 3 27.2 
Q6XQN6 Nicotinate phosphoribosyltransferase 0 1.85 8 25.3 
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P63104 14-3-3 protein zeta/delta 0 1.84 14 62 
H7C0V0 m-AAA protease-interacting protein 1. 
mitochondrial (Fragment) 
0 1.84 1 4.4 
P61421 V-type proton ATPase subunit d 1 0 1.83 6 30.8 
F8VYE8 Serine/threonine-protein phosphatase 0 1.82 2 12.2 
P60228 Eukaryotic translation initiation factor 3 
subunit E 
0 1.81 7 20.9 
P07355 Annexin A2 0 1.80 17 55.8 
Q9UJY5 ADP-ribosylation factor-binding protein 
GGA1 
0 1.75 3 10.3 
Q15067 Peroxisomal acyl-coenzyme A oxidase 1 0 1.75 11 29.4 
P13861 cAMP-dependent protein kinase type II-
alpha regulatory s 
0 1.74 7 24.8 
O75663 TIP41-like protein 0 1.74 2 10.7 
Q07666 KH domain-containing. RNA-binding. 
signal transduction-associated protein 1 
0 1.73 3 9.7 
P01023 Alpha-2-macroglobulin 0 1.73 18 15.2 
Q10567 AP-1 complex subunit beta-1 0 1.73 8 12.8 
O75607 Nucleoplasmin-3 0 1.73 2 17.4 
Q5T8U5 Surfeit 4 0 1.72 4 26.9 
Q5R3B4 Mitochondrial pyruvate carrier 
(Fragment) 
0.001
3 
1.72 1 9.5 
P30084 Enoyl-CoA hydratase. mitochondrial 0 1.72 9 45.2 
Q16666 Gamma-interferon-inducible protein 16 0 1.72 5 11.3 
P38606 V-type proton ATPase catalytic subunit A 0 1.71 15 40 
O00764 Pyridoxal kinase 0 1.69 6 30.4 
B4E0K5 Mitogen-activated protein kinase 0 1.68 6 34.6 
G3V1U5 Golgi transport 1 homolog B (S. 
cerevisiae). isoform CRA 
0 1.67 1 18.9 
O75915 PRA1 family protein 3 0 1.67 3 20.7 
Q9BWF3 RNA-binding protein 4 0 1.66 3 14.3 
O75947 ATP synthase subunit d. mitochondrial 0 1.66 7 59 
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Q93034 Cullin-5 0 1.65 2 4.9 
H7C089 Tetratricopeptide repeat protein 38 
(Fragment) 
0.002
1 
1.64 1 7.6 
Q15397 Pumilio homolog 3 0 1.64 2 4.2 
P32119 Peroxiredoxin-2 0 1.64 8 48.5 
P27348 14-3-3 protein theta 0 1.63 9 45.3 
P52888 Thimet oligopeptidase 0 1.63 13 26.3 
J3KMY5 Epididymal secretory protein E1 0 1.63 5 46.6 
Q9Y678 Coatomer subunit gamma-1 0 1.62 23 42.2 
Q14240 Eukaryotic initiation factor 4A-II 0 1.62 9 30.5 
J3QQK6 Myelin basic protein 0 1.62 2 15.8 
Q9H4M9 EH domain-containing protein 1 0 1.62 6 17.8 
P05455 Lupus La protein 0 1.60 13 37.5 
Q969S3 Zinc finger protein 622 0 1.59 2 6.5 
Q9P0J0 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 
0 1.59 2 20.1 
P09543 2.3-cyclic-nucleotide 3-
phosphodiesterase 
0 1.58 4 14.7 
A0A0B4J2A4 3-ketoacyl-CoA thiolase. mitochondrial 0 1.58 5 26.4 
Q13724 Mannosyl-oligosaccharide glucosidase 0 1.58 5 8.2 
P06748 Nucleophosmin 0 1.57 9 41.8 
P61981 14-3-3 protein gamma 0 1.57 5 33.2 
P30085 UMP-CMP kinase 0 1.56 6 35.7 
A5YKK6 CCR4-NOT transcription complex subunit 
1 
0.005
9 
1.55 2 0.9 
H7C3C4 Anion exchange protein (Fragment) 0 1.55 2 5.1 
O15145 Actin-related protein 2/3 complex 
subunit 3 
0 1.54 4 32 
P31946 14-3-3 protein beta/alpha 0 1.53 7 46.7 
P62191 26S proteasome regulatory subunit 4 0 1.52 11 34.8 
A0A1W2PRL9 Transcription elongation factor A protein 
1 
0 1.52 5 28.6 
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Q9Y263 Phospholipase A-2-activating protein 0 1.51 4 8.3 
Q9Y371 Endophilin-B1 0 1.49 2 7.1 
P49756 RNA-binding protein 25 0 1.48 4 6.8 
P05362 Intercellular adhesion molecule 1 0 1.47 8 20.3 
Q96HY6 DDRGK domain-containing protein 1 0 1.47 5 30.9 
P04179 Superoxide dismutase [Mn]. 
mitochondrial 
0 1.45 4 19.8 
P61769 Beta-2-microglobulin 0 1.44 3 35.3 
P62834 Ras-related protein Rap-1A OS 0 1.43 4 29.3 
P62258 14-3-3 protein epsilon 0 1.43 16 64.3 
P00403 Cytochrome c oxidase subunit 2 0 1.42 4 24.7 
Q9UL46 Proteasome activator complex subunit 2 0 1.42 8 48.1 
Q15050 Ribosome biogenesis regulatory protein 
homolog 
0 1.40 3 14.5 
H3BQZ7 HCG2044799 0 1.40 10 22 
Q99878 Histone H2A type 1-J 0 1.40 1 14.8 
Q27J81 Inverted formin-2 0 1.39 16 22.4 
Q9Y376 Calcium-binding protein 39 0 1.39 6 20.5 
Q8TAQ2 SWI/SNF complex subunit SMARCC2 0 1.39 6 7 
P28070 Proteasome subunit beta type-4 0 1.38 6 37.9 
Q9ULV4 Coronin-1C 0 1.36 11 33.8 
P33241 Lymphocyte-specific protein 1 0 1.35 4 26.3 
Q9UL25 Ras-related protein Rab-21 0 1.34 4 25.3 
P31146 Coronin-1A 0 1.34 10 31.7 
Q00722 1-phosphatidylinositol 4.5-bisphosphate 
phosphodiesteras beta-2 
0 1.33 7 7.9 
X1WI28 60S ribosomal protein L10 (Fragment) 0 1.32 1 13.5 
P55072 Transitional endoplasmic reticulum 
ATPase 
0 1.31 28 50 
P35637 RNA-binding protein FUS 0 1.30 5 18.6 
P55957 BH3-interacting domain death agonist 0 1.29 5 44.1 
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K7EJE8 Lon protease homolog. mitochondrial 0 1.29 17 31.1 
Q05823 2-5A-dependent ribonuclease 0 1.28 1 1.2 
Q8WX92 Negative elongation factor B 0 1.28 1 1.7 
A0A0A0MTI6 Elongation of very long chain fatty acids 
protein 
0 1.26 1 5 
P56134 ATP synthase subunit f. mitochondrial 0 1.25 3 39.4 
P08133 Annexin A6 0 1.25 13 25 
P11234 Ras-related protein Ral-B 0 1.25 4 14.6 
P50552 Vasodilator-stimulated phosphoprotein 0 1.24 10 32.4 
Q13148 TAR DNA-binding protein 43 0 1.23 5 25.6 
D6R9P3 Heterogeneous nuclear 
ribonucleoprotein A/B 
0 1.22 5 21.8 
C9J3L8 Translocon-associated protein subunit 
alpha 
0 1.22 3 12.8 
Q9Y679 Ancient ubiquitous protein 1 0 1.22 4 12.8 
Q9P0L0 Vesicle-associated membrane protein-
associated protein 
0 1.22 2 13.7 
M0QZS6 SUMO-activating enzyme subunit 1 0 1.21 6 40.4 
A8MVU1 Putative neutrophil cytosol factor 1C 0 1.20 2 9.3 
Q9BWD1 Acetyl-CoA acetyltransferase. cytosolic 0 1.20 6 30.2 
P27797 Calreticulin 0 1.18 19 68.1 
O14773 Tripeptidyl-peptidase 1 0 1.18 9 23.6 
H3BUX2 Cytochrome b5 type B 0 1.18 4 52.9 
Q9NY65 Tubulin alpha-8 chain 0 1.16 3 10.9 
P35268 60S ribosomal protein L22 0 1.15 3 39.1 
P54578 Ubiquitin carboxyl-terminal hydrolase 14 0 1.15 6 19 
A0A1W2PR68 Malic enzyme 0 1.15 10 27.7 
P31939 Bifunctional purine biosynthesis protein 
PURH 
0 1.13 20 51.5 
P60174 Triosephosphate isomerase 0 1.13 12 58.7 
P50995 Annexin A11 0 1.11 8 19.8 
Q9BR76 Coronin-1B 0 1.10 8 23.1 
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A0A087X1W2 Protein arginine N-methyltransferase 1 0 1.08 1 10.9 
Q32Q12 Nucleoside diphosphate kinase 0 1.08 4 18.2 
Q9BXP5 Serrate RNA effector molecule homolog 0 1.07 6 12.6 
Q86UE4 Protein LYRIC 0 1.07 10 28.7 
P12277 Creatine kinase B-type 0 1.06 10 44.9 
B4DY09 Interleukin enhancer-binding factor 2 0 1.06 11 48 
Q14690 Protein RRP5 homolog 0 1.06 4 2.9 
Q9Y3L3 SH3 domain-binding protein 1 0 1.06 1 2.6 
O14828 Secretory carrier-associated membrane 
protein 3 
0 0.99 2 8.6 
P13498 Cytochrome b-245 light chain 0 0.98 1 15.9 
O95433 Activator of 90 kDa heat shock protein 
ATPase homolog 1 
0 0.96 8 38.5 
O14579 Coatomer subunit epsilon 0 0.93 8 51 
Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15 0 0.89 3 4 
P61009 Signal peptidase complex subunit 3 0 0.84 2 12.8 
Q02218 2-oxoglutarate dehydrogenase. 
mitochondrial 
0 0.84 18 24.6 
P12955 Xaa-Pro dipeptidase 0 0.75 7 18.1 
P08708 40S ribosomal protein S17 0 0.71 4 41.5 
P55210 Caspase-7 0 0.69 2 10.9 
Q96KC8 DnaJ homolog subfamily C member 1 0.002
9 
0.63 2 4.2 
Q6P2E9 Enhancer of mRNA-decapping protein 4 0 -0.36 8 9 
P06730 Eukaryotic translation initiation factor 4E 0 -0.85 5 29.5 
A0A087X2D0 Serine/arginine-rich-splicing factor 3 0 -0.91 2 22.1 
P08621 U1 small nuclear ribonucleoprotein 70 
kDa 
0 -0.92 5 19 
P50416 Carnitine O-palmitoyltransferase 1. liver 
isoform 
0 -1.03 7 10.2 
Q71UI9 Histone H2A.V 0 -1.16 2 18.8 
P26447 Protein S100-A4 0 -1.27 4 35.6 
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F5GWH5 Transmembrane protein 258 0.004
4 
-1.33 1 16.3 
P37837 Transaldolase 0 -1.39 10 30.3 
Q8TCJ2 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit STT3B 
0 -1.43 4 5.1 
A0A024R4M0 40S ribosomal protein S9 0 -1.44 6 26.3 
Q9HAB8 Phosphopantothenate--cysteine ligase 0 -1.48 8 26.7 
E7ETA6 Pericentriolar material 1 protein 0 -1.53 11 7.9 
Q9Y3C8 Ubiquitin-fold modifier-conjugating 
enzyme 1 
0 -1.72 2 11.4 
Q8TEM1 Nuclear pore membrane glycoprotein 210 0 -1.92 7 5.7 
P21266 Glutathione S-transferase Mu 3 0 -1.96 5 28 
P04181 Ornithine aminotransferase. 
mitochondrial 
0 -2.02 8 25.1 
H0YN26 Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
0 -2.18 3 18.6 
Q8N573 Oxidation resistance protein 1 0 -2.24 4 7.3 
P62851 40S ribosomal protein S25 0 -2.30 4 24 
P05386 60S acidic ribosomal protein P1 0 -2.39 2 36.8 
Q9NRH3 Tubulin gamma-2 chain 0 -2.55 3 13.1 
C9JA28 Translocon-associated protein subunit 
gamma 
0 -2.60 1 8 
Q16401 26S proteasome non-ATPase regulatory 
subunit 5 
0 -2.63 4 10.5 
P11142 Heat shock cognate 71 kDa protein 0 -2.63 2 5.1 
Q5T0I0 Gelsolin (Fragment) 0 -3.02 2 3.8 
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Table 6-9: Dysregulated proteome from LAM-stimulated macrophages (volcano plots).  
These were calculated using the volcano plots. 
M
ed
ia
 
Protein 
ID Protein Name 
Unique 
Peptides 
q-
value 
Fold 
Change 
Sequence 
Coverage (%) 
P62979 
Ubiquitin-40S ribosomal 
protein S27a  6 0 2.20 40.4 
P78527 
DNA-dependent protein kinase 
catalytic subunit 76 0 2.55 24.4 
Q00610 Clathrin heavy chain 1 42 0 3.30 44.5 
  
Protein 
ID Protein Name 
Unique 
Peptides 
q-
value 
Fold 
Change 
Sequence 
Coverage (%) 
Ly
sa
te
 
P45880 
Voltage-dependent anion-
selective channel protein 2  13 0 3.00 61.6 
P54725 
UV excision repair protein 
RAD23 homolog A  2 0 3.32 15.2 
P61586 Transforming protein RhoA  2 0 3.26 18.7 
Q16401 
26S proteasome non-ATPase 
regulatory subunit 5  4 0 -2.63 10.5 
C9JA28 
Translocon-associated protein 
subunit gamma  1 0 -2.60 8 
Q5T0I0 Gelsolin (Fragment) 2 0 -3.02 3.8 
 
 
 
 
 
